JP6458028B2 - Novel derivatives of indole and pyrrole, processes for their preparation and pharmaceutical compositions containing them - Google Patents

Description

  The present invention relates to novel indole and pyrrole compounds, methods for their preparation and pharmaceutical compositions containing them.

  The compounds of the present invention are new and have very valuable pharmacological features in the fields of apoptosis and oncology.

Apoptosis, or programmed cell death, is a critical physiological process with respect to embryonic development and tissue homeostasis.
Apoptotic cell death is like morphological changes such as nuclear condensation, DNA fragmentation, and caspase activation (causing damage to the key structural components of the cell, thus inducing its degradation and death) It is also related to other biochemical phenomena. Control of the apoptotic process is complex and is associated with activation or suppression of several intracellular signaling pathways (Cory S. and al., Nature Review Cancer, 2002, 2, 647-656).
Deviations from the control of apoptosis are associated with certain lesions. Increased apoptosis is associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and ischemia. Conversely, the lack of occurrence of apoptosis plays an important role in cancer progression and its chemotherapeutic resistance, autoimmune diseases, inflammatory diseases and viral infections. Thus, the absence of apoptosis is one of the characteristics of cancer in the phenotype (Hanahan D. et al., Cell 2000, 100, 57-70).

  The Bcl-2 family of anti-apoptotic proteins has been associated with numerous lesions. Bcl-2 family proteins are involved in many types such as colorectal cancer, breast cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphocytic leukemia, follicular lymphoma, myeloma, etc. In cancer. Overexpression of the Bcl-2 family of apoptosis-inhibiting proteins has been implicated in tumor formation, resistance to chemotherapy and the clinical prognosis of patients affected by cancer. Accordingly, there is a therapeutic need for compounds that inhibit the anti-apoptotic activity of Bcl-2 family proteins.

  In addition to being novel, the compounds of the present invention have pro-apoptotic properties, which in lesions associated with a lack of apoptosis, such as cancer, autoimmune diseases and the immune system. It makes it possible to use them in the treatment of diseases.

［式中、
Ｗは、基Ｃ−Ａ_３又は窒素原子を表し；
Ａ_１、Ａ_２及びＡ_３は、各々互いに独立して、水素又はハロゲン原子、直鎖状又は分岐鎖状ポリハロ（Ｃ_１−Ｃ_６）アルキル、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基若しくはシクロアルキルを表すか、又は、
Ａ_１及びＡ_２は、それらを有している炭素原子と共に、シクロアルキル又はベンゾ環を形成し、これら２種の環は、場合によりハロゲン原子、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基、直鎖状又は分岐鎖状ポリハロ（Ｃ_１−Ｃ_６）アルキル基、ヒドロキシ基、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルコキシ基若しくは−ＣＯＯＨで置換されており；
Ａ_１及びＡ_２が、互いに独立して、水素又はハロゲン原子、直鎖状又は分岐鎖状ポリハロ（Ｃ_１−Ｃ_６）アルキル、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基若しくはシクロアルキルを表すとき、Ｗは必然的に基Ｃ−Ａ_３を表すと理解され、
Ｔは、水素原子、場合により１〜３個のハロゲン原子で置換されている直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基、基（Ｃ_１−Ｃ_４）アルキル−ＮＲ_１Ｒ_２若しくは基（Ｃ_１−Ｃ_４）アルキル−ＯＲ_６を表し；
Ｒ_１及びＲ_２は、互いに独立して、水素原子若しくは直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基を表すか、又は、
Ｒ_１及びＲ_２は、それらを有する窒素原子と共にヘテロシクロアルキルを形成し；
Ｒ_３は、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基、直鎖状又は分岐鎖状（Ｃ_２−Ｃ_６）アルケニル基、直鎖状又は分岐鎖状（Ｃ_２−Ｃ_６）アルキニル 基、シクロアルキル基、（Ｃ_３−Ｃ_１０）シクロアルキル−（Ｃ_１−Ｃ_６）アルキル基(前記アルキル部は直鎖状又は分岐鎖状である)、ヘテロシクロアルキル基、アリール基若しくはヘテロアリール基を表し、前記の基の１個以上の炭素原子、又はそれらの可能な置換基の炭素原子は、重水素化されていてもよいと理解され；
Ｒ_４は、アリール基、ヘテロアリール基、シクロアルキル基若しくは直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基を表し、前記の基の１個以上の炭素原子、又はそれらの可能な置換基の炭素原子は、重水素化されていてもよいと理解され；
Ｒ_５は、水素又はハロゲン原子、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル 基若しくは直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルコキシ基を表し；
Ｒ_６は、水素原子若しくは直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基を表し；
Ｒ_ａ、Ｒ_ｂ、Ｒ_ｃ及びＲ_ｄは、各々互いに独立して、Ｒ_７、ハロゲン原子、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルコキシ基、ヒドロキシ基、直鎖状又は分岐鎖状ポリハロ（Ｃ_１−Ｃ_６）アルキル基、トリフルオロメトキシ基、−ＮＲ_７Ｒ_７’、ニトロ、Ｒ_７−ＣＯ−（Ｃ_０−Ｃ_６）アルキル−、Ｒ_７−ＣＯ−ＮＨ−（Ｃ_０−Ｃ_６）アルキル−、ＮＲ_７Ｒ_７’−ＣＯ−（Ｃ_０−Ｃ_６）アルキル−、ＮＲ_７Ｒ_７’−ＣＯ−（Ｃ_０−Ｃ_６）アルキル−Ｏ−、Ｒ_７−ＳＯ_２−ＮＨ−（Ｃ_０−Ｃ_６）アルキル−、Ｒ_７−ＮＨ−ＣＯ−ＮＨ−（Ｃ_０−Ｃ_６）アルキル−、Ｒ_７−Ｏ−ＣＯ−ＮＨ−（Ｃ_０−Ｃ_６）アルキル−、ヘテロシクロアルキル基を表すか、又は、対（Ｒ_ａ、Ｒ_ｂ）、（Ｒ_ｂ、Ｒ_ｃ）又は（Ｒ_ｃ、Ｒ_ｄ）のうちの１つの対の置換基は、それらを有する炭素原子と共に、５〜７個の環員で構成され、酸素及び硫黄より選択される１〜２個のヘテロ原子を含んでいてもよい環を形成し、また、先に定義された環の１個以上の炭素原子は、重水素化されるか、又はハロゲン及び直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキルより選択される１〜３個の基で置換されていてもよいと理解され；
Ｒ_７及びＲ_７’は、互いに独立して、水素、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基、直鎖状又は分岐鎖状（Ｃ_２−Ｃ_６）アルケニル基、直鎖状又は分岐鎖状（Ｃ_２−Ｃ_６）アルキニル基、アリール基又はヘテロアリール基を表すか、又は、Ｒ_７及びＲ_７’は、それらを有する窒素原子と共に５〜７個の環員で構成される複素環を形成し；
前記式（Ｉ）の化合物がヒドロキシ基を含むとき、後者は場合により、下記の基：
−ＰＯ（ＯＭ）（ＯＭ’）、−ＰＯ（ＯＭ）（Ｏ⁻Ｍ_１ ^＋）、−ＰＯ（Ｏ⁻Ｍ_１ ^＋）（Ｏ⁻Ｍ_２ ^＋）、−ＰＯ（Ｏ⁻）（Ｏ⁻）Ｍ_３ ^２＋、−ＰＯ（ＯＭ）（Ｏ［ＣＨ_２ＣＨ_２Ｏ］_ｎＣＨ_３）又は−ＰＯ（Ｏ⁻Ｍ_１ ^＋）（Ｏ［ＣＨ_２ＣＨ_２Ｏ］_ｎＣＨ_３）（式中、Ｍ及びＭ’は、互いに独立して、水素原子、直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基、直鎖状又は分岐鎖状（Ｃ_２−Ｃ_６）アルケニル基、直鎖状又は分岐鎖状（Ｃ_２−Ｃ_６）アルキニル基、シクロアルキル又はヘテロシクロアルキル（これら両者は、５〜６個の環員で構成される）を表し、一方、Ｍ_１ ^＋及びＭ_２ ^＋は、互いに独立して、薬学的に許容し得る一価陽イオンを表し、Ｍ_３ ^２＋は、薬学的に許容し得る二価陽イオンを表し、ｎは、１〜５の整数である）
のうちの１種で置換されていてもよいと理解され；また、
「アリール」は、フェニル、ナフチル、ビフェニル又はインデニル基を意味し、
「ヘテロアリール」は、少なくとも１個の芳香族部を有し、かつ酸素、硫黄及び窒素（４級窒素を含む）より選択される１〜４個のヘテロ原子を含有する、５〜１０個の環員で構成される任意の単環又は二環式基を意味し、
「シクロアルキル」は、３〜１０個の環員を含有する、任意の単環又は二環式非芳香族炭素環基を意味し、
「ヘテロシクロアルキル」は、３〜１０個の環員で構成され、かつ酸素、硫黄、ＳＯ、ＳＯ_２及び窒素より選択される１〜３個のヘテロ原子を含有する、任意の単環又は二環式非芳香族基を意味する
と理解され；
前記の通り定義されるアリール、ヘテロアリール、シクロアルキル及びヘテロシクロアルキル基、並びに前記アルキル、アルケニル、アルキニル及びアルコキシの各基については、場合により置換されている直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル、（Ｃ_３−Ｃ_６）スピロ、場合により置換されている直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルコキシ、（Ｃ_１−Ｃ_６）アルキル−Ｓ−、ヒドロキシ、オキソ（又は、適切であればＮ−オキシド）、ニトロ、シアノ、−ＣＯＯＲ’、−ＯＣＯＲ’、ＮＲ’Ｒ”、直鎖状又は分岐鎖状ポリハロ（Ｃ_１−Ｃ_６）アルキル、トリフルオロメトキシ、（Ｃ_１−Ｃ_６）アルキルスルホニル、ハロゲン、場合により置換されているアリール、ヘテロアリール、アリールオキシ, アリールチオ、シクロアルキル、場合により１個以上のハロゲン原子又はアルキル基で置換されているヘテロシクロアルキル（Ｒ’及びＲ”は、各々互いに独立して、水素原子又は場合により置換されている直鎖状又は分岐鎖状（Ｃ_１−Ｃ_６）アルキル基を表すと理解される）より選択される１〜３個の基で置換されることがあり得る］
で示される化合物、並びにそのエナンチオマー、ジアステレオ異性体及び薬学的に許容し得る酸又は塩基との付加塩に関する。 More specifically, the present invention relates to the following formula (I):

[Where:
W represents a group C—A ₃ or a nitrogen atom;
A ₁ , A ₂ and A ₃ are each independently of each other hydrogen or a halogen atom, linear or branched polyhalo (C ₁ -C ₆ ) alkyl, linear or branched (C ₁ -C). ₆ ) represents an alkyl group or cycloalkyl, or
A ₁ and A ₂ together with the carbon atom carrying them form a cycloalkyl or benzo ring, and these two rings are optionally halogen atoms, straight or branched (C ₁ -C ₆ ) substituted with alkyl group, linear or branched polyhalo (C ₁ -C ₆ ) alkyl group, hydroxy group, linear or branched (C ₁ -C ₆ ) alkoxy group or —COOH ;
A ₁ and A ₂ are independently of each other a hydrogen or halogen atom, a linear or branched polyhalo (C ₁ -C ₆ ) alkyl, a linear or branched (C ₁ -C ₆ ) alkyl group. Or when representing cycloalkyl, W is understood to necessarily represent the group C—A ₃ ;
T is a hydrogen atom, a linear or branched (C ₁ -C ₆ ) alkyl group optionally substituted with 1 to 3 halogen atoms, a group (C ₁ -C ₄ ) alkyl-NR ₁ R ₂ or the group (C ₁ -C ₄ ) alkyl-OR ₆ ;
R ₁ and R ₂ each independently represent a hydrogen atom or a linear or branched (C ₁ -C ₆ ) alkyl group, or
R ₁ and R ₂ together with the nitrogen atom bearing them form a heterocycloalkyl;
R ₃ is a linear or branched (C ₁ -C ₆ ) alkyl group, a linear or branched (C ₂ -C ₆ ) alkenyl group, a linear or branched (C ₂ -C) ₆₎ alkynyl group, a cycloalkyl _group, (C 3 _{-C 10)} cycloalkyl - is _(C 1 -C ₆₎ alkyl group (said alkyl part is linear or branched), a heterocycloalkyl group, an aryl It is understood that one or more carbon atoms of said group or their possible substituents may be deuterated, representing a group or heteroaryl group;
R ₄ represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched (C ₁ -C ₆ ) alkyl group, one or more carbon atoms of said group, or their possible It is understood that the carbon atom of the substituent may be deuterated;
R ₅ represents a hydrogen or halogen atom, a linear or branched (C ₁ -C ₆ ) alkyl group or a linear or branched (C ₁ -C ₆ ) alkoxy group;
R ₆ represents a hydrogen atom or a linear or branched (C ₁ -C ₆ ) alkyl group;
R _a , R _b , R _c and R _d are each independently R ₇ , a halogen atom, a linear or branched (C ₁ -C ₆ ) alkoxy group, a hydroxy group, a linear or branched group chain polyhalo _(C 1 -C ₆₎ alkyl group, a trifluoromethoxy group, _-NR 7 _{R 7} ', _{nitro, R 7 -CO- (C 0 -C} 6) alkyl _-, R 7 -CO-NH- ( C ₀ -C ₆₎ alkyl _{-, NR 7 R 7 '-CO-} (C 0 -C 6) alkyl _{-, NR 7 R 7' -CO-} (C 0 -C 6) alkyl -O-, _{R 7} - _{SO 2 -NH- (C 0 -C 6} ) alkyl _{-, R 7 -NH-CO-} NH- (C 0 -C 6) alkyl _{-, R 7 -O-CO-} NH- (C 0 -C 6) Represents an alkyl-, heterocycloalkyl group or a pair (R _a , R _b ), (R _b , R _c ) Or one pair of substituents of (R _c , R _d ), together with the carbon atom having them, is composed of 5 to 7 ring members, and is selected from 1 to 2 hetero atoms selected from oxygen and sulfur Forms a ring which may contain atoms, and one or more carbon atoms of the ring as defined above are deuterated, or halogen and linear or branched (C _1- C ₆₎ it is understood by one to three groups selected from alkyl which may be substituted;
R ₇ and R ₇ ′ are independently of each other hydrogen, a linear or branched (C ₁ -C ₆ ) alkyl group, a linear or branched (C ₂ -C ₆ ) alkenyl group, chain or branched (C 2 _{-C 6)} alkynyl group, an aryl group or a heteroaryl group, or, R ₇ and R _{7 'is} a five to seven ring members together with the nitrogen atom which carries them Forming a composed heterocycle;
When the compound of formula (I) contains a hydroxy group, the latter optionally has the following groups:
^{-PO (OM) (OM ')} , - PO (OM) (OM 1 +), - PO (OM 1 +) (OM 2 +), - PO (O -) (O -) ^{_{M 3 2+, -PO (OM)}} (O [CH 2 CH 2 O] n CH 3) or ^{_{-PO (OM 1 +) (O}} [CH 2 CH 2 O] n CH 3) ( in the formula, M And M ′, independently of each other, are a hydrogen atom, a linear or branched (C ₁ -C ₆ ) alkyl group, a linear or branched (C ₂ -C ₆ ) alkenyl group, a linear Or a branched (C ₂ -C ₆ ) alkynyl group, cycloalkyl or heterocycloalkyl (both of which are composed of 5 to 6 ring members), while M ₁ ⁺ and M ₂ ⁺ are , independently of one another, represent monovalent cations pharmaceutically acceptable, M ₃ ²⁺ represents a divalent cation pharmaceutically acceptable n is an integer of 1 to 5)
It is understood that it may be substituted with one of:
“Aryl” means a phenyl, naphthyl, biphenyl or indenyl group;
“Heteroaryl” has 5 to 10 heteroatoms having at least one aromatic moiety and containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen (including quaternary nitrogen). Means any monocyclic or bicyclic group composed of ring members;
“Cycloalkyl” means any monocyclic or bicyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,
“Heterocycloalkyl” is any monocyclic or bicyclic group composed of 3 to 10 ring members and containing 1 to 3 heteroatoms selected from oxygen, sulfur, SO, SO ₂ and nitrogen. Understood to mean a cyclic non-aromatic group;
The aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups defined above, and the alkyl, alkenyl, alkynyl and alkoxy groups are optionally substituted linear or branched (C ₁ -C _{6) alkyl, (C} 3 -C ₆₎ spiro, optionally linear or branched and is substituted _(C 1 -C _{6) alkoxy, (C} 1 -C ₆₎ alkyl -S-, hydroxy , Oxo (or N-oxide, if appropriate), nitro, cyano, —COOR ′, —OCOR ′, NR′R ″, linear or branched polyhalo (C ₁ -C ₆ ) alkyl, trifluoro _{methoxy, (C} 1 -C ₆₎ alkylsulfonyl, halogen, aryl which is optionally substituted, heteroaryl, aryloxy, arylthio, Chloalkyl, optionally substituted by one or more halogen atoms or alkyl groups, heterocycloalkyl (R ′ and R ″ each independently of one another a hydrogen atom or optionally substituted linear or branched May be substituted with 1 to 3 groups selected from a chain (understood to represent a C ₁ -C ₆ ) alkyl group]
As well as enantiomers, diastereoisomers and pharmaceutically acceptable acid or base addition salts thereof.

  Pharmaceutically acceptable acids include, without any limitation, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutar Examples include acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid and the like.

  Examples of the pharmaceutically acceptable base include sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine and the like without implying any limitation.

In preferred compounds of the invention, R ₄ is, in the para position, the formula —OPO (OM) (OM ′), —OPO (OM) (O ⁻ M ₁ ⁺ ), —OPO (O ⁻ M ₁ ⁺ ) ( ^{_{OM 2 +), - OPO (}} O -) (O -) M 3 2+, -OPO (OM) (O [CH 2 CH 2 O] n CH 3) , or -OPO ^(OM ₁ ^{+) (} O [CH ₂ CH ₂ O] _n CH ₃ ) (wherein M and M ′ are independently of each other a hydrogen atom, a linear or branched (C ₁ -C ₆ ) alkyl group, linear Or a branched (C ₂ -C ₆ ) alkenyl group, a linear or branched (C ₂ -C ₆ ) alkynyl group, a cycloalkyl or a heterocycloalkyl (both of which are 5 to 6 ring members) represents configured), whereas _{one M} ^{1 +} and _M ^{2 +} is that independently of one another, a pharmaceutically acceptable Represents a cation, M ₃ ²⁺ represents a divalent cation the pharmaceutically acceptable, n represents represents phenyl which is substituted with a group of a a) an integer from 1 to 5, wherein the phenyl group, Included are compounds of formula (I), which are understood to be optionally substituted with one or more halogen atoms.

Preferably, W represents a group C—H, while A ₁ and A ₂ represent a hydrogen atom and a methyl group, respectively.

Alternatively, W represents the group C—H, while A ₁ and A ₂ together with the carbon atom carrying them form a cyclohexenyl or benzo ring optionally substituted with a halogen atom. .

In another embodiment of the invention, W represents a nitrogen atom, while A ₁ and A ₂ together with the carbon atom having them form a benzo ring.

  Preferably, T is methyl, aminomethyl, dimethylaminomethyl, morpholinylmethyl, (4-methyl-1-piperazinyl) methyl, (3aR, 6aS) -hexahydrocyclopenta [c] pyrrole-2 (1H) -Ylmethyl, (4,4-difluoropiperidin-1-yl) methyl, (4-cyclopentylpiperazin-1-yl) methyl, (4-cyclobutylpiperazin-1-yl) methyl, pyrrolidin-1-ylmethyl, piperidine- It represents a group selected from 1-ylmethyl or 2- (morpholin-4-yl) ethyl. Even more preferably, T represents a morpholinylmethyl or (4-methyl-1-piperazinyl) methyl group.

Preferably, R _a , R _b , R _c and R _d are each independently R ₇ , a halogen atom, a linear or branched (C ₁ -C ₆ ) alkoxy group, a hydroxy group, a linear group Represents a branched or branched polyhalo (C ₁ -C ₆ ) alkyl group, trifluoromethoxy group, —NR ₇ R ₇ ′, nitro, or a pair (R _a , R _b ), (R _b , R _c) ) Or (R _c , R _d ), one pair of substituents, together with the carbon atom having them, composed of 5 to 7 ring members and selected from oxygen and sulfur Forms a ring which may contain heteroatoms, and one or more carbon atoms of the ring as defined above are deuterated or halogen and linear or branched (C ₁ is understood may be substituted by -C ₆₎ 1 to 3 groups selected from alkyl .

In preferred compounds of the invention, R _a and R _d each represent a hydrogen atom, and (R _b , R _c ), together with the carbon atom bearing them, are the following groups: 3-dioxolane; optionally substituted 1,4-dioxane; cyclopentane; tetrahydrofuran; 2,3-dihydrofuran, or one of R _a , R _c, and R _d is Each represents a hydrogen atom, and R _b represents a hydroxy or methoxy group, a halogen atom, a trifluoromethyl or a trifluoromethoxy group. Even more preferably,
R _a and R _d each represent a hydrogen atom and (R _b , R _c ) together with the carbon atom having them form a 1,3-dioxolane group, or
R _a , R _c and R _d each represent a hydrogen atom, and R _b represents a halogen atom.

Alternatively, one or two of the radicals R _a , R _b , R _c and R _d represent a halogen atom, while the other represents hydrogen.

In another embodiment of the invention, R _a and R _d each represent a hydrogen atom, R _b represents a hydrogen, halogen, hydroxy or methoxy group and R _c represents the following groups: hydroxy, methoxy , Amino, 3-phenoxyazetidine, 2- (phenylsulfanyl) acetamide or 2- (phenoxy) acetamide.

Preferred groups R ₄ are: butyl; phenyl; 4-hydroxyphenyl; 4-methoxyphenyl; 4-methylphenyl; 3-chloro-4-hydroxyphenyl; 3-fluoro-4-hydroxyphenyl. Even more preferably, R ₄ represents a 4-hydroxyphenyl group.

In preferred compounds of the invention, R ₃ represents a linear (C ₁ -C ₆ ) alkyl (preferably butyl or 2-phenylethyl), cycloalkyl (preferably cyclohexyl), aryl or heteroaryl group, All of these are optionally substituted. Aryl and heteroaryl groups are particularly preferred. Finally, R ₃ is preferably phenyl, 1H-indole, benzothiophene, benzofuran, 2,3-dihydro-1H-indole, 1H-indazole, 2,3-dihydro-1H-isoindole, 1H-pyrrolo [2,3-b] pyridine, phenoxyphenyl, 2,3-dihydro-1H-pyrrolo [2,3-b] pyridine, represents a group selected from 1H-pyrrole, these groups optionally halogen, One selected from linear or branched (C ₁ -C ₆ ) alkyl, trifluoromethoxy, 4-methylpiperazinyl, linear or branched (C ₁ -C ₆ ) alkoxy and cyano Including the above substituents.

Preferred compounds according to the invention are the following groups:
N- (4-hydroxyphenyl) -1- {6-[(3S) -3- (morpholin-4-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3 -Benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide N- (4-hydroxyphenyl) -N- (1-methyl-1H-pyrrolo [2,3-b] pyridine- 5-yl) -1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxy Sole-5-yl) -4,5,6,7-tetrahydro-1H-indole-3-carboxamide 1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3 , 4-Dihydroiso Norin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -4,5-dimethyl-N- (1-methyl-2,3-dihydro-1H-pyrrolo [2,3- b] Pyridin-5-yl) -1H-pyrrole-3-carboxamide 1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinoline-2 ( 1H) -yl] carbonyl} phenyl) -N- (5-cyano-1,2-dimethyl-1H-pyrrol-3-yl) -N- (4-hydroxyphenyl) -4,5-dimethyl-1H-pyrrole -3-carboxamide N- (4-hydroxyphenyl) -N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroiso Norin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide N- (4-hydroxyphenyl) -N- (1H-indole-5 -Yl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1, 3-benzodioxol-5-yl) -1H-indole-3-carboxamide N- (4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1- (6- { [(3S) -3-[(4-Methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl ) -1H-India 3-Carboxamide 1- (5-chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl ] Carbonyl} phenyl) -N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide 1- (5-chloro-2-{[(3S) -3 -[(4-Methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -N- (1H-indole- 5-yl) -1H-indole-3-carboxamide N- (4-hydroxyphenyl) -1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2 , 3 4-tetrahydroisoquinolin-2-carbonyl] -2H-1,3-benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide and its enantiomers, diastereoisomers and pharmaceutically acceptable In addition salts with any possible acid or base.

［式中、Ａｌｋは（Ｃ_１−Ｃ_６）アルキル基を表し、Ｗ、Ａ_１、Ａ_２、Ｒ_ａ、Ｒ_ｂ、Ｒ_ｃ及びＲ_ｄは、式（Ｉ）のものと同義である］
の化合物を出発物質として用い、
次いで、前記式（ＩＩ）の化合物を、下記式（ＩＩＩ）：

［式中、Ｔ及びＲ_５は、式（Ｉ）のものと同義である］
の化合物とのペプチドカップリングに付して、下記式（ＩＶ）：

［式中、Ａｌｋは先に定義された通りであり、Ｗ、Ａ_１、Ａ_２、Ｒ_ａ、Ｒ_ｂ、Ｒ_ｃ、Ｒ_ｄ、Ｒ_５及びＴは、式（Ｉ）のものと同義である］
の化合物を生成し、
前記式（ＩＶ）の化合物のエステル官能基を加水分解して、対応するカルボン酸又はカルボキシラートを生成し、前記対応するカルボン酸又はカルボキシラートは、アミンＮＨＲ_３Ｒ_４（式中、Ｒ_３及びＲ_４は、式（Ｉ）のものと同義である）とカップリングさせ、そのようにして得られた化合物を、場合により塩基性条件下でピロリン酸又はリン酸化合物の作用に付して前記式（Ｉ）の化合物を生成してもよい前に、対応する塩化アシル又は無水物といった酸誘導体に変換してもよく、
前記式（Ｉ）の化合物は、従来の分離技術に従って精製してもよく、所望であれば、その薬学的に許容し得る酸又は塩基との付加塩に変換され、また場合により、従来の分離技術に従ってその異性体に分離され、
上記の方法の途上の適切と見なされた任意のときに、合成の試薬又は中間体のある種の基（ヒドロキシ、アミノ…）を、合成上の必要に応じて保護し、次いで脱保護してよいと理解されることを特徴とする方法に関する。 The present invention is also a process for the preparation of a compound of formula (I) comprising:
Formula (II) below:

[Wherein Alk represents a (C ₁ -C ₆ ) alkyl group, and W, A ₁ , A ₂ , R _a , R _b , R _c and R _d have the same meanings as those in formula (I)]
As a starting material,
Next, the compound of the formula (II) is converted into the following formula (III):

[Wherein T and R ₅ have the same meanings as those in formula (I)]
Subsequent to peptide coupling with a compound of formula (IV):

[Wherein Alk is as defined above, and W, A ₁ , A ₂ , R _a , R _b , R _c , R _d , R ₅ and T are as defined in formula (I). is there]
Produces a compound of
Hydrolysis of the ester functionality of the compound of formula (IV) to produce the corresponding carboxylic acid or carboxylate, wherein the corresponding carboxylic acid or carboxylate is an amine NHR ₃ R ₄ (wherein R ₃ and R ₄ is synonymous with that of formula (I) and the compound thus obtained is subjected to the action of pyrophosphoric acid or phosphoric acid compound, optionally under basic conditions. Before the compound of formula (I) may be formed , it may be converted into the corresponding acid derivative such as acyl chloride or anhydride,
The compound of formula (I) may be purified according to conventional separation techniques and, if desired, converted to its addition salt with a pharmaceutically acceptable acid or base, and optionally with conventional separation. Separated into its isomers according to technology,
At any time deemed appropriate in the course of the above method, certain groups (hydroxy, amino ...) of the synthetic reagents or intermediates may be protected as necessary for synthesis and then deprotected. It relates to a method characterized by being understood as good.

More specifically, when one of the groups R ₃ or R ₄ of the amine NHR ₃ R ₄ is substituted with a hydroxy functional group, the latter is replaced with a carboxylic acid formed from the compound of formula (IV). Prior to any coupling with the acid or with the corresponding acid derivative, the protected compound of formula (I) which has been subjected to a protection reaction in advance and subsequently undergoes a deprotection reaction, and then optionally It may be converted to one of the addition salts with pharmaceutically acceptable acids or bases.

［式中、Ｗ、Ａ_１、Ａ_２、Ｒ_ａ、Ｒ_ｂ、Ｒ_ｃ、Ｒ_ｄ、Ｒ_３及びＲ_４は、式（Ｉ）のものと同義である］
で定義される化合物を出発物質として用い、
次いで、前記式（Ｖ）の化合物を、下記式（ＩＩＩ）：

［式中、Ｔ及びＲ_５は、式（Ｉ）のものと同義である］
の化合物とのペプチドカップリングに付し、
そのようにして得られた化合物を、場合により塩基性条件下でピロリン酸又はリン酸化合物の作用に付して、前記式（Ｉ）の化合物を生成し、
前記式（Ｉ）の化合物は、従来の分離技術に従って精製してもよく、所望であれば、その薬学的に許容し得る酸又は塩基との付加塩に変換され、また場合により、従来の分離技術に従ってその異性体に分離され、
上記の方法の途上の適切と見なされた任意のときに、合成の試薬又は中間体のある種の基（ヒドロキシ、アミノ…）を、合成上の必要に応じて保護し、次いで脱保護してよいと理解される
ことを特徴とする方法により得てもよい。 Alternatively, the compound of formula (I) can be prepared by the following method of preparation, namely the following formula (V):

[Wherein W, A ₁ , A ₂ , R _a , R _b , R _c , R _d , R ₃ and R ₄ have the same meanings as those in formula (I)]
As a starting material,
Next, the compound of the formula (V) is converted into the following formula (III):

[Wherein T and R ₅ have the same meanings as those in formula (I)]
To peptide coupling with the compound of
The compound thus obtained is optionally subjected to the action of a pyrophosphate or phosphate compound under basic conditions to produce the compound of formula (I),
The compound of formula (I) may be purified according to conventional separation techniques and, if desired, converted to its addition salt with a pharmaceutically acceptable acid or base, and optionally with conventional separation. Separated into its isomers according to technology,
At any time deemed appropriate in the course of the above method, certain groups (hydroxy, amino ...) of the synthetic reagents or intermediates may be protected as necessary for synthesis and then deprotected. It may be obtained by a method characterized by being understood as good.

The compounds of formula (II), (III), (V) and the amine NHR ₃ R ₄ are either commercially available or can be obtained by one skilled in the art using conventional chemical reactions described in the literature.

  Pharmacological studies of the compounds of the present invention have shown that they have pro-apoptotic properties. The ability to reactivate the apoptotic process in cancerous cells is of great therapeutic interest in the treatment of cancer, autoimmune diseases and diseases of the immune system.

  More specifically, the compounds of the invention will be useful in the treatment of chemotherapeutic agents and radiation resistant cancers, malignant blood diseases and small cell lung cancer.

  Expected cancer treatments include, without any limitation, bladder, brain, breast and uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal and liver cancer, lymphoblastic leukemia, Mention may be made of treatment of non-Hodgkin lymphoma, melanoma, malignant blood disease, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer and small cell lung cancer. Among non-Hodgkin lymphomas, more preferable examples include follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, and marginal zone B-cell lymphoma.

  The present invention also relates to a pharmaceutical composition comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.

  More specifically, the pharmaceutical composition of the present invention is suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, oral, ophthalmic or respiratory administration, In particular, tablets or dragees, sublingual tablets, sachets, paquets, capsules, glossettes, troches, suppositories, creams, ointments, skin gels and drinking or injection ampoules be able to.

  The dosage will vary depending on the patient's gender, age and weight, route of administration, the nature of the therapeutic indication or the nature of any concomitant treatment, but as one or more doses per 24 hours, It is in the range of 0.01 mg to 1 g.

  Furthermore, the present invention also provides an association of a compound of formula (I) with an anticancer agent selected from genotoxic substances, fission toxins, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies, Pharmaceutical composition comprising the combination and its use in the manufacture of a medicament for use in the treatment of cancer.

  The compounds of the present invention may also be used in combination with radiation therapy in the treatment of cancer.

Finally, the compounds of the present invention may be conjugated to a monoclonal antibody or fragment thereof, or a scaffold protein that can or cannot be associated with a monoclonal antibody.
Antibody fragments can be understood as Fv, scFv, Fab, F (ab ′) ₂ , F (ab ′), scFv-Fc type or bispecific antibodies and generally have the same binding specificity as the antibody from which they are derived. Must have. According to the present invention, antibody fragments can be obtained starting from antibodies by methods such as digestion with enzymes such as pepsin and papain and / or cleavage of disulfide bridges by chemical reactions. In another method, the antibody fragments included in the present invention can be obtained by an automated peptide synthesizer such as those provided by genetic recombination techniques well known to those skilled in the art or by companies such as Applied Biosystems. Can be obtained by peptide synthesis.

  A scaffold protein that can or cannot be associated with a monoclonal antibody is understood to mean a protein that contains or does not contain an immunoglobulin fold and that provides similar binding ability as a monoclonal antibody. The person skilled in the art knows how to select a scaffold protein. More specifically, it is known that scaffold proteins should exhibit several characteristics to be selected (Skerra A., J. Mol. Recogn., 13, 2000). 167-187): good phylogenetic retention, robust structure with well-known three-dimensional molecular organization (such as crystallography or NMR), small size, no translation modification Or it must be of minor extent and easy to manufacture, express and purify. Such scaffold proteins include, but are not limited to, fibronectin (particularly the tenth fibronectin type III domain (FNfn10)), lipocalin, anticalin (Skerra A., J. Biotechnol., 2001, 74 (4): 257- 75), protein Z derived from domain B of staphylococcal protein A, thioredoxin A or repeating domains ("Ankyrin repeat" (Kohl et al., PNAS, 2003, vol.100, No.4, 1700-1705), "armadillo It can be of a structure selected from the group consisting of any protein having a "repeat", "leucine rich repeat" or "tetratricopeptide repeat".

  Mention may also be made of scaffold proteins derived from toxins (such as scorpions, insects, plants or mollusc toxins) and neuronal nitric oxide synthase (PIN).

  The following preparations and examples illustrate the invention without limiting it in any way.

General Procedure All reagents and anhydrous solvents were obtained from commercial sources and used without further purification or drying. Flash chromatography is performed on an ISCO CombiFlash Rf 200i instrument with a packed silica gel cartridge (SiliaSep ™ F60 (40-63 μm, 60 cm)). Thin layer chromatography was performed on 5 × 10 cm plates coated with Merck Type 60 _F254 silica gel. Microwave heating was performed using a CEM Discover (registered trademark) SP apparatus.

LC-MS for analysis
The compounds of the present invention can be produced using an Agilent HP1200 rapid-resolution instrument connected to a 6140 mass detector with a multimode ion source (m / z range 150 to 1000 atomic mass units (amu)) or an electrospray ionization source (m / z Characterization was performed by high performance liquid chromatography (HPLC-MS) connected to a mass spectrometer on an Agilent HP1100 instrument connected to a 1946D mass detector with range 150 to 1000 amu). The conditions and methods listed below are the same for both machines.
Detection: 230, 254 and 270 nm UV detection Injection volume: 2 μL
Mobile phase: A-water + 10 mMol / ammonium formate + 0.08% (v / v) formic acid, pH about 3.5
B-95% acetonitrile + 5% A + 0.08% (v / v) formic acid Method A (3.75 min; pos or pos / neg ionization)
Column: Gemini 5μm, C18, 30mm x 4.6mm (Phenomenex)
Temperature: 35 ° C
Slope:

Method B (1.9 minutes; pos or posit / neg ionization)
Column: Gemini 5μm, C18, 30mm x 4.6mm (Phenomenex)
Temperature: 35 ° C
Slope:

Preparative HPLC
Some of the compounds of the present invention were operated at a flow rate of 20 cm ³ .min ⁻¹ , fitted with a Gemini ™ 5 μm, C18 (2), 100 mm × 20 mm id (Phenomenex) column, with a diode array UV detector (210 -400 nm) and a fraction collector and purified by preparative HPLC on a Waters FractionLynx MS apparatus (using automatic purification system) combined with mass spectrometry. The gradient used for each compound is shown in Table 1.

At pH 4: Solvent A = 10 mM ammonium acetate in HPLC grade water + 0.08% v / v formic acid, Solvent B = 95% v / v HPLC grade acetonitrile + 5% v / v solvent A + 0.08% v / v formic acid At pH 9: solvent A = 10 mM ammonium acetate in HPLC grade water + 0.08% v / v ammonia solution, solvent B = 95% v / v HPLC grade acetonitrile + 5% v / v solvent A + 0.08% v / v ammonia solution

  The mass spectrometer is a Waters Micromass ZQ2000 instrument, operating in positive or negative mode electrospray ionization, with a molecular weight detection range of 150-1000.

Preparation 1: 2- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid To a solution of 8.3 g (48 mmol) of 2-aminobenzoic acid in acetic acid (20 mL) was added 4-oxo. 8.7 g of ethyl pentanoate (prepared according to the method described in WO 2005/040128) is added. The whole is then heated under reflux overnight. The reaction mixture is then evaporated to dryness and purified by chromatography on silica gel (dichloromethane / EtOH gradient). The title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; dmso-d6; 300K): 13.0 (m, 1H, OH); 7.91 (d, 1H, aryl); 7.70 (t, 1H, aryl); 7 .62 (t, 1H, aryl); 7.40 (d, 1H, aryl); 7.30 (s, 1H, pyrrole); 6.30 (s, 1H, pyrrole); 4.18 (q, 2H) _{, OC H 2 CH 3);} 1.95 (t, 3H, OCH 2 C H 3)
IR: ν: -OH: 2800-2000cm ^-1 acid; ν: C = O 1716 and ^{1667cm -1; ν: C = C} 1600cm -1

Preparation 2: 4- (Benzyloxy) -2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid 2-Aminobenzoic acid is converted to 2-amino-4-benzyloxybenzoic acid The title compound is obtained according to the procedure of Preparation 1.

Preparation 3: 2- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -4- (trifluoromethyl) benzoic acid 2-Aminobenzoic acid was converted to 2-amino-4- (trifluoro Substitution with methyl) benzoic acid gives the title compound according to the procedure of Preparation 1.

Preparation 4: 4-chloro-2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid Substituting 2-amino-4-chlorobenzoic acid for 2-aminobenzoic acid, The title compound is obtained according to the method of Preparation 1.

Preparation 5: 4-Fluoro-2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid Substituting 2-amino-4-fluorobenzoic acid for 2-aminobenzoic acid, The title compound is obtained according to the method of Preparation 1.

Preparation 6: 4,5-Dibromo-2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid 2-Aminobenzoic acid was converted to 2-amino-4,5-dibromobenzoic acid The title compound is obtained according to the procedure of Preparation 1.

Preparation 7: 2-Chloro-6- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid Substituting 2-amino-6-chlorobenzoic acid for 2-aminobenzoic acid, The title compound is obtained according to the method of Preparation 1.

Preparation 8: 2- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -5- (trifluoromethoxy) benzoic acid 2-Aminobenzoic acid was converted to 2-amino-5- (trifluoro Substitution with methoxy) benzoic acid gives the title compound according to the procedure of Preparation 1.

Preparation 9: 2- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -4,5-difluorobenzoic acid 2-Aminobenzoic acid is converted to 2-amino-4,5-difluorobenzoic acid The title compound is obtained according to the procedure of Preparation 1.

Preparation 10: 4-Bromo-2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid 2-Aminobenzoic acid was replaced with 2-amino-4-bromobenzoic acid, The title compound is obtained according to the method of Preparation 1.

Preparation 11: 6- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -1,3-benzodioxole-5-carboxylic acid 2-aminobenzoic acid to 6-amino-1 , 3-Benzodioxol-5-carboxylic acid (from 6-nitro-1,3-benzodioxole-5-carbaldehyde, literature: N. Mahindoo et al., Med Chem. Res. 14 (6) , 347, 2006) to give the title compound according to the method of Preparation 1.

Preparation 12: 4-Chloro-2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -5-fluorobenzoic acid 2-Aminobenzoic acid was converted to 2-amino-4-chloro-5 Substitution with fluorobenzoic acid gives the title compound according to the method of Preparation 1.

Preparation 13: 5-Bromo-2- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -benzoic acid Substituting 2-amino-5-bromobenzoic acid for 2-aminobenzoic acid The title compound is obtained according to the method of Preparation 1.

Preparation 14: 6- [3- (Methoxycarbonyl) -1H-indol-1-yl] -1,3-benzodioxole-5-carboxylic acid 2- (2-bromophenyl) -3-oxo in 20 mL of methanol Methyl propanoate (prepared according to Heterocycles, 2008 2973-2980) To a solution of 2 g (7.8 mmol), 6-amino-1,3-benzodioxole-5-carboxylic acid (reference: N. Mahindoo et al., 1.4 g (7.8 mmol) is added) (obtained according to the protocol from Med Chem. Res. 14 (6), 347, 2006). The reaction mixture is stirred for 48 hours at ambient temperature and then evaporated to dryness. Next, 73 mg (0.38 mmol) of CuI, 3.3 g (15.6 mmol) of K ₃ PO ₄ , 0.9 mL (15.6 mmol) of ethylene glycol and 31 mL of dimethylformamide (DMF) are added successively. The reaction mixture is then heated at 80 ° C. for 15 hours. The solvent is evaporated and 200 mL of 1M aqueous hydrochloric acid is added to the residue. The aqueous phase is extracted with ethyl acetate (3 x 100 mL). The organic phases are combined and dried over magnesium sulfate, then filtered and evaporated to dryness. The crude product so obtained is then purified by chromatography on silica gel (dichloromethane / methanol gradient) (performed before trituration in a dichloromethane / diisopropyl ether mixture) to give the desired product as a powder. Generate in the form of
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 12-13 (m, 1H, CO ₂ H); 8.10 (s, 1H, aromatic H); 8.05 (dd, 1H, 7.45 (s, 1H, aromatic H); 7.25 (m, 2H, H indole); 7.05 (d, 1H, H indole); 6.25 (s, 2H, methylene) Dioxy); 3.85 (s, 3H, OCH3)
IR: νOH: 3100-2500 cm ⁻¹ ; ν> C═O: 1687 cm ⁻¹ (split band)

Preparation 15: 4-Bromo-2- [3- (methoxycarbonyl) -1H-indol-1-yl] benzoic acid 6-amino-1,3-benzodioxole-5-carboxylic acid to 2-amino-4 Substituting bromobenzoic acid to give the title compound according to the method of Preparation 14.

Preparation 16: 4-chloro-2- [3- (methoxycarbonyl) -1H-indol-1-yl] benzoic acid 6-amino-1,3-benzodioxole-5-carboxylic acid to 2-amino-4 Substituting chlorobenzoic acid to give the title compound according to the procedure of Preparation 14.

Preparation 17: 2,4-Dichloro-6- [4- (ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] benzoic acid 2-Aminobenzoic acid was converted to 2-amino-4,6-dichlorobenzoic acid The title compound is obtained according to the procedure of Preparation 1.

Preparation 18: 6- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -2,3-dihydro-1H-indene-5-carboxylic acid Reference (T. Yoshino et al., Chemistry) The anthranilic acid derivative is prepared in two steps starting from 20 g (150 mmol) of 2,3-dihydro-1H-indene-5-amine according to the protocol from letters, 38 (3), 200, 2009). The title product is obtained with 8% of its regioisomer, which is removed by an acid-base wash.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 9.5-7.5 (m, 1H, COOH); 7.55 (s, 1H, aromatic H); 6.55 (s, 1H, aromatic H); 2.7 (m, 4H, H-indan); 1.95 (m, 2H, H-indan)
_{IR: ν: NH 2: 3494-3384cm} -1; ν: OH: 3000-2200cm -1 (OH ^{acid); cm -1; ν:>} C = O: 1672cm -1

Preparation 19: 6- [3- (Ethoxycarbonyl) -4,5,6,7-tetrahydro-1H-indol-1-yl] -1,3-benzodioxole-5-carboxylic acid Step A: (2 , 2-Diethoxycyclohexyl) ethyl acetate and ethyl (2-ethoxycyclohex-2-en-1-yl) ethyl acetate according to the method described in the literature (International Publication No. 2007/054739) 40 mL Starting from a solution of 15 g (81.4 mmol) of ethyl (2-oxocyclohexyl) acetate in 25 mL of absolute ethanol in the presence of (244 mmol) and 1.4 g (8.13 mmol) of APTS as catalyst, the title compound mixture is obtained. The reaction mixture is heated at 95 ° C. overnight and then concentrated to dryness. A mixture of the two compounds is obtained in the form of an oil and used as such in the next step.
¹ H-NMR: δ (300 MHz; CDCl ₃ ; 300 K): 4.60 (t, 1H); 4.17-4.09 (m, 4H); 3.76-3.58 (m, 4H); 3.47-3.41 (m, 3H); 3.11 (s, 1H); 2.71-2.63 (m, 2H); 2.58-2.40 (m, 1H); 37-2.09 (m, 4H); 2.07-1.97 (m, 4H); 1.91-1.33 (m, 8H); 1.31-1.16 (m, 14H)
R: ν:> C═O: 1740 cm ⁻¹ ester

Step B: Ethyl 3-oxo-2- (2-oxocyclohexyl) propanoate 2.15 g (89.5 mmol) sodium hydride in 40 mL anhydrous THF placed at 0 ° C. in an inert atmosphere (60% in oil) 20.6 g (77.8 mmol) of the mixture obtained in step A and 12.6 mL (155.6 mmol) of ethyl formate in a solution in 25 mL of THF are added dropwise. The whole is stirred for 2 hours at 0 ° C. and then for 12 hours at ambient temperature. The reaction mixture is hydrolyzed. The aqueous phase is acidified by adding concentrated HCl solution and then extracted with ethyl acetate. The organic phase is then dried over MgSO ₄ , filtered and concentrated to dryness. The desired product is obtained in the form of an oil.
¹ H-NMR: δ (300 MHz; CDCl ₃ ; 300 K): 8.4 (s, 1 H, C H 2 O); 4.25-4.1 (m, 2 H, aliphatic H, COOC H ₂ CH ₃ ) 2.9-2.75 (m, 1H, aliphatic H, CHO CH COOEt); 2.5-1.45 (m, 9H, aliphatic H, cyclohexanone); 1.3 (m, 3H, fat Group H, COOCH ₂ CH ₃ )

Step C: 6- [3- (Ethoxycarbonyl) -4,5,6,7-tetrahydro-1H-indol-1-yl] -1,3-benzodioxole-5-carboxylic acid Step in 20 mL acetic acid To a solution of 4 g (18.84 mmol) of the compound of B, then 6-amino-1,3-benzodioxole-5-carboxylic acid (reference: N. Mahindoo et al., Med Chem. Res. 14 (6 ), 347, 2006) 3.4 g (18.84 mmol) are added in small portions. The whole is heated at 110 ° C. for 2 hours. The reaction mixture is then concentrated to dryness while coevaporating with toluene. The solid so obtained is triturated in a mixture of pentane and diisopropyl ether (50/50), filtered and dried to produce the title product.
¹ H-NMR: δ (300 MHz; CDCl 3; 300 K): 7.5 (s, 1 H, H-pyrrole); 7.20 (s, 1 H, aromatic H); 6.70 (s, 1 H, aromatic H); 6.12 (s, 2H, O— CH ₂ —O); 4.28 (q, 2H, aliphatic H, COO CH ₂ CH ₃ ); 2.80 (m, 2H, aliphatic H, 2.20 (m, 2H, aliphatic H, tetrahydroindole); 1.75 (m, 4H, aliphatic H, tetrahydroindole); 1.30 (t, 3H, aliphatic H, COOCH ₂ CH ₃₎
IR: ν: OH acid: 2800-2300 cm ⁻¹ ; ν:> C═O: 1672 cm ⁻¹ (split band acid + ester); ν: aromatic> C═C <: 1616 cm ⁻¹ )

Preparation 20: 6- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -2,3-dihydro-1-benzofuran-5-carboxylic acid 2-aminobenzoic acid to 6-amino- Substituting 2,3-dihydro-1-benzofuran-5-carboxylic acid, the title compound is obtained according to the procedure of Preparation 1.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 8.00 (s, 1 H, H dihydrobenzofuran); 7.25 (d, 1 H, H pyrrole); 6.65 (s, 1 H, H 6.40 (d, 1 H, H pyrrole); 4.75 (t, 2 H, H dihydrobenzofuran); 4.30 (q, 2 H, COO CH ₂ CH ₃ ); 3.30 (t, 2H, H dihydrobenzofuran); 2.0 (s, 3H, CH ₃ -pyrrole); 1.30 (t, 3H, COOCH ₂ CH ₃ )
IR: ν: —OH: 3000-2000 cm ⁻¹ ; ν: C═O: 1702-1669 cm ⁻¹

Preparation 21: 6- [4- (Ethoxycarbonyl) -2-methyl-1H-pyrrol-1-yl] -1-benzofuran-5-carboxylic acid 2-aminobenzoic acid to 6-amino-1-benzofuran-5 Substitution with the carboxylic acid gives the title compound according to the procedure of Preparation 1.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 12.80 (broad s, 1H, COOH); 8.25 (s, 1H, H benzofuran); 8.20 (s, 1H, H pyrrole) 7.75 (s, 1H, H benzofuran); 7.30 (s, 1H, H pyrrole); 7.20 (s, 1H, H benzofuran); 6.30 (s, 1H, benzofuran); _{.20 (q, 2H, COO CH} 2 CH 3); 1.9 (s, 3H, CH 3 - pyrrole); 1.25 (t, 3H, COOCH 2 CH 3)
IR: ν: —OH: 2720-2450 cm ⁻¹ ; C═O: 1698-1682 cm ⁻¹

Preparation 22: 4-chloro-2- [4- (methoxycarbonyl) -2,3-dimethyl-1H-pyrrol-1-yl] benzoic acid (Synthetic uses of tosylmethyl isocyanide (TosMIC) Organic Reactions (Hoboken, NJ, United States) (2001), 57, No 418) 3.35 g (153.18 mmol) methyl 4-5-dimethyl-1H-pyrrole-3-carboxylate and 4-chloro-2-iodobenzoic acid 63 g (16.4 mmol) are dissolved in 50 mL of acetonitrile. To this is added copper powder (45μ) (280 mg, 4.37 mmol) and cesium carbonate (14.25 g, 43.74 mmol). The reaction mixture is heated under reflux for 12 hours. The progress of the reaction is monitored by liquid chromatography (LC). The suspension is allowed to return to ambient temperature, then filtered, washed with acetonitrile and evaporated to dryness. Dissolve the residue in ethyl acetate. The solution is then washed with 1M hydrochloric acid and then with saturated sodium chloride solution, dried over magnesium sulphate, filtered and then evaporated to dryness. The compound thus obtained is purified on a silica gel column using dichloromethane and ethanol as solvents.
Mass spectrometry (ESI ⁺ ):
Empirical formula: C ₁₅ H ₁₄ ClNO ₂
Monoisotopic mass = 307.07 Da
[M + H] ⁺ , measured value: 308.12
(Isotope ratio is consistent with one chlorine atom)

Preparation 1 ': [(3S) -1,2,3,4-Tetrahydroisoquinolin-3-ylmethyl] tert-butyl carbamate Step A: (3S) -3- (hydroxymethyl) -3,4-dihydro-1H Benzyl isoquinoline-2-carboxylate (3S) in solution in dichloromethane in the presence of benzyl chloroformate and triethylamine using the protocol from the literature (RB Kawthekar et al. South Africa Journal of Chemistry 63, 195, 2009) Starting from 15 g (91.9 mmol) of -1,2,3,4-tetrahydroisoquinolin-3-ylmethanol, this compound is obtained. After purification on silica gel (petroleum ether / AcOEt gradient), the title compound is obtained in the form of an oil.
¹ H-NMR: δ (300 MHz; DMSO-d6; 300 K): 7.33 (m, 5H, aromatic H, O-benzyl); 7.15 (s, 4H, aromatic H, H tetrahydroisoquinoline); 5.13 (s, 2 H, C H ₂ -Ph); 4.73 (d, 1 H, H tetrahydroisoquinoline); 4.47 (m, H, C H ₂ OH); 4.36 (m, 1 H, H tetrahydroisoquinoline); 4.28 (d, 1H, H tetrahydroisoquinoline); 3.39 (dd, 1H, CH ₂ OH); 3.23 (dd, 1H, CH ₂ OH); 2.93 (dd, 1H, H tetrahydroisoquinoline); 2.86 (dd, 1H, H tetrahydroisoquinoline)
IR: ν: OH: 3416 cm ⁻¹ ; ν: <C═O 1694 cm ⁻¹ ; ν: aromatic> C—H: 754 cm ⁻¹

Step B: (3S) -3- (azidomethyl) -3,4-dihydroisoquinoline-2 (1H) -benzyl carboxylate from literature (D. Page et al. J. Med. Chem, 44, 2387, 2001) Using the protocol, starting with 23 g of the compound obtained in step A in a solution of THF in the presence of diphenylphosphoryl azide and triphenylphosphine, this compound is obtained. After purification on silica gel (petroleum ether / AcOEt gradient), the title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.36 (m, 5H, aromatic H, O-benzyl); 7.19 (m, 4H, aromatic H, H tetrahydroisoquinoline); _{5.16 (s, 2H, CH 2} -Ph); 4.76 (d, 1H, H -tetrahydroisoquinoline); 4.53 (m, 1H, H -tetrahydroisoquinoline); 4.30 (m, 1H, H -tetrahydro 3.28 (m, 2H, CH ₂ N ₃ ); 3.06 (dd, 1H, H tetrahydroisoquinoline); 2.78 (dd, 1H, H tetrahydroisoquinoline);
IR: ν: N ₃ : 2095 cm ⁻¹ ; ν: <C═O: 1694 cm ⁻¹ ; aromatic> C—H: 754 cm ⁻¹

Step C: (3S) -3- (Aminomethyl) -3,4-dihydroisoquinoline-2 (1H) -carboxylate 20.9 g (64.5 mmol) of the azide compound obtained in Step B in 650 mL of THF To the solution are subsequently added 25.5 g (97.2 mmol) of triphenylphosphine and 157 mL of water. The whole is refluxed for 2.5 hours. The reaction mixture is then concentrated to dryness and the residual oil is then dissolved in isopropyl ether. A white precipitate appears; this is filtered off and washed with isopropyl ether. The filtrate is then concentrated to dryness (this is done prior to purification by chromatography on silica gel (CH ₂ Cl ₂ / MeOH gradient)). The title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.40 (m, 5H, aromatic H, O-benzyl); 7.20 (m, 4H, aromatic H, H tetrahydroisoquinoline); _{5.15 (s, 2H, CH 2} -Ph); 4.75-4.3 (m, 2H, H -tetrahydroisoquinoline); 4.30 (d, 1H, H -tetrahydroisoquinoline); 2.90 (m, 2H, CH ₂ NH ₂ ); 2.45 (m, 2H, H tetrahydroisoquinoline); 1.40 (m, 2H, NH ₂ )
IR: ν: NH ₂ : 3400-3300 cm ⁻¹ ; ν: <C═O: 1688 cm ⁻¹

Step D: (3S) -3-{[(tert-Butoxycarbonyl) amino] methyl} -3,4-dihydroisoquinoline-2 (1H) -carboxylic acid benzyl in 630 mL of dichloromethane 18.4 g of the compound obtained in Step C To a solution of (62.1 mmol), 17.5 mL (124 mmol) of triethylamine and 14.9 g (68.3 mmol) of di-tert-butyl dicarbonate (in small portions) are successively added. The whole is stirred for 2 hours at ambient temperature. The reaction mixture is then concentrated (done before adding ethyl acetate). The organic phase is washed successively with 1M HCl solution, saturated NaCl solution, saturated NaHCO ₃ solution and then saturated NaCl solution. After drying, concentrating to dryness and purification by chromatography on silica gel (petroleum ether / AcOEt gradient), the title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.35 (m, 5H, aromatic H, O-benzyl); 7.15 (m, 4H, aromatic H, H tetrahydroisoquinoline); 6.51 (m, 1H, NH Boc ); 5.12 (s, 2H, CH 2 -Ph); 4.76 (d, 1H, H -tetrahydroisoquinoline); 4.51 (m, 1H, H -tetrahydroisoquinoline 4.36 (d, 1H, H tetrahydroisoquinoline); 2.95 (m, 3H, H tetrahydroisoquinoline + CH ₂ NHBoc); 2.71 (d, 1H, H tetrahydroisoquinoline); 1.34 (s , 9H, NH Boc )
IR: ν: NH: 3351 cm ⁻¹ ; ν: <C═O: 1686 cm ⁻¹

Step E: [(3S) -1,2,3,4-Tetrahydroisoquinolin-3-ylmethyl] tert-butyl carbamate in 600 mL of ethyl acetate to a solution of 21 g (53 mmol) of the compound obtained in Step D in 10% carbon 2.1 g of supported palladium is added. The whole is stirred for 5 hours at ambient temperature under 1.3 bar molecular hydrogen pressure. The reaction mixture is then filtered (performed prior to concentration to dryness). The title product is obtained in the form of a solid.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.15 (m, 4H, aromatic H, H tetrahydroisoquinoline); 6.85 (t, 1H, NH Boc); 3.90 (m , 2H, H tetrahydroisoquinoline); 3.00 (m, 2H, CH ₂ NHBoc); 2.80 (m, 1H, H tetrahydroisoquinoline); 2.65 (dd, 1H, H tetrahydroisoquinoline); 2.40 (Dd, 1H, H tetrahydroisoquinoline); 1.40 (s, 9H, NH Boc )
IR: ν: NH: 3386-3205 cm ⁻¹ (NH amide); ν: <C═O: 1688 cm ⁻¹ ; ν: NH: 1526 cm ⁻¹ (NH amine)

Preparation 2 ': (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline Step A: (3S) -3- (4-morpholinylcarbonyl) -3,4 Benzyl dihydro-2 (1H) -isoquinolinecarboxylate 5 g (16 mmol) of (3S) -2-[(benzyloxy) carbonyl] -1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid in 160 mL of dichloromethane To the solution, 1.5 mL (17.6 mmol) of morpholine, and then 9 mL (64 mmol) of N, N, N-triethylamine, 1-ethyl-3- (3′-dimethylaminopropyl) -carbodiimide (EDC). 3 g (19.2 mmol) and 2.6 g (19.2 mmol) of hydroxybenzotriazole (HOBT) are added. The reaction mixture is stirred overnight at ambient temperature, then poured into ammonium chloride solution and extracted with ethyl acetate. The organic phase is then dried over magnesium sulfate (performed before filtering) and evaporated to dryness. The crude product so obtained is then purified by chromatography on silica gel (dichloromethane / methanol gradient). The product is obtained in the form of a foam.
¹ H-NMR: δ (400 MHz; dmso-d6; 353 ° K): 7.30 (m, 5H benzyl); 7.15 (m, 4 aromatic H); 5.2-5.0 ( m, 3H, 2H benzyl, 1H dihydroisoquinoline); 4.75-4.5 (2d, 2H dihydroisoquinoline); 3.55-3.3 (m, 8H morpholine); 3.15-2.9 (2dd) , 2H dihydroisoquinoline)
IR: ν:> C═O: 1694-1650 cm ⁻¹

Step B: benzyl (3S) -3- (4-morpholinylmethyl) -3,4-dihydro-2 (1H) -isoquinolinecarboxylate 5.3 g (13. 9 mmol) is added 14 mL (27.8 mmol) of BH ₃ Me ₂ S at ambient temperature. The whole is heated at 80 ° C. for 4 hours. Allow the mixture to return to ambient temperature and then add 7 mL (14 mmol) of BH ₃ Me ₂ S. The reaction mixture is again heated at 80 ° C. for 2 hours. The tetrahydrofuran is then evaporated and then methanol is added followed by 5.6 mL (27.8 mmol) of 5N hydrochloric acid. The mixture is stirred overnight at ambient temperature and then at 80 ° C. for 1 hour. The saturated NaHCO ₃ solution is then added to the reaction mixture placed at 0 ° C. until pH = 8 and extracted with ethyl acetate. The organic phase is then dried over magnesium sulfate (performed before filtering) and evaporated to dryness. The title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; dmso-d6; 353 ° K): 7.43-7.30 (unresolved peak, 5H benzyl); 7.19 (m, aromatic 4H); 5.16 (M, 2H, 2H benzyl); 4.79-4.29 (d, 2H dihydroisoquinoline); 4.58 (m, 1H dihydroisoquinoline); 3.50 (m, 4H morpholine); 3.02-2 .80 (dd, 2H dihydroisoquinoline); 2.42-2.28 (unresolved peak, 5H, 4H morpholine, 1H morpholine); 2.15 (dd, 1H morpholine)
IR: v:> CH: 2810 cm ⁻¹ ; v:> C═O: 1694 cm ⁻¹ ; v:> C—O—C <: 1114 cm ⁻¹ ; v:> CH—Ar: 751; 697 cm ^−1.

Step C: (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline A solution of 4.9 g (13.4 mmol) of the compound of Step B in 67 mL of ethanol was added to ambient temperature. At 0.980 g (20% by weight) of palladium dihydroxide. The reaction mixture is placed under 1.2 bar hydrogen pressure at ambient temperature for 4 hours. Pass this through Whatman filter, then rinse palladium several times with ethanol. The filtrate is evaporated to dryness. The title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.12-7.0 (unresolved peak, aromatic 4H); 3.92 (s, 2H tetrahydroisoquinoline); 3.60 ( 2.98 (m, 1H tetrahydroisoquinoline); 2.68 (dd, 1H tetrahydroisoquinoline); 2.5-2.3 (unresolved peak, 8H, 1H tetrahydroisoquinoline, 6H morpholine); , 1HNH)
IR: v:> NH: 3322 cm ⁻¹ ; v:> C—O—C <: 1115 cm ⁻¹ ; v:> CH—Ar: 742 cm ⁻¹

Preparation 3 ': (3S) -3-[(4-Methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline The procedure replaced the morpholine used in Step A with 1-methyl-piperazine. According to the method of Preparation 2 ′.

Preparation 4 ′: (3S) -3-[(3aR, 6aS) -Hexahydrocyclopenta [c] pyrrol-2 (1H) -ylmethyl] -1,2,3,4-tetrahydroisoquinoline Follow the procedure of Preparation 2 ′, replacing the morpholine used with (3aR, 6aS) -octahydrocyclopenta [c] pyrrole.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.05 (m, 4H, aromatic H, H tetrahydroisoquinoline); 3.90 (s, 2H, H tetrahydroisoquinoline); 2.85 ( m, 1H, H tetrahydroisoquinoline); 2.70 (dd, 1H, H tetrahydroisoquinoline); 2.7-2.3 (m, 6H); 2; 4-2.3 (2dd, 2H); 2-2.1 (2dd, 2H, bicyclic amine); 1.7-1.3 (2m, 6H, bicyclic amine)

Preparation 5 ′: (3S) -3-[(4,4-difluoropiperidin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline The procedure is to convert the morpholine used in Step A to 4,4-difluoro. Follow the procedure of Preparation 2 ′, substituting -1-piperidine.
¹ H-NMR: δ (300 MHz; DMSO-d6; 300 K): 10.2 (broad s, 1H, NH ₂ ⁺ ); 7.25 (m, 4H, aromatic H, H tetrahydroisoquinoline); 4.40 (S, 2H, H tetrahydroisoquinoline); 4.20 (m, 1H, H tetrahydroisoquinoline); 3.75-3.35 (m, 6H, H difluoropiperidine); 3.3-3.1 (2dd, 2H, H tetrahydroisoquinoline); 2.4 (m, 4H, H difluoropiperidine)
IR: ν: NH ₂ ⁺ : 2782-2381 cm ⁻¹

Preparation 6 ′: (3S) -3-[(4-cyclopentylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline The procedure replaced the morpholine used in Step A with 1-cyclopentylpiperazine. According to the method of Preparation 2 ′.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.20 (m, 4H, aromatic H, H tetrahydroisoquinoline); 4.30 (broad s, 2H, H tetrahydroisoquinoline); 3.70 (M, 1H, H tetrahydroisoquinoline); 3.50 (m, 3H, H piperazine); 3.10 (m, 4H); 3.1-2.75 (2m, 4H, H piperazine); 2.85 (Dd, 1H); 2.60 (m, 1H); 2.00 (m, 2H, H cyclopentyl); 1.75 (m, 4H, H cyclopentyl); 1.55 (m, 2H, H cyclopentyl)
IR: ν: NH ⁺ / NH ₂ ⁺ : 3550-2000 cm ⁻¹ ; ν: aromatic> CH—: 761 cm ⁻¹

Preparation 7 ': (3S) -3-[(4-Cyclobutylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline The procedure is to convert the morpholine used in Step A to 1-cyclobutylpiperazine. Follow the method of Preparation 2 ′, replaced.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.20 (m, 4H, aromatic H, H tetrahydroisoquinoline); 4.20 (2d, 2H, H tetrahydroisoquinoline); 3.55 ( m, 1H, H tetrahydroisoquinoline); 3.00 (dd, 1H, H tetrahydroisoquinoline); 2.85 (m, 1H); 2.75 (dd, 1H, H tetrahydroisoquinoline); 2.7-2. 2 (m, 8H, H piperazine); 2.65 (dd, 1H); 2.55 (dd, 1H); 2.1-1.5 (m, 6H, H cyclobutyl)
IR: ν: NH ⁺ : 2900-2050 cm ⁻¹ ; ν: <C═C <: 1603 cm ⁻¹ ; ν: aromatic> C—H: 754 cm ⁻¹

Preparation 8 ′: (3S) -3- (Pyrrolidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline The procedure is according to the method of Preparation 2 ′, replacing the morpholine used in Step A with pyrrolidine.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.10 (m, 4H, aromatic H, H tetrahydroisoquinoline); 3.90 (s, 2H, H tetrahydroisoquinoline); 2.90 ( m, 1H, H tetrahydroisoquinoline); 2.70 (dd, 1H, H tetrahydroisoquinoline); 2.5-2.4 (m, 7H); 1.7 (m, 4H, pyrrolidine)
IR: ν: NH: 3400-3300 cm ⁻¹

Preparation 9 ′: (3R) -3-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride Step A: {(3S) -2-[(4-methylphenyl) sulfonyl] -1,2,3 4-Tetrahydroisoquinolin-3-yl} methyl-4-methylbenzenesulfonate A solution of 30.2 g (185 mmol) of [(3S) -1,2,3,4-tetrahydroisoquinolin-3-yl] methanol in 750 mL of dichloromethane 91.71 g (481 mmol) of tosyl chloride and then 122.3 mL (740 mmol) of N, N, N-triethylamine (drop) are added in succession. The reaction mixture is then stirred for 20 hours at ambient temperature. It is then diluted with dichloromethane and washed successively with 1M HCl solution, saturated NaHCO ₃ solution, then saturated NaCl solution (until it is neutral). The organic phase is then dried over MgSO ₄ , filtered and concentrated to dryness. The resulting solid is then dissolved in a minimum amount of dichloromethane and then cyclohexane is added until a precipitate is formed. The precipitate is then filtered off and washed with cyclohexane. After drying, the title product is obtained in crystalline form.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.75 (d, 2H, aromatic H, ortho-O-tosyl); 7.6 (d, 2H, aromatic H, ortho-N-tosyl) 7.5 (d, 2H, aromatic H, meta O-tosyl); 7.3 (d, 2H, aromatic H, meta N-tosyl); 7.15-6.9 (m, 4H, Aromatic H, tetrahydroisoquinoline); 4.4.15 (dd, 2H, aliphatic H, tetrahydroisoquinoline); 4.25 (m, 1H, aliphatic H, tetrahydroisoquinoline); 4.0-3. 8 (2dd, 2H, aliphatic _H, CH 2 -O- tosyl); 2.7 (2dd, 2H, aliphatic H, _{tetrahydroisoquinoline); 2.45 (s, 3H,} O-SO 2 -Ph- CH _{3); 2.35 (s, 3H} , N-SO 2 -Ph- CH 3)
IR: ν: —SO ₂ : 1339-1165 cm ⁻¹

Step B: 8.15 g of LiAlH _{4 in} 800 mL of (3R) -3-methyl-2-[(4-methylphenyl) sulfonyl] -1,2,3,4-tetrahydroisoquinoline methyl tert-butyl ether (MTBE) (214 Is added to a suspension of 101.2 g (214.8 mmol) of the ditosyl compound obtained in step A in 200 mL of MTBE. The whole is then heated at 50 ° C. for 2 hours. Allow the mixture to cool and place at 0 ° C., then add 12 mL of 5N NaOH solution dropwise. The whole is stirred for 45 minutes at ambient temperature. The solid so obtained is then filtered off and washed with MTBE and then dichloromethane. The filtrate is then concentrated to dryness. The title product is obtained in the form of a solid.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.70 (d, 2H, aromatic H, ortho N-tosyl); 7.38 (d, 2H, aromatic H, meta N-tosyl) 7.2-7.0 (m, 4H, aromatic H, tetrahydroisoquinoline); 4.4 (m, 2H, aliphatic H); 4.3 (m, 1H, aliphatic H, tetrahydroisoquinoline) ; 2.85-2.51 (2dd, 2H, aliphatic H, _{tetrahydroisoquinoline); 2.35 (s, 3H,} N-SO 2 -Ph- CH 3); 0.90 (d, 3H, tetrahydroisoquinoline - CH ₃₎
IR: ν: —SO ₂ : 1322-1154 cm ⁻¹

Step C: (3R) -3-Methyl-1,2,3,4-tetrahydroisoquinoline In 500 mL of anhydrous methanol, a solution of 31.15 g (103.15 mmol) of the monotosyl compound obtained in Step B was added to a piece of magnesium (turnings 3.92 g (161 mmol) are added in small portions. The whole is stirred for 96 hours in the presence of ultrasound. The reaction mixture is then filtered and the solid is washed several times with methanol. The filtrate is then concentrated to dryness. After purification by column chromatography on silica gel (dichloromethane / EtOH / NH ₄ OH), the title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.05 (m, 4H, aromatic H, tetrahydroisoquinoline); 3.90 (m, 2H, aliphatic H, tetrahydroisoquinoline); 85 (m, 1H, aliphatic H, tetrahydroisoquinoline); 2.68-2.4 (2dd, 2H, aliphatic H, tetrahydroisoquinoline); 1.12 (d, 3H, tetrahydroisoquinoline - _CH 3); 2 .9-2.3 (m, broad, 1H, HN (tetrahydroisoquinoline))
IR: ν: —NH: 3248 cm ⁻¹

Step D: (3R) -3-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride In 20 mL of absolute ethanol, a solution of 14.3 g (97.20 mmol) of the compound obtained in Step C was added to 1M HCl in ether. 100 mL of the solution is added dropwise. The whole is stirred for 1 hour at ambient temperature and then filtered. The crystals so obtained are washed with ethyl ether. After drying, the title product is obtained in crystalline form.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 9.57 (m, broad, 2H, NH ₂ ⁺ (tetrahydroisoquinoline)); 7.22 (m, 4H, aromatic H, tetrahydroisoquinoline) 4.27 (s, 2H, aliphatic H, tetrahydroisoquinoline); 3.52 (m, 1H, aliphatic H, tetrahydroisoquinoline); 3.03-2.85 (2dd, 2H, aliphatic H, tetrahydro); isoquinoline); 1.39 (d, 3H, tetrahydroisoquinoline _-CH 3)
IR: ν: —NH ₂ ⁺ : 3000-2300 cm ⁻¹ ; ν: aromatic —CH: 766 cm ⁻¹

Preparation 10 ': (3S) -3- [2- (morpholin-4-yl) ethyl] -1,2,3,4-tetrahydroisoquinoline hydrochloride Step A: (3S) -3- (2-morpholino-2 -(Oxo-ethyl) -3,4-dihydro-1H-isoquinoline-2-carboxylate tert-butyl dichloromethane in 100 ml of [(3S) -2- (tert-butoxycarbonyl) -1,2,3,4-tetrahydro To a solution of 3 g (10.30 mmol) of isoquinolin-3-yl] acetic acid, 1.10 mL (11.32 mmol) of morpholine is added dropwise, and then 4.3 mL (30.9 mmol) of triethylamine, 2.20 g of 1,2-dichloromethane. (12.40 mmol) and 1.70 g (1.68 mmol) of hydroxybenzotriazole are also added dropwise. The whole is stirred for 15 hours at ambient temperature. The reaction mixture is then diluted with dichloromethane and washed successively with 1M HCl solution, saturated NaHCO ₃ solution, then saturated NaCl solution (until this is neutral). The organic phase is then dried over MgSO ₄ , filtered and concentrated to dryness. After purification by column chromatography on silica gel (dichloromethane / MeOH), the title product is obtained in the form of an oil.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.20-7.10 (m, 4H, aromatic H, tetrahydroisoquinoline); 4.70 (m, 1H, aliphatic H, CH tetrahydro isoquinoline); 4.75-4.20 (2m, 2H, CH 2 aliphatic H, with respect to N tetrahydroisoquinoline α); 3.60 (m, 8H , aliphatic H, morpholine); 3.00 and 2.70 (2dd, 2H, aliphatic H, tetrahydroisoquinoline); 2.50-2.20 (2d, 2H, aliphatic H, CH ₂ CO); 1.40 (s, 9H, ^t Bu)
IR: v: C = O: 1687; 1625 cm ⁻¹

Step B: 1- (Morpholin-4-yl) -2-[(3S) -1,2,3,4-tetrahydroisoquinolin-3-yl] ethanone hydrochloride Compound obtained in step A in 16 mL of dichloromethane. To a solution of 88 g (7.18 mmol) is added dropwise 80 mL of 1M HCl solution in ether. The whole is stirred for 15 hours at ambient temperature, then the suspension is filtered and the precipitate is washed with ether. After drying, the title product is obtained in the form of a solid.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 9.80-9.50 (m, 2H, NH ₂ ⁺ ); 7.30-7.10 (m, 4H, aromatic H, tetrahydro 4.30 (CH ₂ which is α to m, 2H, aliphatic H, N tetrahydroisoquinoline); 3.80 (m, 1H, aliphatic H, CH tetrahydroisoquinoline); 3.70-3. 40 (2m, 8H, aliphatic H, morpholine); 3.15 and 2.8 (m, 4H, aliphatic H, CH ₂ tetrahydroisoquinoline and _CH 2 CO)
IR: ν: —NH ₂ ⁺ : 2800-1900 cm ⁻¹ ; ν: C═O: 1620 cm ⁻¹

Step C: (3S) -3- [2- (morpholin-4-yl) ethyl] -1,2,3,4-tetrahydroisoquinoline hydrochloride 2.2 g of compound obtained in step B in 22 mL MTBE and 5 mL dichloromethane A solution of (7.44 mmol) is prepared. After cooling in an ice bath at 0 ° C., 15 mL (15 mmol) of a LiAlH ₄ solution in 1M tetrahydrofuran is added dropwise. Then stir at ambient temperature for 6 hours. This is placed at 0 ° C. and then 1 mL of 5N NaOH solution is added dropwise. The whole is stirred for 45 minutes at ambient temperature. The solid is then filtered off and washed with MTBE and then with dichloromethane, and the filtrate is concentrated to dryness. The oil so obtained is diluted with dichloromethane and 6.3 mL of 1M HCl solution in ether is added dropwise. The whole is stirred for 1 hour at ambient temperature and then filtered. The crystals so obtained are washed with ethyl ether. After drying, the title product is obtained in the form of a solid.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 11.35 + 9.80 (2 m, 2H, NH ₂ ⁺ ); 10.00 (m, H, NH ⁺ ); 7.20 (m, 4H) , Aromatic H, tetrahydroisoquinoline); 4.30 (CH ₂ which is α to s, 2H, aliphatic H, N tetrahydroisoquinoline); 4.00 + 3.85 (2m, 4H, aliphatic H, N to morpholine 3.70 (m, 1H, aliphatic H, CH tetrahydroisoquinoline);; 3.55-3.30 (m, 4H , CH and aliphatic H, with respect to O morpholine alpha _CH 2) that is against alpha CH ₂ morpholine); 3.15 (dd, 1H, aliphatic H, CH ₂ tetrahydroisoquinoline); 3.10 (m, 2H, aliphatic H, with respect to O morpholine is α CH); 2.90 (dd , 1H, fat Aliphatic H, CH ₂ tetrahydroisoquinoline); 2.30 + 2.15 (2m, 2H, aliphatic H, CH ₂ tetrahydroisoquinoline)
IR: ν: NH ⁺ / −NH ₂ ⁺ : between 3500 and 2250 cm ⁻¹ ; ν: C═C: weak 1593 cm ⁻¹ ; ν: aromatic C—H: 765 cm ⁻¹

Preparation 11 ′: (3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline The procedure follows the method of Preparation 2 ′, replacing the morpholine used in Step A with piperidine.
¹ H-NMR: δ (400 MHz; DMSO-d6; 300 K): 7.15 (m, 4H, aromatic H, H tetrahydroisoquinoline); 3.85 (s, 2H, H tetrahydroisoquinoline); 2.90 ( m, 1H, H tetrahydroisoquinoline); 2.75 (dd, 1H, H tetrahydroisoquinoline); 2.5-2.4 (m, 7H); 1.7 (m, 6H, piperidine)

Preparation 12 ′: N, N-dimethyl-1-[(3S) -1,2,3,4-tetrahydroisoquinolin-3-yl] methanimine The procedure replaces the morpholine used in Step A with N, N-dimethylamine. The method of Preparation 2 ′ is followed.

Preparation 1 ": 4-Benzyloxy -N- phenyl - in aniline acetonitrile (400 mL), 4-hydroxy -N- phenyl - aniline; To a solution of (30 g 162 _mmol), was added _{Cs 2 CO 3 58g (178mmol)} , Stir for 15 minutes at ambient temperature, then add benzyl bromide (22.5 mL; 178 mmol) dropwise and heat the reaction mixture under reflux for 4 hours After filtration and rinsing with acetonitrile, concentrate the filtrate. Chromatography on silica gel (petroleum ether / AcOEt gradient) and the title product is obtained in the form of a colorless solid.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.80 (m, 1H, NH); 7.45 (m, 2H, aryl); 7.40 (m, 2H, aryl); 7 .30 (m, 1H, aryl); 7.15 (s, 2H, aryl); 7.05 (d, 2H, aryl); 6.9-7.0 (m, 4H, aryl); 6.70 (T, 1H, aryl); 5.05 (s, 2H, benzyl)
IR: ν:> NH: 3408 cm ⁻¹

Preparation 2 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1-benzothiophen-5-amine Step A: 4-{[tert-butyl (dimethyl) silyl] oxy} aniline 4-aminophenol in THF in the presence of imidazole and tert-butyl (dimethyl) silyl chloride according to the protocol described in the literature (S. Knaggs et al., Organic & Biomolecular Chemistry, 3 (21), 4002-4010; 2005) Starting with, the title compound is obtained.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 6.45-6.55 (dd, 4H, aromatic H); 4.60 (m, 2H, NH ₂ -Ph); 0.90 _{(s, 9H, Si (CH} 2) 2 CH (CH 3) 2); 0.10 (s, 6H, Si (CH 2) 2 CH (CH 3) 2)
IR: ν: —NH ₂ ⁺ : 3300-3400 cm ⁻¹

Step B: N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1-benzothiophen-5-amine A solution of 6 g (26.9 mmol) of the compound obtained in Step A in 250 mL of anhydrous toluene. Sodium tert-butoxide (2.8 g; 23.5 mmol), Pd (OAc) ₂ (500 mg; 2.3 mmol), 1,1-bis (diphenylphosphino) ferrocene (2.6 g; 4.7 mmol) and 5-Bromobenzothiophene (5 g; 23.5 mmol) is added in succession. The whole is degassed under argon for 30 minutes and then heated at reflux for 17 hours. Allow the mixture to cool. The reaction mixture is concentrated to dryness, then dissolved in dichloromethane, filtered through celite and then concentrated to dryness again. The residue is then purified by chromatography on silica gel (CHCl ₂ / AcOEt gradient) to give the desired product in the form of a solid.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.90 (s, 1H, NH); 7.75 (d, 1H, aromatic CH); 7.65 (d, 1H, CH thiophene) 7.40 (d, 1H, aromatic CH); 7.30 (d, 1H, CH thiophene); 7.05 (d, 2H, aromatic CH); 7.00 (dd, 1H, aromatic) CH); 6.80 (d, 2H , aromatic ^{CH); 0.95 (s, 9H} , t Bu); 0.20 (s, 6H, SiCH 3)
IR: ν> NH: 3397 cm ⁻¹

Preparation 3 ″: tert-butyl 5- (phenylamino) -1H-indole-1-carboxylate The procedure is to convert the 5-bromobenzothiophene used to tert-butyl 5-bromo-1H-indole-1-carboxylate and Follow the method of Step 2 of Preparation 2 ″, replacing 4-{[tert-butyl (dimethyl) silyl] oxy} aniline with aniline.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 8.04 (s, 1H); 7.92 (d, 1H); 7.59 (s, 1H); 7.31 (d, 1H) 7.20 (t, 2H); 7.07 (dd, 1H); 7.03 (d, 2H); 6.76 (t, 1H); 6.61 (d, 1H); 1.63 (S, 9H)

Preparation 4 ″: tert-butyl 6- (phenylamino) -1H-indole-1-carboxylate The procedure is to convert the 5-bromobenzothiophene used to tert-butyl 6-bromo-1H-indole-1-carboxylate and Follow the method of Step 2 of Preparation 2 ″, replacing 4-{[tert-butyl (dimethyl) silyl] oxy} aniline with aniline.
¹ H-NMR: δ (400 MHz; CDCl ₃ ; 300 K): 8.00 (s, 1H); 7.92 (d, 1H); 7.50 (s, 1H); 7.31 (d, 1H) 7.20-7.03 (m, 4H); 6.76 (t, 1H); 6.80 (d, 1H); 1.65 (s, 9H);

Preparation 5 ″: 5-[(4-{[tert-Butyl (dimethyl) silyl] oxy} phenyl) amino] -1H-indole-1-carboxylate The procedure uses 5-bromobenzothiophene as 5- Follow the procedure of Preparation 2 ″, substituting tert-butyl bromo-1H-indole-1-carboxylate.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.85 (d, 1H); 7.78 (s, 1H); 7.55 (d, 1H); 7.15 (d, 1H) 6.95 (m, 3H); 6.75 (d, 2H); 6.58 (d, 1H); 1.65 (s, 9H); 1.00 (s, 9H); 0.2 (S, 6H)

Preparation 6 ": 4-{[tert-butyl (dimethyl) silyl] oxy} -3-chloro-N-phenylaniline The procedure is to use 5-bromobenzothiophene to bromobenzene and 4-{[tert-butyl ( Replaces (dimethyl) silyl] oxy} aniline with 4-{[tert-butyl (dimethyl) silyl] oxy} -3-chloroaniline (obtained according to protocol from Bioorg Med Chem Lett 22 (14), 4839-4843) In accordance with the method of Step 2 of Preparation 2 ″.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.2-7.1 (m, 3H); 7.15-7.05 (m, 2H); 7-6.8 (m, 4H); (s, 9H); 0.20 (s, 6H)

Preparation 7 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -3-phenoxyaniline The procedure is to convert 5-bromobenzothiophene used in Step B to 1-bromo-3-phenoxybenzene. Follow the method of Preparation 2 ″, replaced.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.98 (s, 1H, NH); 7.38 (d, 1H); 7.15 (m, 2H); 7.00 (d 6.95 (d, 2H); 6.75 (d, 2H); 6.70 (d, 2H); 6.50 (t, 1H); 6.35 (dd, 1H); 0 .95 (s, 9H, ^t Bu); 0.20 (s, 6H, SiCH ₃ )
IR: ν> NH: 3300 cm ⁻¹

Preparation 8 ": 4-{[tert-butyl (dimethyl) silyl] oxy} -N- (2-phenylethyl) aniline 4- [tert-butyl (dimethyl) in a mixture of isopropanol (270 mL) and water (27 mL) To a solution of silyl] oxyaniline (6 g; 26.9 mmol) and phenylacetaldehyde (4 g; 33.6 mmol) are added 17 g (270 mmol) of ammonium formate and Pd / C (2 g) After stirring at ambient temperature for 17 hours, The reaction mixture is filtered through celite and then concentrated to dryness, then the residue is diluted with saturated sodium bicarbonate solution (this is done before extraction with dichloromethane) and the organic phase is dried over MgSO ₄ . Concentrate to dryness and purify the residue by chromatography on silica gel (heptane / AcOEt gradient) to give the desired product in the form of an oil. .
IR: ν> NH: 3300 cm ⁻¹

Preparation 9 ″: N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1-benzofuran-5-amine The procedure is the same as 5-bromobenzothiophene used in Step B as 5-bromo-1- Follow the procedure of Preparation 2 ", substituting benzofuran.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.78 (s, 1 H, H furan); 7.70 (s, 1 H, NH); 7.40 (d, 1 H, aromatic H 7.20 (s, 1H, aromatic H); 6.95 (dd, 1H, aromatic H); 6.95 (d, 2H, aromatic H); 6.80 (d, 1H, H) furan); 6.70 (d, 2H, aromatic ^{H); 0.95 (s, 9H} , t Bu); 0.20 (s, 6H, SiCH 3)
IR: ν> NH: 3401 cm ⁻¹

Preparation 10 ": 4-{[tert-Butyl (dimethyl) silyl] oxy} -N- (4-methoxyphenyl) aniline The procedure is to convert 5-bromobenzothiophene used in Step B to 1-bromo-4-methoxybenzene. Follow the method of Preparation 2 ″, replaced.
¹ H-NMR: δ (400 MHz; dmso-d6; 300K): 4.52 (s, 1H, NH); 6.95 (d, 2H, aromatic H); 6.85 (d, (d, 1H) , Aromatic H); 7.20 (s, 1H, aromatic H); 6.95 (dd, 1H, aromatic H); 6.95 (d, H, aromatic H); 6.85 (d , 2H, aromatic H); 6.70 (d, 2H, aromatic H); 3.70 (s, 3H, OCH ₃ ); 1.00 (s, 9H, ^t Bu); 0.20 (s , 6H, SiCH ₃ )

Preparation 11 ": 4-{[tert-butyl (dimethyl) silyl] oxy} -N- [4- (trifluoromethoxy) phenyl] aniline The procedure is the same as 5-bromobenzothiophene used in Step B. Follow the procedure of Preparation 2 ", replacing with fluoromethyl ether.
¹ H-NMR: δ (400 MHz; CDCl 3; 300 K): 7.1-6.8 (m, 8H); 5.70 (s, 1H); 1 (s, 9H); 0.25 (s, 6H) )

Preparation 12 ": tert-butyl 5-[(4-methylphenyl) amino] -1H-indole-1-carboxylate The procedure uses 5-bromobenzothiophene to tert-bromo-5H-1indole-1-carboxylate Follow the procedure of Preparation B, Step B, substituting 4-butyl and 4-{[tert-butyl (dimethyl) silyl] oxy} aniline with 4-methylaniline.
¹ H-NMR: δ (400 MHz; CDCl ₃ ; 300 K): 8.0 (s, 1 H); 7.5 (m, 1 H); 7.1-6.9 (m, 6 H); 6.45 ( d, 1H); 2.25 (s, 3H); 1.65 (s, 9H)

Preparation 13 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -3-chloro-4-fluoroaniline The procedure is the same as 5-bromobenzothiophene used in Step B as 4-bromo-2 -Follow the procedure of Preparation 2 ", substituting chloro-1-fluorobenzene.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 8.0 (s, 1H); 7.3 (t, 1H); 7.0-6.7 (m, 6H); 1.00 (S, 9H); 0.20 (s, 6H)

Preparation 14 ": 4-{[tert-Butyl (dimethyl) silyl] oxy} -3-chloro-N- (4-methylphenyl) aniline The procedure uses 5-bromobenzothiophene as 1-bromo-4-methylbenzene In addition, 4-{[tert-butyl (dimethyl) silyl] oxy} aniline is converted into 4-{[tert-butyl (dimethyl) silyl] oxy} -3-chloroaniline (Reference: Bioorg Med Chem Lett 22 (14), Follow the method of Step 2 of Preparation 2 ", substituting for the protocol from 4839-4843).
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.90 (s, 1H, NH); 7.00 (m, 3H); 6.90 (m, 4H); 2.20 (s ^{, 3H); 1.00 (s,} 9H, t Bu); 0.20 (s, 6H, SiCH 3)

Preparation 15 ": 4-{[tert-Butyl (dimethyl) silyl] oxy} -3-chloro-N- [4- (propan-2-yl) phenyl] aniline The procedure uses 5-bromobenzothiophene as 1- Bromo-4- (propan-2-yl) benzene and 4-{[tert-butyl (dimethyl) silyl] oxy} aniline into 4-{[tert-butyl (dimethyl) silyl] oxy} -3-chloroaniline According to the procedure of preparation 2 ″, step B, replaced by (obtained according to the protocol from literature: Bioorg Med Chem Lett 22 (14), 4839-4843).
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.12 (s, 1H, NH); 7.10 (d, 2H); 6.95 (d, 2H); 6.85 (m , 1H); 6.80 (d, 1H); 2.85 (m, 1H); 1.25 (d, 6H); 1.05 (s, 9H, ^t Bu); 0.25 (s, 6H) , SiCH ₃ )

Preparation 16 ″: tert-butyl 5-[(4-methylphenyl) amino] -1H-indazole-1-carboxylate The procedure uses 5-bromobenzothiophene to tert-bromo-5H-1indazole-1-carboxylic acid tert Follow the method of Step B of Preparation 2 ″, replacing 4-butyl and 4-{[tert-butyl (dimethyl) silyl] oxy} aniline with 4-methylaniline.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 8.25 (s, 1H); 8.15 (s, 1H); 7.95 (d, 1H); 7.40 (d, 1H) 7.30 (dd, 1H); 7.08 (d, 2H); 7.02 (d, 2H); 2.25 (s, 3H); 1.65 (s, 9H)

Preparation 17 ": N- (4-{[tert-Butyl (dimethyl) silyl] oxy} -3-chlorophenyl) -1-methyl-1H-indole-5-amine The procedure uses 5-bromobenzothiophene as 5- Bromo-1-methyl-1H-indole and 4-{[tert-butyl (dimethyl) silyl] oxy} aniline into 4-{[tert-butyl (dimethyl) silyl] oxy} -3-chloroaniline (reference: The procedure of Preparation 2 ", step B, is followed, substituting for the protocol from Bioorg Med Chem Lett 22 (14), 4839-4843).
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.70 (s, 1H); 7.35 (d, 1H); 7.25 (s, 1H); 7.28 (d, 1H 6.92 (d, 1H); 6.85 (m, 3H); 6.30 (d, 1H); 3.75 (s, 3H); 1.00 (s, 9H); 0.20 (S, 6H)

Preparation 18 ": 5-[(4-{[tert-butyl (dimethyl) silyl] oxy} -3-chlorophenyl) amino] -1H-indole-1-carboxylate The procedure is 5-bromobenzothiophene used To tert-butyl 5-bromo-1H-indole-1-carboxylate and 4-{[tert-butyl (dimethyl) silyl] oxy} aniline to 4-{[tert-butyl (dimethyl) silyl] oxy}- Follow the procedure of Preparation 2 ″, Step B, substituting 3-chloroaniline (obtained according to the protocol from Bioorg Med Chem Lett 22 (14), 4839-4843).
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 8.0 (s, 1H); 7.9 (d, 1H); 7.6 (d, 1H); 7.25 (d, 1H 7.1-6.8 (m, 4H); 6.60 (d, 1H); 1.60 (s, 9H), 1.00 (s, 9H); 0.20 (s, 6H)

Preparation 19 ″: tert-butyl 4- (4-methylphenylamino) piperidine-1-carboxylate To a solution of 4 g (20 mmol) tert-butyl 4-aminopiperidine-1-carboxylate in dichloromethane was added (4-methylphenyl). ) Boronic acid (5.4 g; 40 mmol), triethylamine (5.6 mL; 40 mmol) and copper acetate (3.6 g; 20 mmol) are added The reaction mixture is stirred at ambient temperature for 24 hours and then at reflux for 17 hours. After evaporation to dryness, the residue is dissolved in ethyl acetate and washed with 1N hydrochloric acid, water and brine The organic phase is dried over MgSO ₄ and then concentrated to dryness and chromatographed on silica gel (CH ₂ Cl ₂ / AcOEt gradient) The title product is obtained in the form of a solid.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 6.85 (d, 2H); 6.50 (d, 2H); 5.65 (d, 1H); 3.85 (m, 2H) 3.35 (m, 1H); 2.90 (m, 2H); 2.15 (s, 3H); 2.15 (s, 3H); 1.85 (m, 2H); 1.40 (S, 9H), 1.20 (m, 2H)

Preparation 20 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1-methylpiperidin-4-amine 4- [tert-butyl (dimethyl) silyl] oxyaniline (5 g) in dichloromethane 22.4 mmol) and 1-methylpiperidin-4-one (2.5 g; 22.4 mmol) are added in portions with sodium triacetoxyborohydride (4.8 g; 22.4 mmol). After 24 hours of stirring, the reaction mixture is slowly poured into sodium bicarbonate solution, the aqueous phase is extracted with dichloromethane, the organic phase is dried over MgSO ₄ , concentrated to dryness and the residue is chromatographed on silica gel. Purification by (CH ₂ Cl ₂ / MeOH gradient) produces the desired product in solid form.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 6.62 (2d, 4H); 3.15 (m, 1H); 2.88-2.18 (m, 4H); 2.30 (S, 3H); 1.98-1.48 (m, 4H); 0.98 (s, 9H); 0.15 (s, 6H)

Preparation 21 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -3- (4-methylpiperazin-1-yl) aniline The procedure is analogous to 5-bromobenzothiophene used in Step B. Follow the procedure of Preparation 2 ", substituting 1- (3-bromophenyl) -4-methylpiperazine.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.68 (s, 1H); 7.00 (t, 1H); 6.96 (d, 2H); 6.74 (d, 2H) 6.46 (m, 1H); 6.4-6.35 (m, 2H); 3.04 (m, 4H); 2.42 (m, 4H); 2.20 (s, 3H) 0.95 (s, 9H); 0.16 (s, 6H)

Preparation 22 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -2-methyl-2,3-dihydro-1H-isoindole-5-amine The procedure is as used in Step B -Follow the procedure of Preparation 2 ", replacing bromobenzothiophene with 5-bromo-2-methyl-2,3-dihydro-1H-isoindole.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.02 (d, 1H); 6.95 (d, 2H); 6.75 (m, 4H); 5.45 (s, 1H ); 3.85 (s, 4H); 2.78 (s, 3H); 1.00 (s, 9H); 0.20 (s, 6H)

Preparation 23 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1- [2- (morpholin-4-yl) ethyl] -1H-indole-5-amine Step A: 5 -Bromo-1- [2- (morpholin-4-yl) ethyl] -1H-indole To a suspension of NaH (4.5 g; 112 mmol) in anhydrous THF (300 mL) was added 5-bromoindole (10.4 g). 51 mmol) is added in small portions at 0 ° C. After stirring for 20 minutes at 0 ° C., 4- (2-chloroethyl) morpholine hydrochloride (10.4 g; 56 mmol) is added in small portions over 1 hour. after overnight then five hours at 80 ° C., the reaction mixture is poured into a mixture of aqueous sodium bicarbonate and dichloromethane. the aqueous phase is extracted with dichloromethane. the organic phase is dried over MgSO _4, concentrated to dryness Purification of the residue by chromatography (CH 2 _Cl 2 _/ MeOH gradient) on silica gel Te, the desired product, provided in the form of a slightly yellow oil.
¹ H-NMR: δ (400 MHz; CDCl ₃ ; 300 K): 7.75 (d, 1H); 7.30 (dd, 1H); 7.20 (d, 1H); 7.15 (d, 1H) 6.40 (d, 1H); 4.20 (t, 2H); 3.70 (m, 4H); 2.75 (t, 2H); 2.45 (m, 4H);

Step B: 5-Bromo-1- [2- (morpholin-4-yl) ethyl] -1H-indole The procedure replaces 5-bromobenzothiophene used in Step B with the compound obtained in Step A, Preparation 2. Is followed.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 K): 7.35 (d, 1H); 7.15 (s, 1H); 6.85 (d, 3H); 6.70 (d, 2H) 7.30 (d, 1H); 6.25 (d, 1H); 4.20 (t, 2H); 3.55 (m, 4H); 2.65 (t, 2H); 2.45 (M, 4H); 1.45 (s, 9H), 0.15 (s, 6H)

Preparation 24 ": N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1-methyl-1H-pyrrolo [2,3-b] pyridin-5-amine The procedure is used in Step B Preparation 2 in which 5-bromobenzothiophene was replaced by 5-bromo-1-methyl-1H-pyrrolo [2,3-b] pyridine (obtained according to the protocol from Heterocycles, 60 (4), 865, 2003) Is followed.
IR: ν: —NH—: 3278 cm ⁻¹ ; ν: aromatic —C═C— moiety: 1605 cm ⁻¹

Preparation 25 ": 4-{[tert-butyl (dimethyl) silyl] oxy} -N-phenylaniline A solution of 12 g (64.7 mmol) of 4-anilinophenol in 200 mL of acetonitrile at 6.7 g of imidazole at ambient temperature ( 97.05 mmol) and 11.7 g (77.64 mmol) of tert-butyl (chloro) dimethylsilane are added, the whole is stirred for 4 hours at 70 ° C. The reaction mixture is then poured into water and extracted with ether. The organic phase is then dried over magnesium sulphate and then filtered and evaporated to dryness.The crude product so obtained is then subjected to column chromatography on silica gel (petroleum ether / dichloromethane gradient). The title product is obtained in the form of a powder.
¹ H-NMR: δ (400 MHz; dmso-d6; 300 ° K): 7.84 (s, 1HNH); 7.17 (t, 2H aniline); 6.98 (d, 2H phenoxy); 6.94 (D, 2H aniline); 6.76 (d, 2H phenoxy); 6.72 (t, 1H aniline); 0.95 (s, 9H tert-butyl); 0.15 (s, 6H dimethyl)
IR: ν:> NH: 3403 cm ⁻¹ ; ν:> Ar: 1597 cm ⁻¹

Preparation 26 ": 4-({4-[(tert-butyldimethylsilyl) oxy] phenyl} amino) -1,5-dimethyl-1H-pyrrole-2-carbonitrile Step A: 4-Bromo-1,5- Dimethyl-1H-pyrrole-2-carbonitrile Using a dropping funnel, a solution of bromine (6.58 mL, 0.13 mol) in acetic acid (60 mL) was added to 1,5-dimethyl-1H-pyrrole in acetic acid (300 mL). The solution is added dropwise to a solution of 2-carbonitrile (15.0 g, 0.12 mol), the whole is stirred for 24 hours at ambient temperature, and the reaction mixture is then poured into a beaker containing 300 mL of water. Filter off and rinse with water, then dissolve it in dichloromethane (300 mL) and wash the organic phase with brine, dry over sodium sulfate, filter and concentrate under reduced pressure to give the desired product as a solid of Give in Thailand.
¹ H-NMR: (CDCl ₃ ) δ ppm: 2.25 (s, 3H), 3.67 (s, 3H), 6.74 (s, 1H)

Step B: 4-({4-[(tert-Butyldimethylsilyl) oxy] phenyl} amino) -1,5-dimethyl-1H-pyrrole-2-carbonitrile The compound of the previous step in toluene (20 mL) ( 1.5 g, 7.53 mmol), 4-[(tert-butyldimethylsilyl) oxy] aniline (2.02 g, 9.04 mmol), sodium tert-butoxide (1.45 g, 15.06 mmol) and 2-di- A solution of tert-butylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl (0.13 g, 0.30 mmol) is purged with nitrogen. Tris (dibenzylideneacetone) dipalladium (0) (0.28 g, 0.30 mmol) is added and the reaction mixture is then heated at 90 ° C. until the reaction is complete (monitored by TLC). Heat is turned off and the mixture is allowed to return to ambient temperature. Water (75 mL) is added and the mixture is extracted with ethyl acetate (3 × 75 mL). The combined organic phases are washed with brine and then concentrated. The crude product is absorbed onto silica gel and purified by flash chromatography on silica gel using a mixture of ethyl acetate and heptane (0-30%).
The product so obtained is dissolved in heptane with warming and precipitated with stirring at ambient temperature and then at 0 ° C. The solid is filtered off and the operation is repeated on the filtrate to give the desired compound in the form of a solid.
¹ H-NMR: (400 MHz, CDCl ₃ ) δ ppm: 0.15 (s, 6H), 0.97 (s, 9H), 2.13 (s, 3H), 3.66 (s, 3H), 4 .68 (br.s, 1H), 6.49 (d, J = 8.5 Hz, 2H), 6.64 (s, 1H), 6.66 (d, J = 8.7 Hz, 2H)
¹³ C-NMR (100 MHz, CDCl 3) δ ppm: 4.34, 9.72, 18.30, 25.88, 32.94, 101.27, 114.37, 114.70, 116.41, 120.73 , 124.52, 131.23, 141.54, 148.27
MS (ESI ⁺ ): [M + H] ⁺ measured value: 342.3

The amines NHR ₃ R ₄ in which R ₃ and R ₄ each independently represent an aryl or heteroaryl group are described in literature (Surry DS et al., Chemical Science, 2011, 2, 27-50, Charles MD et al. al., Organic Letters, 2005, 7, 3965-3968). Reactions protecting the hydroxy functionality of 4-anilinophenol described in Preparation 25 "can be performed using a variety of secondary amines NHR ₃ R ₄ having one or more hydroxy functionality (as defined herein above). As long as they are commercially available, secondary amines having at least one hydroxy substituent can be directly attached in protected form (ie, the hydroxy functionality is Synthesis may be carried out starting from a pre-protected reagent, of which tert-butyl (dimethyl) silyloxy and benzyloxy are particularly preferred.

Among the amines NHR ₃ R ₄ having a hydroxy substituent used for the synthesis of the compounds of the present invention, 4- (4-toluidino) phenol, 4- (4-chloroanilino) phenol, 4- (3-fluoro -4-methylanilino) phenol, 4- [4- (trifluoromethoxy) anilino] phenol, 4- [4-hydroxyanilino] phenol, {4-[(1-methyl-1H-indol-6-yl) amino Phenyl} methanol, 4- (2,3-dihydro-1H-indol-6-ylamino) phenol, 4-[(1-methyl-2,3-dihydro-1H-indol-6-yl) amino] phenol, 4-[(1-Methyl-1H-indol-6-yl) amino] phenol, 4-[(1-Methyl-1H-indol-6-yl) Mino] cyclohexanol, 4-[(1-methyl-1,2,3,4-tetrahydro-6-quinolinyl) amino] phenol, 4-[(4-methyl-3,4-dihydro-2H-1,4 -Benzoxazin-7-yl) amino] phenol, 4- [4- (diethylamino) anilino] phenol, 4- (2,3-dihydro-1H-inden-5-ylamino) phenol, 4-[(1-methyl) -1H-indazol-5-yl) amino] phenol, 4-[(1'-methyl-1 ', 2'-dihydrospiro [cyclopropane-1,3'-indole] -5'-yl) amino] phenol 4-[(1,3,3-trimethyl-2,3-dihydro-1H-indol-5-yl) amino] phenol, 4- [4-methoxy-3- (trifluoromethyl) anily No] phenol, 4- [4- (methylsulfanyl) -3- (trifluoromethyl) anilino] phenol, 2-fluoro-4-[(1-methyl-1H-indol-5-yl) amino] phenol, 4 -[(1-ethyl-1H-indol-5-yl) amino] phenol, 4-[(1-ethyl-2,3-dihydro-1H-indol-5-yl) amino] phenol, 4-[(1 -Isopropyl-2,3-dihydro-1H-indol-5-yl) amino] phenol, 4- (butylamino) phenol, 3-[(1-methyl-1H-indol-5-yl) amino] -1- Propanol, 4-[(1-methyl-1H-indol-5-yl) amino] -1-butanol, 4-[(3-fluoro-4-methylphenyl) amino] pheno 4-[(3-chloro-4-methylphenyl) amino] phenol, 4-[(4-fluorophenyl) amino] phenol, 4-[(1-methyl-1H-pyrrolo [2,3-b] pyridine -5-yl) amino] phenol, 4-[(4-fluorophenyl) amino] phenol, 4-[(2-fluorophenyl) amino] phenol, 4-[(3-fluorophenyl) amino] phenol, 4- [(2,4-difluorophenyl) amino] phenol, 4-[(3,4-difluorophenyl) amino] phenol, 3-[(4-hydroxyphenyl) amino] benzonitrile, 4-[(3-methoxyphenyl) ) Amino] phenol, 4-[(3,5-difluorophenyl) amino] phenol, 4-[(3-methylphenyl) amino] pheno 4-[(4-hydroxyphenyl) amino] benzonitrile, 4-[(3-chlorophenyl) amino] phenol, 4- (pyrimidin-2-ylamino) phenol, 4-[(cyclobutylmethyl) amino] phenol 2-[(4-hydroxyphenyl) amino] benzonitrile, 4-{[(1-methyl-1H-pyrazol-4-yl) methyl] amino} phenol, 4-[(cyclopropylmethyl) amino] phenol, 4-{[(1-methyl-1H-pyrazol-3-yl) methyl] amino} phenol, 4- (but-2-yn-1-ylamino) phenol, 4- (pyrazin-2-ylamino) phenol, 4 -(Pyridin-2-ylamino) phenol, 4- (pyridazin-3-ylamino) phenol, 4- (pyrimidine- 5-ylamino) phenol, 4- (pyridin-3-ylamino) phenol, 4-[(3,5-difluoro-4-methoxyphenyl) amino] phenol, 4- (pyridin-4-ylamino) phenol, 4- [ (3-Fluoro-4-methoxyphenyl) amino] phenol, 2- (phenylamino) pyrimidin-5-ol, 5-[(4-hydroxyphenyl) amino] -2-methoxybenzonitrile and 4-{[3- Mention may be made of (trifluoromethyl) phenyl] amino} phenol.

  The hydroxy functions of the secondary amines listed above are protected beforehand with a suitable protecting group prior to any coupling with the acid derivative of the compound of formula (IV) as defined in the general method above. The

Preparation 2a: N- [4- (benzyloxy) phenyl] -N-phenyl-1H-indole-3-carboxamide Step A: 1-{[2- (trimethylsilyl) ethoxy] methyl} -1H-indole-3-carboxylic Methyl acid anhydrous tetrahydrofuran (200 mL) and methyl 1H-indole-3-carboxylate (20 g, 114.17 mmol) were cooled to 0 ° C., then 60% sodium hydride in oil (9.12 g, 228 mmol) was added. The whole is stirred for 10 minutes under nitrogen. [2- (Chloromethoxy) ethyl] trimethylsilane (24.25 mL, 137 mmol) is added and the reaction mixture is stirred at ambient temperature under nitrogen for about 16 hours. The reaction mixture is made inert with water and extracted with ethyl acetate, dried over magnesium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica gel with a gradient of isohexane to isohexane (10%) / ethyl acetate mixture to give the compound in the form of an oil.
LC / MS (C ₁₆ H ₂₃ NO ₃ Si) 306 [M + H] ⁺ ; RT 2.75 (Method A)
(RT is understood to refer to retention time)

Step B: N- [4- (benzyloxy) phenyl] -N-phenyl-1-{[2- (trimethylsilyl) ethoxy] methyl} -1H-indole-3-carboxamide cooled to −78 ° C. under nitrogen, To a solution of 4- (benzyloxy) -N-phenylaniline (8.59 g, 31.2 mmol) in tetrahydrofuran (40 mL) is added lithium bis (trimethylsilyl) amide (1M, 43 mL, 43 mmol). After 10 minutes, the indole obtained in step A in 40 mL of tetrahydrofuran is added and the reaction mixture is allowed to warm to ambient temperature again (this is done before heating to 50 ° C. under nitrogen for about 16 hours). ). The reaction mixture is partitioned between ethyl acetate and water according to its solubility, the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product is purified on silica gel with a gradient of isohexane to isohexane (20%) / ethyl acetate mixture to give an oil.
_{LC / MS (C 34 H 36} N 2 O 3 Si) 549 [M + H] +; RT2.95 ( Method A)

Step C: N- [4- (Benzyloxy) phenyl] -N-phenyl-1H-indole-3-carboxamide The compound obtained in Step B (14.24 g, 25.95 mmol) and ethylenediamine (5.22 mL) in tetrahydrofuran. , 77.85 mmol), TBAF (1M, 78 mL, 78 mmol) is added and the mixture is heated under reflux for about 16 hours under nitrogen. The reaction mixture is concentrated and partitioned between ethyl acetate and brine according to its solubility. The organic phase is then dried over magnesium sulfate, filtered and stirred with CaCO ₃ (6.5 g) and ion exchange resin DOWEX 50WX8-100 (5 g) for 1 hour. The mixture is then filtered, concentrated and triturated with ether. The solid product is isolated by filtration and dried under reduced pressure.
_{LC / MS (C 28 H 22} N 2 O 2) 419 [M + H] +; RT2.36 ( Method A)

Preparation 2b: N, N-diphenyl-1H-indole-3-carboxamide The procedure is the same as Preparation 2a, replacing 4- (benzyloxy) -N-phenylaniline used in Step B with N-phenylaniline. The product is obtained in solid form.
_{LC / MS (C 21 H 16} N 2 O) 313.2 [M + H] +; RT2.47 ( Method A)

Preparation 2c: N, N-dibutyl-1H-indole-3-carboxamide To a solution of 1H-indole-3-carboxylic acid (1.5 g, 9.31 mmol) in N, N-dimethylformamide (60 mL) was added dibutylamine. (3.14 mL, 18.62 mmol), DIPEA (1.95 mL, 11.17 mmol) and HBTU (4.24 g, 11.17 mmol) are added and the reaction mixture is stirred at ambient temperature for 16 hours. The reaction mixture is concentrated under reduced pressure, diluted with saturated aqueous NaHCO ₃ and extracted with ethyl acetate. The organic phase is washed with saturated aqueous NaHCO ₃ solution, brine, dried over magnesium sulfate and concentrated under reduced pressure. The resulting material is dissolved in dichloromethane and stirred with 5 g of pre-washed MP-Carbonate resin for 20 minutes, filtered and washed with dichloromethane, then concentrated under reduced pressure to isohexane, then 3: 1. Subsequent purification by chromatography on silica gel with a 3: 2 isohexane: ethyl acetate mixture gives the product in the form of a solid.
_{LC / MS (C 17 H 24} N 2 O) 273 [M + H] +; RT2.53 ( Method A)

Preparation 2d: N- [4- (Benzyloxy) phenyl] -5-fluoro-N-phenyl-1H-indole-3-carboxamide Same as Preparation 2a, replaced with methyl -1H-indole-3-carboxylate. The product is obtained in solid form.
_{LC / MS (C 28 H 21} N 2 O 2 F) 437 [M + H] +; RT2.71 ( Method A)

Preparation 2e: 6- (Benzyloxy) -N, N-diphenyl-1H-indole-3-carboxamide Step A: 1- (Benzenesulfonyl) -6- (benzyloxy) -3-iodo-1H-indole -78 ° C To a solution of 6- (benzyloxy) -1H-indole (942 mg, 4.22 mmol) in tetrahydrofuran (20 mL) cooled to 0, a solution of n-butyllithium (4.02 mL, 8.44 mmol) was added, The whole is then stirred at 0 ° C. for 1 hour. The resulting solution was then cannulated into a solution of iodine (1.07 g, 4.22 mmol) in tetrahydrofuran (20 mL), cooled to -78 ° C, and the resulting mixture was heated at 0 ° C at 2 ° C. Stir for hours. The reaction mixture is deactivated by adding methanol (1 drop), cooled to −78 ° C., then the lithium diisopropylamide solution prepared in the following manner is added: in 10 mL of tetrahydrofuran cooled to −78 ° C. A solution of diisopropylamine (0.596 mL, 4.22 mmol) is treated with n-butyllithium solution (2.01 mL, 4.22 mmol) and the resulting mixture is stirred at ambient temperature for 1 hour.

After the addition of the lithium diisopropylamide solution, phenylsulfonyl chloride (0.565 mL, 4.43 mmol) is added and after 30 minutes the reaction mixture is allowed to warm to ambient temperature again and stirred for about 16 hours. The reaction mixture is inactivated with water and partitioned according to its solubility between ethyl acetate and saturated aqueous sodium bicarbonate solution, the organic phase is washed with sodium thiosulfate solution, dried over magnesium sulfate, filtered and filtered under reduced pressure. Concentrate. The crude material is purified by chromatography on silica gel with an ethyl acetate (10%) / isohexane mixture to give an oil.
LC / MS (C ₂₁ H ₁₆ NO ₃ SI) 490 [M + H] ⁺ ; RT 2.83 (Method A)

Step B: 1- (Benzenesulfonyl) -6- (benzyloxy) -N, N-diphenyl-1H-indole-3-carboxamide obtained in Step A in tetrahydrofuran (8 mL) cooled to −78 ° C. under nitrogen. To a solution of the iodide (200 mg, 0.41 mmol) is added a solution of n-butyllithium (0.41 mL, 0.82 mmol). After 5 minutes, N, N-diphenylcarbamoyl chloride (142 mg, 0.61 mmol) in tetrahydrofuran (4 mL) is added and the reaction mixture is stirred at −78 ° C. for 90 minutes. The reaction mixture is inactivated with water, extracted with ethyl acetate, dried over magnesium sulfate, filtered and evaporated. The crude material is purified by chromatography on silica gel with an ethyl acetate (10%) / isohexane mixture and then 5: 1 isohexane / ethyl acetate to give a gum.
_{LC / MS (C 34 H 26} N 2 O 4 S) 559 [M + H] +; RT2.84 ( Method A)

Step C: 6- (Benzyloxy) -N, N-diphenyl-1H-indole-3-carboxamide To a solution of the product obtained in Step B (0.68 g, 1.21 mmol) in tetrahydrofuran (8 mL) was added TBAF. Solution (3.63 mL, 3.63 mmol) is added and the reaction mixture is heated by microwave irradiation at 100 ° C. for 45 min. The reaction mixture is concentrated under reduced pressure, partitioned between ethyl acetate and water according to its solubility and dried over magnesium sulfate. The solvent is removed under reduced pressure and the crude product is purified by chromatography on silica gel eluting with a gradient of isohexane to 1: 2 ethyl acetate / isohexane mixture to give a solid.
_{LC / MS (C 28 H 22} N 2 O 2) 419 [M + H] +; RT2.62 ( Method A)

Preparation 2f: N- (4-Fluorophenyl) -N-phenyl-1H-indole-3-carboxamide The procedure is for 4- (benzyloxy) -N-phenylaniline used in Step B to 4-fluoro-N-phenylaniline. Same as Preparation 2a, replaced with The product is obtained in solid form.

Preparation 2g: N- (4-Methylphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure is to convert 4- (benzyloxy) -N-phenylaniline used in Step B to 4-methyl-N-phenylaniline. Same as Preparation 2a, replaced with The product is obtained in solid form.

Preparation 3a: 5- (Benzyloxy) -2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-methoxybenzoic acid Obtained in Preparation 2a N- [4- (benzyloxy) phenyl] -N-phenyl-1H-indole-3-carboxamide (1.17 g, 2.79 mmol), 5-benzyloxy-2-bromo-4-methoxybenzoic acid (940 mg, 2.79 mmol) and potassium carbonate (771 mg, 5.58 mmol) are combined and suspended in N, N-dimethylformamide (10 mL). The reaction mixture is degassed with nitrogen, then copper iodide (55 mg, 0.28 mmol) is added and the whole is heated to 80 ° C. under nitrogen for about 16 hours. The reaction mixture is diluted with water and acidified with 2M aqueous HCl. The resulting precipitate is filtered off, washed with water, dissolved in dichloromethane, dried over magnesium sulfate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a gradient of isohexane to ethyl acetate to give the product in the form of a foam.
_{LC / MS (C 43 H 34} N 2 O 6) 675 [M + H] +; RT2.89 ( Method A)

Preparation 3b: 2- [6- (benzyloxy) -3- (diphenylcarbamoyl) -1H-indol-1-yl] benzoic acid The procedure was followed by N- [4- (benzyloxy) phenyl] -N-phenyl-1H -Replacing indole-3-carboxamide with N, N-diphenyl-1H-indole-3-carboxamide obtained in Preparation 2b and replacing 5-benzyloxy-2-bromo-4-methoxybenzoic acid with 2-bromobenzoic acid Same as Preparation 3a.

Preparation 3c: 5- (benzyloxy) -2- [3- (diphenylcarbamoyl) -1H-indol-1-yl] -4-methoxybenzoic acid The procedure was followed by N- [4- (benzyloxy) phenyl] -N Same as Preparation 3a, replacing phenyl-1H-indole-3-carboxamide with N, N-diphenyl-1H-indole-3-carboxamide obtained in Preparation 2b.

Preparation 3d: 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) benzoic acid Step A: 2- [3- (methoxycarbonyl) -1H-indole -1-yl] benzoic acid To a solution of methyl 1H-indole-3-carboxylate (1.1 g, 6.28 mmol) in N, N-dimethylformamide (10 mL) was added potassium carbonate (1.3 g, 9.42 mmol). ) And 2-iodobenzoic acid (1.56 g, 6.28 mmol) and the reaction mixture is degassed with nitrogen (this is done before adding copper iodide (120 mg, 0.628 mmol)). The reaction mixture is heated at 90 ° C. for about 16 hours, then allowed to cool to ambient temperature, diluted with water and extracted with ethyl acetate. The pH of the aqueous phase is adjusted with 2M aqueous HCl until acidic and extracted with ethyl acetate again. The combined organic extracts are dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of isohexane to ethyl acetate to give the product in the form of a solid.
_{LC / MS (C 17 H 13} NO 4) 296 [M + H] +; RT2.25 ( Method A)

Step B: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) benzoic acid in anhydrous tetrahydrofuran (10 mL) cooled to −78 ° C. under nitrogen To a solution of 4- (benzyloxy) -N-phenylaniline (570 mg, 2.07 mmol), lithium bis (trimethylsilyl) amide (1M in THF, 3.1 mL, 3.11 mmol) was added and the reaction mixture was- Stir at 78 ° C. for 20 minutes. Next, a solution of the compound obtained in Step A (610 mg, 2.07 mmol) in tetrahydrofuran (5 mL) is added to the reaction mixture, which is allowed to warm to ambient temperature again (this is allowed to reach 50 ° C. over about 16 hours). And 5.1 ml of lithium bis (trimethylsilyl) amide is added in two parts during this heating). The reaction mixture is allowed to cool to ambient temperature, diluted with water and extracted with ethyl acetate. The aqueous phase is acidified and extracted again with ethyl acetate, the combined organic extracts are dried over magnesium sulfate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give an oil which is used without further purification.
_{LC / MS (C 35 H 26} N 2 O 4) 539 [M + H] +; RT2.72 ( Method A)

Preparation 3e: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-methoxybenzoic acid Step A: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-methoxybenzoic acid methyl procedure was followed by replacing 5-benzyloxy-2-bromo-4-methoxybenzoic acid with 2-bromo-4 -Same as Preparation 3a, replaced with methyl methoxybenzoate.
_{LC / MS (C 37 H 30} N 2 O 5) 583 [M + H] +; RT2.85 ( Method A)

Step B: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-methoxybenzoic acid in tetrahydrofuran / methanol (1: 1, 4 mL) To a solution of the compound obtained in step A (314 mg, 0.54 mmol) is added aqueous NaOH (2M, 1 mL) and the reaction mixture is stirred overnight at ambient temperature. The resulting solution is acidified with 2M aqueous HCl, extracted with ethyl acetate, dried over magnesium sulfate, filtered and evaporated to give the product in the form of an oil that is used without further purification. .
_{LC / MS (C 36 H 28} N 2 O 5) 569 [M + H] +; RT2.74 ( Method A)

Preparation 3f: 2- [3- (Diphenylcarbamoyl) -1H-indol-1-yl] benzoic acid Is the same.

Preparation 3g: 2- [3- (Diphenylcarbamoyl) -1H-indol-1-yl] -4-methoxybenzoic acid The procedure is N- [4- (benzyloxy) phenyl] -N-phenyl-1H-indole- Replacing 3-carboxamide with N, N-diphenyl-1H-indole-3-carboxamide obtained in Preparation 2b, replacing 5-benzyloxy-2-bromo-4-methoxybenzoic acid with 2-iodo-4-methoxybenzoic acid Same as replaced Preparation 3a.

Preparation 3h: 6- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -2H-1,3-benzodioxole-5-carboxylic acid Same as Preparation 3a, replacing 5-benzyloxy-2-bromo-4-methoxybenzoic acid with 6-bromo-2H-1,3-benzodioxole-5-carboxylic acid.

Preparation 3i: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-chlorobenzoic acid Procedure is 5-benzyloxy-2-bromo- Same as Preparation 3a, replacing 4-methoxybenzoic acid with 4-chloro-2-iodobenzoic acid.

Preparation 3j: 6- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -2- (2-methylpropyl) -2H-1,3-benzodio The xol-5-carboxylic acid procedure involves the conversion of 5-benzyloxy-2-bromo-4-methoxybenzoic acid to 6-bromo-2- (2-methylpropyl) -2H-1,3-benzodioxole-5 -Same as Preparation 3a, substituting carboxylic acid.

Preparation 3k: 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-, 5-dimethoxybenzoic acid The procedure is 5-benzyloxy-2 -Same as Preparation 3a, replacing bromo-4-methoxybenzoic acid with 2-bromo-4,5-dimethoxybenzoic acid.

Preparation 3l: 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-chloro-5-methoxybenzoic acid Step A: 2- (3- {[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-chloro-5-methoxybenzoic acid methyl procedure -Same as Preparation 3e, substituting methyl bromo-4-chloro-5-methoxybenzoate.

Step B: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4-chloro-5-methoxybenzoic acid tetrahydrofuran (2 mL) and 2M aqueous NaOH The compound obtained in Step A (110 mg, 0.18 mmol) in (2 mL, 4 mmol) is heated under reflux for 1.5 hours. The reaction mixture is partitioned between ethyl acetate and water according to its solubility, and the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude material is applied to a PE-AX column, washed with dichloromethane, the compound eluted with a formic acid (10%) / dichloromethane mixture and subjected to azeotropic distillation with toluene to give a gum.
_{LC / MS (C 36 H 27} N 2 O 5 Cl) 603.2 [M + H] +; RT2.58 ( Method A)

Preparation 3m: 7- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -3-ethyl-2,3-dihydro-1,4-benzodioxin- 6-Carboxylic Acid Step A: Methyl 2-bromo-4,5-dihydroxybenzoate Methyl 2-bromo-4,5-dimethoxybenzoate (2.41 g, 10 mmol) in dichloromethane cooled to −78 ° C. under nitrogen. ) Is added boron tribromide (1M; 77 mL, 77 mmol) and the reaction mixture is allowed to return to ambient temperature. The mixture is poured into MeOH (200 mL) cooled in an ice bath and then evaporated and partitioned between ethyl acetate and water according to its solubility. The organic phase is dried over magnesium sulfate, filtered and evaporated to yield the desired product, which is used in subsequent steps without purification.
_{LC / MS (C 8 H 7} BrO 4) 244 [M-H] -; RT1.82 ( Method A)

Step B: Methyl 7-bromo-3-ethyl-2,3-dihydro-1,4-benzodioxin-6-carboxylate To a solution of the compound of Step A (200 mg, 0.81 mmol) in DMF (3 mL). Cesium carbonate (792 mg, 2.43 mmol) and 1,2-dibromobutane (295 μL, 2.43 mmol) are added. The resulting mixture is heated in a microwave apparatus at 150 ° C. for 20 minutes. The mixture is partitioned between ethyl acetate and water according to its solubility, the organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure.
The crude material is purified by flash chromatography on a silica gel column eluted with a hexane to 4: 1 hexane / ethyl acetate mixture to produce the desired product in the form of an oil.
_{LC / MS (C 12 H 13} BrO 4) 301 [M + H] +; RT2.62 ( Method A)

Step C: 7- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -3-ethyl-2,3-dihydro-1,4-benzodioxin- 6-Carboxylic acid Procedure is the same as Preparation 3e, replacing methyl 2-bromo-4-methoxybenzoate with the compound of Step B.

Preparation 3n: 3- (benzyloxy) -6- (3-{[4- (benzyloxy) phenyl] (phenyl) -carbamoyl} -1H-indol-1-yl) -2-chloro-4-methoxybenzoic acid The procedure is the same as Preparation 3a, replacing 5-benzyloxy-2-bromo-4-methoxybenzoic acid with 3- (benzyloxy) -6-bromo-2-chloro-4-methoxybenzoic acid.

Preparation 3o: 6- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -5-fluoro-1H-indol-1-yl) -2H-1,3-benzodioxole-5 Carboxylic acid procedure replaces 5-benzyloxy-2-bromo-4-methoxybenzoic acid with 6-bromo-2H-1,3-benzodioxole-5-carboxylic acid and replaces the compound of Preparation 2a with Preparation 2d. Same as Preparation 3a, substituting compound.

Preparation 3p: 6- [3- (Diphenylcarbamoyl) -1H-indol-1-yl] -2H-1,3-benzodioxole-5-carboxylic acid The procedure is 5-benzyloxy-2-bromo-4 -Same as Preparation 3a, replacing methoxybenzoic acid with 6-bromo-2H-1,3-benzodioxol-5-carboxylic acid and replacing the compound of Preparation 2a with the compound of Preparation 2b.

Preparation 3q: 4-Chloro-2- [3- (diphenylcarbamoyl) -1H-indol-1-yl] benzoic acid The procedure is as follows: 5-Benzyloxy-2-bromo-4-methoxybenzoic acid is 2-bromo-4 -Same as Preparation 3a, substituting chlorobenzoic acid and replacing the compound of Preparation 2a with the compound of Preparation 2b.

Preparation 3r: 4,5-bis (benzyloxy) -2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) benzoic acid Procedure was 2-bromo Same as Preparation 3e, replacing methyl-4-methoxybenzoate with methyl 4,5-bis (benzyloxy) -2-bromobenzoate.

Preparation 3s: 2- [3- (Dibutylcarbamoyl) -1H-indol-1-yl] -5-nitrobenzoic acid In N, N-dimethylformamide (5 mL), the compound of Preparation 2c (250 mg, 0.92 mmol) and A solution of methyl 2-fluoro-5-nitrobenzoate (365.5 mg, 1.84 mmol) is treated with potassium carbonate (317.12 mg, 2.29 mmol) and heated under reflux for 20 hours under nitrogen. The reaction mixture is cooled to ambient temperature, concentrated under reduced pressure, diluted with water, acidified to pH 1 with 2M aqueous HCl and extracted with ethyl acetate. The organic extract is washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material isolated in acid form is applied to a 20 g silica column and eluted with isohexane, then with a 1: 1 isohexane / ethyl acetate mixture, then with ethyl acetate and finally with a 9: 1 ethyl acetate / methanol mixture. Fractions containing product were combined and concentrated under reduced pressure, applied to a pre-washed 10 g PEAX cartridge, washed with dichloromethane, then methanol, then dichloromethane, and the product was washed with a 9: 1 dichloromethane / formic acid mixture. Elute, then it is concentrated under reduced pressure, diluted with brine and extracted with ethyl acetate. The organic phase is then washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a solid.
_{LC / MS (C 24 H 27} N 3 O 5) 438 [M + H] +; RT2.64 ( Method A)

Preparation 3t: 5- (Benzyloxy) -2- [3- (diphenylcarbamoyl) -1H-indol-1-yl] -4-methoxybenzoic acid Procedure is 5-benzyloxy-2-bromo-4-methoxybenzoic acid Same as Preparation 3a, replacing the acid with 5- (benzyloxy) -2-bromo-4-methoxybenzoic acid and replacing the compound of Preparation 2a with the compound of Preparation 2b.

Preparation 3u: 5- (Benzyloxy) -2- {3-[(4-fluorophenyl) (phenyl) carbamoyl] -1H-indol-1-yl} -4-methoxybenzoic acid The procedure prepared from the compound of Preparation 2a Identical to Preparation 3a, substituting compound of Preparation 2f.

Preparation 3v: 5- (Benzyloxy) -4-methoxy-2- {3-[(4-methylphenyl) (phenyl) carbamoyl] -1H-indol-1-yl} benzoic acid The procedure prepared from the compound of Preparation 2a Same as Preparation 3a, replacing the compound in Preparation 2g.

The compounds of Preparations 4a, 4b and 4c are synthesized following procedures similar to those described in Preparations 1 "-26".
Preparation 4a: 4-[(tert-butyldimethylsilyl) oxy] -N-cyclohexylaniline Preparation 4b: 4- (benzyloxy) -N-butylaniline Preparation 4c: N- (4-{[tert-butyl (dimethyl) Silyl] oxy} phenyl) -1-methyl-1H-indole-5-amine

Preparation 5a: N, N-diphenyl-1H-indazole-3-carboxamide Step A: 3-Iodo-1H-indazole To a solution of 1H-indazole (12 g, 0.1 mol) in N, N-dimethylformamide (190 mL) , Iodine (51.56 g, 0.2 mol) and crushed KOH (8.62 g, 0.375 mol) are added and the reaction mixture is stirred at ambient temperature for 1 hour. The reaction mixture is partitioned between diethyl ether and 10% sodium thiosulfate solution according to its solubility, then the aqueous phase is washed twice with diethyl ether. The combined organic phases are washed with brine, dried over magnesium sulfate, filtered and evaporated, and dried under reduced pressure to give the product in the form of a solid.
_{LC / MS (C 7 H 5} N 2 I) 245 [M + H] +; RT2.13 ( Method A)

Step B: 3-Iodo-2-{[2- (trimethylsilyl) ethoxy] methyl} -2H-indazole To a solution of 3-iodo-1H-indazole (15 g, 0.06 mol) in tetrahydrofuran (150 mL) was added N- Methyldicyclohexylamine (18.3 mL, 0.09 mol) and 2- (trimethylsilyl) ethoxymethyl chloride (15.3 mL, 0.09 mol) are added and the reaction mixture is stirred at ambient temperature over the weekend. The reaction mixture is partitioned between ethyl acetate and 2M NaOH according to its solubility, then the organic phase is washed with brine, dried over magnesium sulfate, filtered and concentrated. This is purified by flash chromatography on a silica gel column with a gradient of isohexane to ethyl acetate (40%) / isohexane mixture to give the product in the form of an oil.
_{LC / MS (C 13 H 19} N 2 OSiI) 375 [M + H] +; RT2.78 ( Method A)

Step C: N, N-diphenyl-2-{[2- (trimethylsilyl) ethoxy] methyl} -2H-indazole-3-carboxamide The compound obtained in Step B (5.0 g, 13. 36 mmol) is added dropwise to a solution of n-butyllithium (2.2 M, 12.15 mL, 26.72 mmol) in anhydrous tetrahydrofuran (100 mL) cooled to −78 ° C. under nitrogen. After 5 minutes, a solution of diphenylcarbamyl chloride (4.64 g, 20.04 mmol) in anhydrous tetrahydrofuran (25 mL) is added dropwise and the reaction mixture is allowed to warm to ambient temperature again over 4 hours. The reaction mixture is partitioned between water and ethyl acetate according to its solubility, the organic phase is dried over magnesium sulfate, filtered and concentrated to give an oil which is an isohexane-ethyl acetate (25%) / isohexane mixture. Purification by flash chromatography on silica gel with a gradient gives the product in solid form.
_{LC / MS (C 26 H 29} N 3 O 2 Si) m / z was not observed; RT2.87 (Method A)

Step D: N, N-diphenyl-1H-indazole-3-carboxamide To a solution of the compound obtained in Step C (3.03 g, 6.82 mmol) in anhydrous tetrahydrofuran (50 mL) was added ethylenediamine (0.48 mL, 7. 16 mmol), then 1 M TBAF solution in tetrahydrofuran (7.16 mL, 7.16 mmol) is added and the reaction mixture is heated to reflux at 80 ° C. overnight under nitrogen. An additional amount of ethylenediamine (0.17 mL, 2.54 mmol) and TBAF (1.36 mL, 1.36 mmol) are added and the reaction mixture is heated at reflux for an additional hour. The reaction mixture is allowed to cool to ambient temperature and then partitioned between water and ethyl acetate according to its solubility. The organic phase is dried over magnesium sulfate, filtered and concentrated. They are purified by flash chromatography on silica gel with a gradient of isohexane to ethyl acetate (80%) / isohexane mixture to give a solid.
_{LC / MS (C 20 H 15} N 3 O) 314 [M + H] +; RT2.36 ( Method A)

Preparation 5b: 5- (benzyloxy) -N, N-diphenyl-1H-indazole-3-carboxamide The procedure was as described in Preparation 5a, replacing 1H-indazole of Step A with 5- (benzyloxy) -1H-indazole. Is the same.
_{LC / MS (C 27 H 21} N 3 O 2) 420 [M + H] +; RT2.63 ( Method A)

Preparation 5c: 6-methoxy-N, N-diphenyl-1H-indazole-3-carboxamide The procedure is the same as that of Preparation 5a, replacing 1H-indazole in Step A with 6- (methoxy) -1H-indazole. .
_{LC / MS (C 21 H 17} N 3 O 2) 344 [M + H] +; RT2.33 ( Method A)

Preparation 5d: N, N-dibutyl-1H-indazole-3-carboxamide A solution of 1H-indazole-3-carboxylic acid (500 mg, 3.08 mmol) in N, N-dimethylformamide (10 mL) under nitrogen. DIPEA (1.1 mL, 6.16 mmol) and dibutylamine (627 μl, 3.70 mmol) are added followed by HBTU (1.4 g, 3.70 mmol) and the reaction mixture is stirred at ambient temperature for 16 hours. Additional dibutylamine (2.61 mL, 15.4 mmol) is added and the reaction mixture is heated at 50 ° C. for 48 hours. The reaction mixture is inactivated with water and concentrated, then diluted with saturated sodium bicarbonate solution, the organic phase is extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on silica gel with an isohexane to 9: 1 isohexane / ethyl acetate mixture and then with a 3: 1 isohexane / ethyl acetate mixture to give the product in the form of a solid.
LC / MS (C ₁₆ H ₂₃ N ₃ O) 274 [M + H] ⁺ ; RT2.51 (Method A)

Preparation 5e: Ethyl 6- (benzyloxy) -1H-indazole-3-carboxylate Step A: 6- (Benzyloxy) -3-iodo-2-{[2- (trimethylsilyl) ethoxy] methyl} -2H-indazole The procedure is the same as the method of Preparation AB, Steps AB, in which 1H-indazole used in Step A is replaced with 6- (benzyloxy) -1H-indazole.

Step B: 6- (Benzyloxy) -2-{[2- (trimethylsilyl) ethoxy] methyl} -2H-indazole-3-carboxylic acid Compound (0.97 g, 2 in 2 mL) in tetrahydrofuran (5 mL) 0.02 mmol) was added to a solution of tetrahydrofuran (10 mL) cooled to −78 ° C. and n-butyllithium (2.5 M, 1.62 mL, 4.04 mmol), then the whole was again added over 30 min. Allow to warm to ambient temperature. An additional 0.41 mL of n-butyllithium is added to the reaction mixture, which is stirred for 30 minutes (this is done again before cooling to -78 ° C). Crushed solid carbon dioxide is added, then the reaction mixture is allowed to warm to ambient temperature again and stirred overnight. The reaction mixture is inactivated with water, the pH is adjusted to 4 with 2M HCl, the mixture is extracted with ethyl acetate, the organic phase is dried over magnesium sulfate, filtered and evaporated.
The crude material is applied to a PE-AX column, washed with methanol, and the compound is eluted with a 5: 1 dichloromethane / acetic acid mixture to give a solid.
_{LC / MS (C 21 H 26} N 2 O 4 Si) 397.1 [M-H] -; RT2.69 ( Method A)

Step C: Ethyl 6- (benzyloxy) -1H-indazole-3-carboxylate To a solution of the compound obtained in Step B (76 mg, 0.19 mmol) in ethanol (5 mL) was added sulfuric acid (0.25 mL). The reaction mixture is heated at reflux overnight. The reaction mixture is made alkaline with 2N NaOH and then extracted with ethyl acetate, the organic phase is dried over magnesium sulfate, filtered and concentrated to give a solid. The product is used in subsequent steps without further purification.
_{LC / MS (C 17 H 16} N 2 O 3) 297.1 [M + H] +; RT2.47 ( Method A)

Preparation 6a: 6- [3- (Diphenylcarbamoyl) -1H-indazol-1-yl] -2H-1,3-benzodioxole-5-carboxylic acid Preparation of 5a in N, N-dimethylformamide (3 mL) N, N-diphenyl-1H-indazole-3-carboxamide (300 mg, 0.96 mmol), potassium carbonate (200 mg, 1.44 mmol) and 6-bromo-2H-1,3-benzodioxole-5 -A solution of the carboxylic acid (235 mg, 0.96 mmol) was degassed with nitrogen, then copper (I) iodide (20 mg, 0.096 mmol) was added and the reaction mixture was 4. Stir for 5 hours. The reaction mixture is cooled to ambient temperature, diluted with ethyl acetate and washed with water. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on a silica gel column with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product as an oil. Give in form.
_{LC / MS (C 28 H 19} N 3 O 5) 478 [M + H] +; RT2.54 ( Method A)

Preparation 6b: 2- [3- (Diphenylcarbamoyl) -1H-indazol-1-yl] -5-nitrobenzoic acid Step A: 2- [3- (Diphenylcarbamoyl) -1H-indazol-1-yl] -5 Methyl nitrobenzoate in a solution of the compound obtained in Preparation 5a (777 mg, 2.48 mmol) and methyl 2-fluoro-5-nitrobenzoate (593 mg, 2.98 mmol) in N, N-dimethylformamide (30 mL). , Potassium carbonate (514 mg, 3.72 mmol) is added and the reaction mixture is heated at 100 ° C. overnight under nitrogen. The reaction mixture is concentrated, dissolved in ethyl acetate, washed with brine, then dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on silica gel with a 6: 1 isohexane / ethyl acetate mixture and then with a 2: 1 isohexane / ethyl acetate mixture to give a solid.
_{LC / MS (C 28 H 20} N 4 O 5) 493 [M + H] +; RT2.69 ( Method A)

Step B: 2- [3- (Diphenylcarbamoyl) -1H-indazol-1-yl] -5-nitrobenzoic acid To a solution of the compound obtained in Step A (816 mg, 1.66 mmol) in tetrahydrofuran (8 mL) 2N NaOH (8 mL) is added and the reaction mixture is stirred overnight at ambient temperature. The reaction mixture is acidified with 2M HCl and the product is extracted with ethyl acetate, dried over magnesium sulfate, filtered and concentrated to give a solid which is used directly in the subsequent steps without further purification.
_{LC / MS (C 27 H 18} N 4 O 5) 479 [M + H] +; RT2.5 ( Method A)

Preparation 6c: 2- [6- (benzyloxy) -3- (diphenylcarbamoyl) -1H-indazol-1-yl] benzoic acid Step A: 2- [6- (benzyloxy) -3- (ethoxycarbonyl)- 1H-indazol-1-yl] benzoic acid In N, N-dimethylformamide (10 mL), the compound obtained in Preparation 5e (240 mg, 0.811 mmol) and potassium carbonate (160 mg, 1.217 mmol) were added to copper iodide. (I) (15 mg, 0.081 mmol) and 2-bromobenzoic acid (196 mg, 0.973 mmol) are added and the reaction mixture is stirred at 140 ° C. overnight. The reaction mixture is concentrated and the residue is dissolved in ethyl acetate and washed successively with water and brine (this is done before drying over magnesium sulfate, filtering and concentrating). The crude material is purified by column chromatography with a 96: 4 dichloromethane / methanol mixture to give an oil.
_{LC / MS (C 24 H 20} N 2 O 5) 417 [M + H] +; RT2.55 ( Method A)

Step B: 2- [6- (Benzyloxy) -3- (diphenylcarbamoyl) -1H-indazol-1-yl] benzoic acid N-phenylaniline (83 mg, in tetrahydrofuran (5 mL) cooled to −78 ° C. To a solution of 0.49 mmol) n-butyllithium (2.5 M, 0.2 mL, 0.49 mmol) is added and the reaction mixture is allowed to warm to ambient temperature over 1 hour. The compound obtained in Step A (68 mg, 0.163 mmol) dissolved in tetrahydrofuran (5 mL) is cooled to −78 ° C. and a solution of N-phenylaniline is added. Allow the reaction mixture to warm to ambient temperature again. After 1.5 hours, the reaction mixture is inactivated with water and neutralized with 2M HCl. The organic phase is extracted with ethyl acetate, then dried over magnesium sulphate, filtered and evaporated. The crude material is purified by column chromatography with a 96: 4 dichloromethane / methanol mixture.
_{LC / MS (C 35 H 26} N 2 O 4) 540 [M + H] +; RT2.67 ( Method A)

Preparation 6d: 2- [3- (Dibutylcarbamoyl) -1H-indazol-1-yl] benzoic acid The procedure replaces the compound of Preparation 5a with the compound of Preparation 5d to give 6-bromo-2H-1,3-benzodio Same as Preparation 6a method, replacing xol-5-carboxylic acid with 2-iodobenzoic acid.

Preparation 6e: 2- [3- (Diphenylcarbamoyl) -1H-indazol-1-yl] benzoic acid The procedure is the same as that of Preparation 6a using 2-iodobenzoic acid.

Preparation 6f: 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indazol-1-yl) benzoic acid Step A: 2- [3- (ethoxycarbonyl) -1H-indazole -1-yl] benzoic acid To a solution of ethyl 1H-indazole-3-carboxylate (200 mg, 1.05 mmol) in N, N-dimethylformamide (20 mL) was added potassium carbonate (218 mg, 1.58 mmol) and 2- Add iodobenzoic acid (313 mg, 1.26 mmol). The solution is degassed with nitrogen and then copper (I) iodide (20 mg, 0.11 mmol) is added (this is done before the whole is heated at 100 ° C. overnight). The reaction mixture is partitioned between ethyl acetate and 2M HCl according to its solubility, then the organic phase is washed with brine, dried over magnesium sulfate, filtered and evaporated to give an oil which is pre- Purify on a PE-AX column washed with methanol. The compound is applied with a minimum amount of methanol containing a few drops of triethylamine. The column is washed with methanol and the product is eluted with a formic acid (10%) / dichloromethane mixture to give an oil that is used directly without further purification.
_{LC / MS (C 17 H 14} N 2 O 4) 311 [M + H] +; RT2.22 ( Method A)

Step B: 2- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indazol-1-yl) benzoic acid in anhydrous tetrahydrofuran (5 mL) cooled to −78 ° C. in 4- To a solution of (benzyloxy) -N-phenylaniline (0.15 g, 0.53 mmol) under nitrogen is added LiHMDS (0.8 mL, 0.8 mmol) and the reaction mixture is stirred at −78 ° C. for 10 minutes. To do. A solution of the compound obtained in Step A (0.17 g, 0.53 mmol) in anhydrous tetrahydrofuran (5 mL) is added and the reaction mixture is allowed to warm to ambient temperature again (this is heated at 50 ° C. over the weekend) Do it before). An additional amount of LiHDMS (0.80 mL) is added and the reaction mixture is heated at 50 ° C. for an additional 4 hours. The reaction mixture is partitioned between ethyl acetate and water according to its solubility, then the organic phase is washed with brine, dried over magnesium sulfate, filtered and concentrated to give an oil that is further purified. Without being used in subsequent steps.
_{LC / MS (C 34 H 25} N 3 O 4) 538 [M-H] -; RT2.72 ( Method A)

Preparation 6g: 2- [3- (diphenylcarbamoyl) -6-methoxy-1H-indazol-1-yl] benzoic acid The procedure of Preparation 6a was applied to the compound obtained in Preparation 5c in the presence of 2-iodobenzoic acid. Heat at 140 ° C.

Preparation 6h: 2- [3- (Diphenylcarbamoyl) -6-hydroxy-1H-indazol-1-yl] benzoic acid Preparation 6 g of compound (464 mg, 1 mmol) in dichloromethane (20 mL) cooled to 0 ° C. under nitrogen. ) With boron tribromide (1M, 0.95 mL, 10 mmol) and the reaction mixture is stirred overnight at ambient temperature under nitrogen. The reaction mixture is diluted with methanol and neutralized with triethylamine (done before concentrating). The residue is extracted with ethyl acetate, washed with dilute HCl, the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (8%) / dichloromethane mixture to give a solid.
_{LC / MS (C 27 H 19} N 3 O 4) 450 [M + H] +; RT2.34 ( Method A)

Preparation 6i: 2- [3- (Diphenylcarbamoyl) -6-hydroxy-1H-indazol-1-yl] benzoic acid Procedure is Preparation 6a using 5- (benzyloxy) -2-bromo-4-methoxybenzoic acid It is the same as the method.

Preparation 6j: 2- [5- (Benzyloxy) -3- (diphenylcarbamoyl) -1H-indazol-1-yl] benzoic acid The procedure replaces the compound of Preparation 5a with the compound of Preparation 5b to give 6-bromo-2H Same method as Preparation 6a, replacing -1,3-benzodioxole-5-carboxylic acid with 2-iodobenzoic acid.

Example 1.1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N, N-dibutyl-5-methyl -1H-pyrrole-3-carboxamide hydrochloride Step A: {[(3S) -2- {2- [4- (dibutylcarbamoyl) -2-methyl-1H-pyrrol-1-yl] benzoyl} -1,2, , 3,4-Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl In Step A, tert-butyl [(3S) -1,2,3,4-tetrahydroisoquinolin-3-ylmethyl] carbamate (Preparation 1 '), In Step C, using N, N-dibutylamine, the title compound is obtained according to steps A to C of the method of Example 8.

Step B: 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N, N-dibutyl-5-methyl- 1H-pyrrole-3-carboxamide hydrochloride To a solution of the NH-Boc compound of step A in dichloromethane (10 mL / mmol) at 0 ° C., trifluoroacetic acid (10 molar equivalents) is added dropwise. The whole is gradually stirred for 12 hours at ambient temperature. The reaction mixture is then concentrated to dryness, taken up with toluene and coevaporated twice and then concentrated to dryness. The residue is then dissolved in dichloromethane. The organic phase is washed with saturated NaHCO ₃ solution, then with saturated NaCl solution, dried over MgSO ₄ and concentrated to dryness. The resulting residue is then dissolved in a minimum amount of dichloromethane. The whole is placed at 0 ° C. and a 1M HCl / Et ₂ O solution (2 molar equivalents) is added. The reaction mixture is stirred at ambient temperature for 1 hour, concentrated to dryness, dissolved in a CH ₃ CN / H ₂ O mixture and lyophilized at low temperature to produce the desired product.
Trace element analysis: (%, theoretical value / measured value)
% C = 69.32: 69.32;% H = 7.69: 7.68;% N = 10.43: 10.43;% Cl = 6.6: 6.79;% Cl- = 6. 6: 6.66

The compounds of Examples 2-4 are obtained according to the method of Example 1 using the appropriate NHR ₃ R ₄ amine.

Example 2.1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N-butyl-5-methyl-N -(2-Phenylethyl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical value / measured value)
% C = 71.84: 71.44;% H = 7.06: 6.73;% N = 9.57: 9.42;% Cl− = 6.06: 6.16

Example 3.1 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N-butyl-5-methyl-N -(3-Phenylpropyl) -1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 72.16: 70.89;% H = 7.23: 6.96;% N = 9.35: 9.21;% Cl− = 5.92: 8.01
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₆ H ₄₂ N ₄ O ₂
[M + H] ⁺ calculated value: 56.3386
[M + H] ⁺ measured value: 563.373

Example 4.1 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N-butyl-5-methyl-N -(4-Phenylbutyl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical value / measured value)
% C = 72.47: 73.11;% H = 7.4: 6.95;% N = 9.14: 9.03;% Cl− = 5.78: 5.81

Example 5.1 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -5-methyl-N, N-diphenyl -1H-pyrrole-3-carboxamide trifluoroacetate salt Step A: {[(3S) -2- {2- [4- (diphenylcarbamoyl) -2-methyl-1H-pyrrol-1-yl] benzoyl} -1 , 2,3,4-Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl In step A, tert-butyl [(3S) -1,2,3,4-tetrahydroisoquinolin-3-ylmethyl] carbamate ( (See Preparation 1 ′), Step C uses N-phenylaniline to give the title compound according to Steps A to C of the method of Example 8.

Step B: 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -5-methyl-N, N-diphenyl- 1H-pyrrole-3-carboxamide trifluoroacetate salt A solution of the NH-Boc compound of Step A in dichloromethane is placed at 0 ° C. To this, 10 molar equivalents of trifluoroacetic acid are added dropwise. The whole is stirred for 4 hours at ambient temperature until the starting material has completely disappeared. The reaction mixture is then concentrated to dryness, taken up with toluene and co-evaporated twice (this is done in a CH ₃ CN / H ₂ O mixture and finally before lyophilization).
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₅ H ₃₂ N ₄ O ₂
[M + H] ⁺ calculated value: 541.2604
[M + H] ⁺ measured value: 541.2612

Example 6.1 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5-hydroxyphenyl) -5-methyl-N , N-Diphenyl-1H-pyrrole-3-carboxamide Step A: {[(3S) -2- {4- (Benzyloxy) -2- [4- (diphenylcarbamoyl) -2-methyl-1H-pyrrole-1 -Il] benzoyl} -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl In Step A, the acid obtained in Preparation 2 and in Preparation 1 ′ [(3S) -1 The title compound is synthesized according to the method of Example 8 using tert-butyl, 2,3,4-tetrahydroisoquinolin-3-ylmethyl] carbamate, N-phenylaniline in Step C.

Step B: {[(3S) -2- {2- [4- (diphenylcarbamoyl) -2-methyl-1H-pyrrol-1-yl] -4-hydroxybenzoyl} -1,2,3,4-tetrahydro Isoquinolin-3-yl] methyl} carbamate tert-butyl The compound of Step A is dissolved in methanol (5 mL / mmol) and Pd / C (10 wt%) is added. After overnight at 1 bar hydrogen pressure, the reaction mixture is filtered and rinsed with ethanol. Concentrate the filtrate to dryness. The desired product is obtained and used in the subsequent steps without purification.

Step C: 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5-hydroxyphenyl) -5-methyl-N, N-diphenyl-1H-pyrrole-3-carboxamide To a solution of NH-Boc intermediate (10 mL / mmol) in dichloromethane at 0 ° C. is added dropwise trifluoroacetic acid (10 molar equivalents). The whole is then stirred for 12 hours at ambient temperature. The reaction mixture is concentrated to dryness, taken up with toluene and coevaporated twice and then concentrated to dryness. The residue is then dissolved in dichloromethane. The organic phase is washed with saturated NaHCO ₃ solution, then with saturated NaCl solution, dried over MgSO ₄ and concentrated to dryness. The resulting residue is then dissolved in a minimum amount of dichloromethane. The whole is placed at 0 ° C. and 1 M HCl / EtO ₂ solution (2 molar equivalents) is added. The reaction mixture is stirred at ambient temperature for 1 hour, concentrated to dryness, dissolved in a CH ₃ CN / H ₂ O mixture and lyophilized at low temperature to produce the desired product.
Trace element analysis: (%, theoretical value / measured value)
% C = 75.52: 74.91;% H = 5.79: 5.17;% N = 10.06: 10.07

Example 7.1 1- (2-{[(3S) -3- (aminomethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5-hydroxyphenyl) -N- (4- Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride The title compound was synthesized according to the method of Example 6 replacing N-phenylaniline with 4-benzyloxy-N-phenyl-aniline. To do.
Trace element analysis: (%, theoretical value / measured value)
% C = 69.01: 67.55;% H = 5.46: 4.86;% N = 9.2: 9.26;% Cl− = 5.82: 6.56
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₅ H ₃₂ N ₄ O ₄
[M + H] ⁺ calculated value: 573.2502
[M + H] ⁺ Measured value: 5733.2493

Example 8.1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxy Phenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide Step A: 1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinoline-2 (1H) -yl] carbonyl} phenyl) -5-methyl-1H-pyrrole-3-carboxylate ethyl acetate In a solution of 1.7 g (6.3 mmol) of the acid obtained in Preparation 1 in 50 mL of dichloromethane is added N, N- Dimethyl-1-[(3S) -1,2,3,4-tetrahydroisoquinolin-3-yl] methanamine 2 g (7.6 mmol), N, N, N-triethylamine 4 mL (28.5 mmol), 1-ethyl- 1.46 g (7.6 mmol) of 3- (3′-dimethylaminopropyl) -carbodiimide (EDC) and 1.03 g (7.6 mmol) of hydroxybenzotriazole (HOBT) are added. The reaction mixture is stirred overnight at ambient temperature, then poured into saturated aqueous NaHCO ₃ solution and extracted with methylene chloride. The organic phase is then dried over magnesium sulfate (this is done before being filtered and evaporated to dryness). The crude product so obtained is then purified by chromatography on silica gel (dichloromethane / methanol gradient) to give the desired product in the form of a powder.
IR: ν:> C = O 1703cm -1 ester; ν:> C = O 1630cm -1 amide; ν: CHN 2768cm ^-1 ball man band

Step B: 1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -5-methyl-1H-pyrrole Lithium 3-carboxylate The compound of step A (0.5 g; 1.1 mmol) is dissolved in 4 mL of dioxane. A solution of LiOH (50 mg; 1.2 mmol) in water (1 mL) is added. The whole is heated at 140 ° C. for 70 minutes in a microwave apparatus (power 100 W). After returning to ambient temperature, the reaction mixture is evaporated to dryness and used as such in the subsequent steps.
¹ H-NMR: (400 MHz; dmso-d6; 353K): 7.6-6.8 (m, 9H, aryl + 1H pyrrole); 6.05 (sl, 1H, pyrrole); 5.0-4.0 (M, 3H, C _tertiary THIQ + 2C _secondary THIQ); 2.68 (m, 2HC _secondary THIQ); 2.2-1.8 (m, 11H, NMe ₂ + CH ₂ N + CH ₃ pyrrole)
IR: ν:> C═O 1626 cm ⁻¹ amide; ν:> C═O—O 1573 cm ⁻¹

Step C: N- [4- (Benzyloxy) phenyl] -1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} phenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In 10 mL of dichloromethane, a suspension of 475 mg (1.1 mmol) of the lithium carboxylate obtained in Step B was added to 0.3 mL of oxalyl chloride ( 3.4 mmol) and 1 drop of DMF. After stirring for 3 hours, the reaction mixture is concentrated to dryness and then dissolved in dichloromethane (10 mL). This solution is then poured into a dichloromethane solution (10 mL) containing the compound from Preparation 1 ″ (470 mg; 1.7 mmol) and pyridine (0.15 mL; 1.7 mmol). After the addition, the reaction mixture is brought to reflux. After cooling, it is poured into a saturated aqueous NaHCO ₃ solution and extracted with methylene chloride, then the organic phase is dried over magnesium sulfate (this is done before being filtered and evaporated to dryness). The crude product so obtained is then purified by chromatography on silica gel (dichloromethane / methanol gradient) to give the desired product in the form of a foam.
¹ H-NMR: δ (400 MHz; dmso-d6; 350 K): 7.6-6.3 (m, 23 H, aromatic H); 5.5 (sl, 1 H, H pyrrole); 5.05 (s , 2H, benzyl H); 4.0-5.0 (m, 3H, HTHIQ); 2.9-2.5 (m, 2H, HTHIQ); 2.3-1.6 (m, 8H, NME) ₂ + CH ₂ N); 1.85 (sl, 3H, CH ₃ pyrrole)
IR: ν:> C═O: 1623 cm ⁻¹ amide

Step D: 1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) ) -5-Methyl-N-phenyl-1H-pyrrole-3-carboxamide To a solution of the product obtained in Step C (510 mg; 0.75 mmol) in ethanol (8 mL) was added cyclohexene (0.5 mL) and 10%. Add Pd, Pd / C (100 mg). Heat the reaction mixture at 80 ° C. overnight. After cooling and filtration through Whatman filter, the filtrate is concentrated to dryness and purified by chromatography on silica gel (dichloromethane / methanol gradient) to give the desired product in the form of a colorless foam.
¹ H-NMR: δ (400 MHz; dmso-d6; 350 K): 9.5 (sl, 1H, OH); 7.55-6.3 (m, 14H, aromatic H + H pyrrole); 6.9 (d , 2H, aromatic H); 6.67 (d, 2H, aromatic H); 5.50 (s, 1H, H pyrrole); 4.80 (m, 1H, HTHIQ); 4.15 (m, 2H, HTHIQ); 2.80 (m, 2H, HTHIQ); 2.3-1.6 (m, 11H, NMe ₂ + CH ₂ N + CH ₃ pyrrole).
IR: ν: OH (H ₂ O) and OH (phenol): 3500-2200 cm ⁻¹ ; ν:> C═O: 1630 cm ⁻¹ Amide trace element analysis: (%, theoretical value / measured value)
% C = 76: 75.62;% H = 6.21: 5.83;% N = 9.58: 9.68

Example 9.1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N, N-bis ( 4-Methoxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide The compound was prepared according to the method of steps AC of Example 8 using 4-methoxy-N- (4-methoxyphenyl) aniline in step C. obtain.
Trace element analysis: (%, theoretical value / measured value)
% C = 74.5: 73.91;% H = 6.41: 6.06;% N = 8.91: 8.9

Example 10.1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (1H-indole -5-yl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide Using the compound of 3 "prepared in Step C, the compound is obtained according to the method of Steps AC in Example 8. Next The 1H-indol-5-yl group is deprotected using methanolic potassium hydroxide following the protocol of Example 48, Step B.
Trace element analysis: (%, theoretical value / measured value)
% C = 77.08: 76.34;% H = 6.14: 5.76;% N = 11.52: 11.3

Example 11.1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (1H-indole -6-yl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide Using the compound of 4 "prepared in Step C, the compound is obtained according to the method of Steps AC in Example 8. Next The 1H-indol-5-yl group is deprotected using methanolic potassium hydroxide following the protocol of Example 48, Step B.
Trace element analysis: (%, theoretical value / measured value)
% C = 77.08: 76.59;% H = 6.14: 5.63;% N = 11.52: 11.01

Example 12.1- [2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5- (trifluoromethyl) phenyl ] -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide Step A: N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1 -[2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5- (trifluoromethyl) phenyl] -5-methyl —N-phenyl-1H-pyrrole-3-carboxamide In step A, the title compound was synthesized according to the method of steps A to C of Example 8 using the acid obtained in Preparation 3 and the compound of Preparation 25 ″ in Step C. That.

Step B: 1- [2-{[(3S) -3-[(Dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5- (trifluoromethyl) phenyl] -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide Compound obtained in step A in 4 mL of methanol Potassium hydroxide dissolved in 2.3 mL of a solution in 8 mL of methanol 0.646 g (11.5 mmol) is added. The whole is stirred for 30 minutes at ambient temperature. The reaction mixture is then diluted with dichloromethane and washed successively with 1N HCl solution, saturated NaHCO ₃ solution, and then saturated NaCl solution (until neutral pH is reached). The organic phase is then dried over magnesium sulfate, filtered and evaporated. The crude product so obtained is purified on silica gel (dichloromethane / methanol gradient) to yield the title product.
Trace element analysis: (%, theoretical value / measured value)
% C = 69.93: 69.34;% H = 5.4: 5.09;% N = 8.58: 8.09

Example 13. 1- (5-Chloro-2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide The title compound is synthesized according to the method of Example 12 using the acid obtained in Preparation 4 in Step A.
Trace element analysis: (%, theoretical value / measured value)
% C = 71.78: 69.85;% H = 5.7: 5.39;% N = 9.05: 8.54
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₅ ³⁵ ClN ₄ O ₃
[M + H] ⁺ calculated value: 619.2476
[M + H] ⁺ measured value: 619.2458

Example 14. 1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -5-fluorophenyl) -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide The title compound is synthesized according to the method of Example 12 using the acid obtained in Preparation 5 in Step A.
Trace element analysis: (%, theoretical value / measured value)
% C = 73.74: 72.75;% H = 5.85: 5.73;% N = 9.3: 9

Example 15. 1- (5-hydroxy-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide (3S) -3- (4-morpholinylmethyl) -1,2, obtained in Preparation 2 ′ in Step A The title compound is synthesized according to the method of Example 7 using 3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 68.97: 68.74;% H = 5.79: 5.65;% N = 8.25: 8.16;% Cl− = 5.22: 4.74

Example 16. 1- (4,5-Dibromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl ] Carbonyl} phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid obtained in Preparation 6 and obtained in Preparation 3 ′ (3S) The title compound is synthesized according to the method of Example 12 using -3-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 60.24: 59.6;% H = 4.93: 4.56;% N = 8.78: 8.31;% Br = 20.04: 19.65

Example 17. 1- (5-hydroxy-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide (3S) -3-[(4-methyl-1) obtained in Preparation 3 ′ in Step A The title compound is synthesized according to the method of Example 7 using -piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 65.93: 66.7;% H = 5.95: 5.61;% N = 9.61: 9.72;% Cl− = 9.73: 7.55

Example 18. 1- (3-Chloro-2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide The title compound is synthesized according to the method of Example 12 using the acid obtained in Preparation 7 in Step A.
Trace element analysis: (%, theoretical value / measured value)
% C = 71.78: 70.82;% H = 5.7: 5.31;% N = 9.05: 8.89

Example 19. N- (4-hydroxyphenyl) -5-methyl-1- [2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H ) -Yl] carbonyl} -4- (trifluoromethoxy) phenyl] -N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid obtained in Preparation 8 and (3S) -3 obtained in Preparation 3 ′ The title compound is synthesized according to the method of Example 12 using-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 68.04: 67.57;% H = 5.57: 5.48;% N = 9.68: 9.73

Example 20.1- (4,5-difluoro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl ] Carbonyl} phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid obtained in Preparation 9 and obtained in Preparation 3 ′ (3S) The title compound is synthesized according to the method of Example 12 using -3-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 71.09: 70.09;% H = 5.82: 5.28;% N = 10.36: 10.24

Example 21.1- (5-Fluoro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid obtained in Preparation 5 and (3S) -3 obtained in Preparation 3 ′ The title compound is synthesized according to the method of Example 12 using-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 73.04: 72.28;% H = 6.13: 5.73;% N = 10.65: 10.52

Example 22.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid from Preparation 10 and (3S) -3 from Preparation 3 ′ The title compound is synthesized according to the method of Example 12 using-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 66.85: 66.38;% H = 5.61: 5.41;% N = 9.74: 9.73;% Br = 11.12: 11.09

Example 23.1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxy Phenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Step A: 5-[(4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) { [1- (2-{[(3S) -3-[(Dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -5-methyl-1H-pyrrole-3 -Il] carbonyl} amino] -1H-indole-1-tert-butyl carboxylate The title compound is synthesized according to the method of Example 8 Steps AC, replacing the compound of Preparation 1 "with the compound of Preparation 5".
Step B: 1- (2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) ) -N- (1H-Indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide The product of Step A is deprotected according to the protocol of Step B of Example 48.
Trace element analysis: (%, theoretical value / measured value)
% C = 75.1: 72.56;% H = 5.98: 5.42;% N = 111.23: 10.71
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₃₇ N ₅ O ₃
[M + H] ⁺ calculated value: 624.2975
[M + H] ⁺ measured value: 624.2994

Example 24. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H ) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -N-phenyl-1H-pyrrole-3-carboxamide In step A, the acid obtained in Preparation 11 and obtained in Preparation 3 ′ ( The title compound is synthesized according to the method of Example 12 using 3S) -3-[(4-Methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₁ H ₄₁ N ₅ O ₅
[M + H] ⁺ calculated value: 6844.3186
[M + H] ⁺ Measured value: 6844.3163

The compounds of Examples 25-27 are obtained according to the method of Example 13 using the appropriate 1,2,3,4-tetrahydroisoquinoline compound and the appropriate NHR ₃ R ₄ amine.

Example 25. 1- (4-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 71.26: 69.72;% H = 5.98: 5.35;% N = 10.39: 10.09
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₄₀ ³⁵ ClN ₅ O ₃
[M + H] ⁺ calculated value: 6742898
[M + H] ⁺ Measured value: 6742873

Example 26. 1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 71.26: 70.06;% H = 5.98: 5.19;% N = 10.39: 10.05;% Cl = 5.26: 5.49
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₄₀ ³⁵ ClN ₅ O ₃
[M + H] ⁺ calculated value: 6742898
[M + H] ⁺ measured value: 6742878

Example 27. N- (3-chloro-4-hydroxyphenyl) -1- (5-chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline -2 (1H) -yl] carbonyl} phenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 64.48: 65.67;% H = 5.41: 5.4;% N = 9.4: 9.45;% Cl = 14.27: 11.82
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₃₉ ³⁵ Cl ₂ N ₅ O ₃
[M + H] ⁺ calculated value: 708.2508
[M + H] ⁺ measured value: 708.2509

Example 28.1- (5-Chloro-4-fluoro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H) -Yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In step A, the acid obtained in preparation 12 and obtained in preparation 3 '( The title compound is synthesized according to the method of Example 12 using 3S) -3-[(4-Methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 69.4: 68.27;% H = 5.68: 5.08;% N = 10.12: 9.81
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₃₉ ³⁵ ClFN ₅ O ₃
[M + H] ⁺ calculated value: 692.2804
[M + H] ⁺ measured value: 692.2818

Example 29.1- (4-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid obtained in Preparation 13 and (3S) -3 obtained in Preparation 3 ′ The title compound is synthesized according to the method of Example 12 using-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 66.85: 64.98;% H = 5.61: 5.2;% N = 9.74: 9.38
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₄₀ ⁷⁹ BrN ₅ O ₃
[M + H] ⁺ calculated value: 718.2393
[M + H] ⁺ Measured value: 718.2380

Example 30. FIG. N, N-bis (4-chlorophenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H)- Yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide In Step A, the acid obtained in Preparation 14, (3S) -3- [ The title compound is synthesized according to the method of Example 12 using (4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline and the appropriate NHR ₃ R ₄ amine.
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₃₉ Cl ₂ N ₅ O ₄
[M + H] ⁺ calculated value: 772.2457
[M + H] ⁺ measured value: 772.2477

Example 31. N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline -2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide Step A: 1- (6-{[(3S) -3-[( 4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxylic Methyl acid Example using the acid obtained in Preparation 14 and (3S) -3-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline obtained in Preparation 3 ′ The method described in Step A of 8 To use.

Step B: N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -N- (4-chlorophenyl) -1- (6-{[(3S) -3-[(4-methylpiperazine -1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide in Step C; Applying the method described in Steps B and C of Example 8 replacing 4-benzyloxy-N-phenyl-aniline with 4- [tert-butyl (dimethyl) silyl] oxy-N- (4-chlorophenyl) aniline. To do.

Step C: N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4 -Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide 250 mg of the product obtained in step B in 1.5 ml of THF ( 0.32 mL (0.32 mmol) of 1M tetrabutylammonium fluoride solution is added to the suspension of 0.29 mmol). After stirring for 2 hours, the reaction mixture is concentrated to dryness and purified by chromatography on silica gel (dichloromethane / methanol gradient) to give the desired product in the form of a foam.
Trace element analysis: (%, theoretical value / measured value)
% C = 70.06: 69.54;% H = 5.34: 4.93;% N = 9.28: 9.29

The compounds of Examples 32-36 are obtained according to the method of Example 31 using the appropriate NHR ₃ R ₄ amine.

Example 32. N- (4-hydroxyphenyl) -N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydro Isoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 73.65: 73.41;% H = 5.91: 5.47;% N = 9.54: 9.58

Example 33. N-butyl-N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H ) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 72.08: 71;% H = 6.48: 6.06;% N = 10.01: 10.02
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₂ H ₄₅ N ₅ O ₅
[M + H] ⁺ calculated value: 700.3499
[M + H] ⁺ measured value: 700.3495

Example 34. N- (3-fluoro-4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H ) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -N-phenyl-1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 71.63: 69.22;% H = 5.46: 4.77;% N = 9.49: 9.36
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₀ FN ₅ O ₅
[M + H] ⁺ calculated value: 73.83092.
[M + H] ⁺ Measured value: 738.38303

Example 35. N- (4-fluorophenyl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydro Isoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 71.63: 69.88;% H = 5.46: 4.72;% N = 9.49: 9.5
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₀ FN ₅ O ₅
[M + H] ⁺ calculated value: 73.83092.
[M + H] ⁺ measured value: 738.38.66

Example 36. N- (4-chlorophenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } -1,3-benzodioxol-5-yl) -N- (2-phenylethyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 72.1: 71.1;% H = 5.79: 5.25;% N = 9.14: 9.34

Example 37. N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3, 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide Step A: 5-[(4-{[tert-butyl (Dimethyl) silyl] oxy} phenyl) {[1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H)- Yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indol-3-yl] carbonyl} amino] -1H-indole-1-carboxylate Preparation 6 ″ Replaced with 5 ”compound Was synthesized the title compound according to the method of Step A~B of Example 31.

Step B: N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide Product obtained in step A in 5 mL of methanol To the 0.49 mmol solution is added 135 mg (2.5 mmol) KOH. After stirring at ambient temperature for 3 hours, the reaction mixture is concentrated, treated with saturated aqueous NaHCO ₃ and extracted with methylene chloride. The organic phase is then dried over magnesium sulfate, filtered and evaporated to dryness. The crude product so obtained is then purified by chromatography on silica gel (dichloromethane / methanol gradient) to give the desired product in the form of a foam.
Trace element analysis: (%, theoretical value / measured value)
% C = 72.81: 72.42;% H = 5.58: 5.34;% N = 11.07: 10.84

Example 38.1- (5-Bromo-2-{[(3S) -3-[(3aR, 6aS) -hexahydrocyclopenta [c] pyrrol-2 (1H) -ylmethyl] -3,4-dihydro Isoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide Acid and preparation obtained in Step A, Preparation 13 (3S) -3-[(3aR, 6aS) -hexahydrocyclopenta [c] pyrrol-2 (1H) -ylmethyl] -1,2,3,4-tetrahydroisoquinoline obtained in 4 ′ The title compound is synthesized according to the method of Example 12.
Trace element analysis: (%, theoretical value / measured value)
% C = 69.13: 67.94;% H = 5.66: 5.25;% N = 7.68: 7.46;% Br = 10.95: 10.49
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₂ H ₄₁ ⁷⁹ BrN ₄ O ₃
[M + H] ⁺ calculated value: 729.2440
[M + H] ⁺ measured value: 729.2454

The compounds of Examples 39-41 are obtained according to the method of Example 31 using the appropriate NHR ₃ R ₄ amine.

Example 39. N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} -1,3-benzodioxol-5-yl) -N- (3-phenoxyphenyl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 73.97: 71.81;% H = 5.59: 5.26;% N = 8.63: 8.1
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₅₀ H ₄₅ N ₅ O ₆
[M + H] ⁺ calculated value: 812.3448
[M + H] ⁺ Measured value: 812.3431

Example 40. N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} -1,3-benzodioxol-5-yl) -N- (2-phenylethyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 73.88: 72.92;% H = 6.06: 5.64;% N = 9.36: 9.38

Example 41. N, N-bis (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 71.82: 70.67;% H = 5.62: 5.33;% N = 9.52: 8.97
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₁ N ₅ O ₆
[M + H] ⁺ calculated value: 736.3135
[M + H] ⁺ measured value: 736.3138

Example 42.1- (5-Bromo-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -5-methyl-N-phenyl-1H-pyrrole-3-carboxamide In Step A, the acid obtained in Preparation 10 and the (3S) -3- (4-morpholine obtained in Preparation 2 ′ The title compound is synthesized according to the method of Example 12 using (nylmethyl) -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 66.38: 65.51;% H = 5.28: 4.91;% N = 7.94: 7.95;% Br = 11.32: 10.2

The compounds of Examples 43-45 are obtained according to the method of Example 31 using the appropriate NHR ₃ R ₄ amine.

Example 43. N- (1-benzothiophen-5-yl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 71.21: 66.87;% H = 5.33: 4.87;% N = 9.03: 8.3; S = 4.13: 5.03
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₆ H ₄₁ N ₅ O ₅ S
[M + H] ⁺ calculated value: 776.2907
[M + H] ⁺ measured value: 776.2922

Example 44. N- (1-benzofuran-5-yl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3, 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 72.71: 70.11;% H = 5.44: 5.08;% N = 9.22: 8.78
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₆ H ₄₁ N ₅ O ₆
[M + H] ⁺ calculated value: 760.3135
[M + H] ⁺ measured value: 760.3135

Example 45. N- (4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl ] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured value)
% C = 73.04: 70.78;% H = 5.74: 5.26;% N = 10.87: 10.28
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₇ H ₄₄ N ₆ O ₅
[M + H] ⁺ calculated value: 773.3451
[M + H] ⁺ measured value: 773.3459

Example 46.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Acid obtained in Preparation 10 in Step A, Preparation 3 ′ The title compound according to the method of Example 12 using (3S) -3-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline and the compound of Preparation 5 ″ obtained in Is synthesized.
Trace element analysis: (%, theoretical value / measured value)
% C = 66.58: 64.54;% H = 5.45: 4.96;% N = 11.09: 10.48;% Br = 10.55: 10.02
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₂ H ₄₁ ⁷⁹ BrN ₆ O ₃
[M + H] ⁺ calculated value: 757.2502
[M + H] ⁺ Measured value: 757.2480

Example 47. N- (2,3-dihydro-1H-indol-5-yl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) ) Methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide The appropriate NHR ₃ R ₄ amine The title compound is synthesized according to the method of Example 31.
Trace element analysis: (%, theoretical value / measured value)
% C = 72.61: 70.73;% H = 5.83: 5.16;% N = 11.05: 10.51
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₆ H ₄₄ N ₆ O ₅
[M + H] ⁺ calculated value: 761.3451
[M + H] ⁺ measured value: 761.3418

Example 48.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1H-indole-3-carboxamide Step A: 5-[{[1- (5-bromo-2- { [(3S) -3-[(4-Methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -1H-indol-3-yl] carbonyl} Tert-Butyl (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) amino] -1H-indole-1-carboxylate The title compound is prepared according to the method of Example 37 using the acid obtained in Preparation 15. Composition That.

Step B: 1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1H-indole-3-carboxamide A solution of 495 mg (0.49 mmol) of the product obtained in Step A in 5 mL of methanol Is added 135 mg (2.5 mmol) of KOH. After stirring at ambient temperature for 3 hours, the reaction mixture is concentrated, treated with saturated aqueous NaHCO ₃ and extracted with methylene chloride. The organic phase is then dried over magnesium sulfate, filtered and evaporated to dryness. The crude product so obtained is then purified by chromatography on silica gel (dichloromethane / methanol gradient) to give the desired product in the form of a foam.
Trace element analysis: (%, theoretical value / measured value)
% C = 68.09: 66.77;% H = 5.21: 4.73;% N = 10.959: 10.29;% Br = 10.007: 9.76
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₄₁ ⁷⁹ BrN ₆ O ₃
[M + H] ⁺ calculated value: 793.2502
[M + H] ⁺ Measured value: 793.2539

Unless otherwise noted, the compounds of the following examples were prepared in step A by (i) the appropriate acid obtained according to one of Preparations 1-22 and (ii) one of Preparations 1′-12 ′. Examples using the appropriate tetrahydroisoquinoline compounds obtained according to Example 1, and in step B, (iii) suitable NHR ₃ R ₄ amines (a non-exhaustive list is provided in Preparations 1 "-26") Synthesize according to method 31. The compound so obtained can be isolated in the form of the hydrochloride salt using the salt formation protocol with methanolic ether shown at the end of step C of Example 1.

Example 49. N- (4-hydroxyphenyl) -N- (4-methoxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydro Isoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 72.08: 71.86;% H = 5.78: 5.49;% N = 9.34: 9.31

Example 50.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-fluorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 65.22: 65.4;% H = 5.34: 4.89;% N = 9.51: 9.53;% Br = 10.85: 10.86

Example 51. N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} -1,3-benzodioxol-5-yl) -N- [4- (trifluoromethoxy) phenyl] -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 67.24: 67.28;% H = 0.02: 4.73;% N = 8.71: 8.78

Example 52. N- (3-fluoro-4-methylphenyl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide Trace elemental analysis: (%, theoretical / measured)
% C = 71.89: 71.45;% H = 5.63: 5.15;% N = 9.31: 9.34

Example 53.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N- (4-methylphenyl) -1H-pyrrole-3-carboxamide Trace element analysis: (%, Theoretical value / Measured value)
% C = 67.21: 67.28;% H = 5.78: 5.62;% N = 9.56: 9.49;% Br = 10.91: 10.87

Example 54.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N, N-bis (4-hydroxyphenyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 67.01: 66.03;% H = 5.23: 5.23;% N = 9.09: 8.74

Example 55. N- (1H-indol-5-yl) -N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3, 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 74.58: 73.82;% H = 5.86: 5.69;% N = 11.1: 1.87

Example 56. N- (3,4-difluorophenyl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4 -Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 69.92: 69.53;% H = 5.2: 4.98;% N = 9.27: 9.07

Example 57.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (4-methylphenyl) -1H-indole-3-carboxamide Trace elemental analysis: (%, Theoretical value / Measured value)
% C = 68.75: 68.42;% H = 5.51: 5.88;% N = 9.11: 8.83;% Br = 10.39: 10.16

Example 58. N- (3-chloro-4-fluorophenyl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, Theoretical / Measured value)
% C = 65.35: 66.91;% H = 4.99: 4.83;% N = 8.66: 8.8;% Cl = 8.77: 7.03;% Cl− = 4. 38: 2.37

Example 59.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% H = 4.98: 5.64;% N = 8.87: 8.4;% C = 65.45: 65.99

Example 60.4-[(4-Methylphenyl) {[1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indol-3-yl] carbonyl} amino] phenyl acetate trace elemental analysis: (%, theoretical / measured) )
% C = 72.76: 71.25;% H = 5.85: 5.71;% N = 9.03: 8.92
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₇ H ₄₅ N ₅ O ₆
[M + H] ⁺ calculated value: 776.3448
[M + H] ⁺ measured value: 776.3398

Example 61.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N, N-bis (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 65.39: 63.91;% H = 5.49: 5.43;% N = 9.53: 9.12
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₄₀ ⁷⁹ BrN ₅ O ₄
[M + H] ⁺ calculated value: 734.2342
[M + H] ⁺ measured value: 734.2298

Example 62.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 63.79: 63.87;% H = 5.22: 5.13;% N = 9.3: 9.58

Example 63. N- (3-chloro-4-hydroxyphenyl) -N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, Theoretical / Measured value)
% C = 64.25: 64.13;% H = 5.27: 5.01;% N = 8.33: 8.18;% Cl− = 8.43: 7.25

Example 64. FIG. N- (3-Chloro-4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H ) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -N- [4- (propan-2-yl) phenyl] -1H-indole-3-carboxamide hydrochloride trace element analysis: %, Theoretical value / measured value)
% C = 64.94: 65.36;% H = 5.57: 5.2;% N = 8.06: 7.95;% Cl− = 8.16: 6.8

Example 65.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 67.79: 67.6;% H = 5.55: 5.52;% N = 9.88: 9.98

Example 66.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-fluorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 69.4: 68.97;% H = 5.68: 5.64;% N = 10.12: 10.08

Example 67.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N, N-bis (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 69.6: 69.52;% H = 5.84: 5.73;% N = 10.15: 10.31

Example 68. N- (1H-indazol-5-yl) -N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3, 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured) )
% C = 66.5: 66.14;% H = 5.46: 5.3;% N = 11.8: 11.86;% Cl− = 8.53: 8.06

Example 69.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured) )
% C = 62.73: 63.57;% H = 5.15: 5.04;% N = 9.54: 9.64;% Cl− = 8.05: 6.7

Example 70.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theory Value / measured value)
% C = 61.14: 62.23;% H = 5.37: 5.27;% N = 9.95: 10.13;% Cl- = 8.39: 7
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₃ H ₄₃ ⁷⁹ BrN ₆ O ₃
[M + H] ⁺ calculated value: 771.2658
[M + H] ⁺ measured value: 771.2645

Example 71.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-fluorophenyl) -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 66.84: 66.66;% H = 0.09: 5.23;% N = 9.06: 8.81;% Br = 10.34: 9.95

Example 72.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1H-indole-3-carboxamide The title compound according to the method of Example 37 using the acid obtained in Preparation 16 Is synthesized.
Trace element analysis: (%, theoretical value / measured value)
% C = 72.13: 71.39;% H = 5.51: 5.45;% N = 111.22: 10.75;% Cl = 4.73: 5.46

Example 73.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N, N-bis (4-hydroxyphenyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 71.11: 70.47;% H = 5.55: 5.45;% N = 9.64: 9.44

Example 74.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (4-methylphenyl) -1H-indole-3-carboxamide Trace elemental analysis: (%, Theoretical value / Measured value)
% C = 72.96: 72.95;% H = 5.84: 5.74;% N = 9.67: 9.57

Example 75.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-fluorophenyl) -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 70.92: 70.28;% H = 5.4: 5.29;% N = 9.62: 9.44

Example 76.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical value / measured value)
% C = 69.35: 69.01;% H = 5.28: 5.16;% N = 9.4: 9.17;% Cl = 9.52: 9.74

Example 77.1- (5-Chloro-4-fluoro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H) -Yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, Theoretical value / measured value)
% C = 63.12: 63.39;% H = 5.42: 5.16;% N = 10.27: 10.04;% Cl = 13: 12.21;% Cl− = 8.67: 7

Example 78.1- (5-Chloro-4-fluoro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H) -Yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, theory Value / measured value)
% C = 64.68: 64.96;% H = 5.19: 4.89;% N = 9.84: 9.63;% Cl = 12.45: 12.01;% Cl− = 8. 3: 6.83

Example 79.1- (5-Bromo-2-{[(3S) -3-[(4,4-difluoropiperidin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl ] Carbonyl} phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Trace elemental analysis: (%, theoretical / measured) )
% C = 64.78: 63.92;% H = 4.92: 4.98;% N = 8.99: 8.97;% Br = 10.26: 10.8

Example 80.1- (5-Bromo-2-{[(3S) -3-[(4-cyclopentylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Trace element analysis: (%, Theoretical / Measured)
% C = 68.06: 66.99;% H = 5.84: 5.75;% N = 10.35: 10.1;% Br = 9.84: 9.81

Example 81. N- (3-Chloro-4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazine-1 -Yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, Theoretical value / measured value)
% C = 64.13: 64.93;% H = 5.15: 4.92;% N = 9.55: 9.57;% Cl = 12.08: 11;% Cl− = 8.06: 6.45

Example 82. N- (3-chloro-4-hydroxyphenyl) -N- (1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl ] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, theory Value / measured value)
% C = 63.78: 64.52;% H = 5: 4.87;% N = 9.7: 9.72;% Cl = 12.28: 11.49;% Cl− = 8.19: 6.77

Example 83. N, N-bis (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline- 2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 70.37: 70.32;% H = 5.91: 5.77;% N = 10.01: 9.91

Example 84. N- (4-fluorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 70.17: 68.82;% H = 5.74: 5.5;% N = 9.98: 9.81
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₁ H ₄₀ FN ₅ O ₅
[M + H] ⁺ calculated value: 702.3092
[M + H] ⁺ Measured value: 702.3096

Example 85. N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3, 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 68.56: 68.13;% H = 5.61: 5.53;% N = 9.75: 9.66

Example 86.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Trace element analysis: (%, Theoretical / Measured)
% C = 70.72: 70.45;% H = 5.79: 5.69;% N = 11.78: 11.56;% Cl = 4.97: 5.5

Example 87. N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl ] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide Trace elemental analysis: (%, theoretical / measured value)
% C = 71.45: 71.1;% H = 5.86: 5.86;% N = 11.63: 11.52

Example 88.5-Chloro-N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazine-1 -Yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (% , Theoretical value / measured value)
% C = 69.64: 69.34;% H = 5.21: 5.21;% N = 10.59: 10.45

Example 89.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1H-pyrrole-3-carboxamide trace elemental analysis: (%, theoretical / measured value)
% C = 71.01: 69.93;% H = 5.96: 5.84;% N = 11.56: 11.2
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₃ ³⁵ ClN ₆ O ₃
[M + H] ⁺ calculated value: 727.3163
[M + H] ⁺ measured value: 727.3126

Example 90. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazine-1 -Yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide trace element analysis: (% , Theoretical value / measured value)
% C = 71.72: 69.98;% H = 6.02: 6.02;% N = 11.41: 11.05
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₄ N ₆ O ₅
[M + H] ⁺ calculated value: 737.3451
[M + H] ⁺ measured value: 737.3444

Example 91.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -5-methyl-N- (4-methylphenyl) -1H-pyrrole-3-carboxamide Trace element analysis: (%, Theoretical value / Measured value)
% C = 71.55: 71.06;% H = 6.15: 6.08;% N = 10.18: 10.02

Example 92.1- (3,5-dichloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl ] Carbonyl} phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Acid prepared in Step A, Preparation 17, Preparation According to the method of Example 12 using (3S) -3-[(4-methyl-1-piperazinyl) methyl] -1,2,3,4-tetrahydroisoquinoline obtained in 3 ′ and the compound of Preparation 5 ″ Synthesize the title compound.
Trace element analysis: (%, theoretical value / measured value)
% C = 67.47: 67.28;% H = 5.39: 5.84;% N = 11.24: 10.07;% Cl = 9.48: 9.21

Example 93.1- (5-Chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 72.38: 71.93;% H = 5.68: 5.94;% N = 11.01: 10.28

Example 94.1- (6-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxole -5-yl) -N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (% , Theoretical value / measured value)
% C = 68.56: 68.21;% H = 5.61: 5.43;% N = 9.75: 9.56;% Cl = 4.94: 5.41;% Cl− = 4. 94: 5.17

Example 95.1- (5-Chloro-2-{[(3S) -3-[(dimethylamino) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 67.79: 67.07;% H = 5.55: 5.34;% N = 9.88: 9.58;% Cl = 10.01: 10.09;% Cl− = 5: 5.41

Example 96. N- (4-hydroxyphenyl) -5-methyl-N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 72.29: 72.01;% H = 6.21: 6.05;% N = 10.04: 9.95

Example 97. N- (3-Fluoro-4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3-[(4-methylpiperazine-1 -Yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide hydrochloride trace element analysis: (%, Theoretical value / measured value)
% C = 65.35: 65.8;% H = 5.25: 5.15;% N = 9.73: 9.57;% Cl− = 8.21: 6.82

Example 98. N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} -1,3-benzodioxol-5-yl) -N- (piperidin-4-yl) -1H-indole-3-carboxamide bis-hydrochloride Step A: 4-[(4-methylphenyl) {[1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3- Benzodioxol-5-yl) -1H-indol-3-yl] carbonyl} amino] piperidine-1-carboxylate tert-butyl Example 31 using the acid from Preparation 14 and the compound from Preparation 19 ″ According to the method of steps A to B The serial compound is synthesized.

Step B: N- (4-Methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -N- (piperidin-4-yl) -1H-indole-3-carboxamide bis-hydrochloride in methylene chloride (7 mL) starting material To a solution of (615 mg; 0.74 mmol) is added trifluoroacetic acid (0.5 mL; 6 mmol). After stirring for 17 hours at ambient temperature, the reaction mixture is poured into a mixture consisting of aqueous sodium bicarbonate solution and dichloromethane. The aqueous phase was extracted with dichloromethane, then dried over MgSO ₄ , concentrated to dryness and the residue was purified by chromatography on silica gel (CH ₂ Cl ₂ / MeOH gradient) to give the free base as a white powder. Give in form. This compound is dissolved in CH ₂ Cl ₂ and then treated with 1M HCl solution in ether (2 mL; 2 mmol) at ambient temperature. The solution is then dried and the residue is lyophilized.
Trace element analysis: (%, theoretical value / measured value)
% C = 63.35: 63.51;% H = 6.16: 6.04;% N = 10.07: 10.14;% Cl = 12.75: 11.53;% Cl− = 12. 75: 11.92

Example 99. N- (1-ethyl-1H-indol-5-yl) -N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl ] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide trace element analysis: (%, theoretical / measured value)
% C = 73.26: 72.93;% H = 5.89: 5.74;% N = 10.68: 10.69

Example 100. N- (4-hydroxyphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} -1,3-benzodioxol-5-yl) -N- [1- (propan-2-yl) -1H-indol-5-yl] -1H-indole-3-carboxamide trace element analysis: (%, Theoretical value / measured value)
% C = 73.48: 74.43;% H = 6.04: 5.81;% N = 10.49: 10.71

Example 101.1- (5-Bromo-2-{[(3S) -3-[(4-methylpiperazin-1-yl) carbonyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl } Phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide Trace element analysis: (%, Theoretical / Measured)
% C = 65.37: 65.39;% H = 0.09: 4.89;% N = 10.89: 10.67;% Br = 10.35: 10.47

Example 102.1- (5-Bromo-2-{[(3S) -3-[(4-cyclobutylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] Carbonyl} phenyl) -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 67.75: 67.81;% H = 5.69: 5.63;% N = 10.53: 10.32;% Br = 10.02: 9.89

Example 103. N- (2,3-dihydro-1H-indol-5-yl) -N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3-[(4-methylpiperazine -1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element Analysis: (%, theoretical value / measured value)
% C = 64.74: 63.93;% H = 5.81: 6.29;% N = 10.53: 8.92;% Cl = 8.89: 10.68;% Cl− = 8. 89: 10.58

Example 104.1- (5-bromo-2-{[(3S) -3- (pyrrolidin-1-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -N- (1H-indol-5-yl) -5-methyl-1H-pyrrole-3-carboxamide trace element analysis: (%, theoretical / measured)
% C = 67.58: 67.45;% H = 5.26: 5.09;% N = 9.61: 9.36;% Br = 10.97: 10.84

Example 105. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3- (pyrrolidin-1-ylmethyl)- 3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured value)
% H = 5.69: 5.51;% N = 9.41: 9.2;% Cl = 4.76: 5.06;% Cl− = 4.76: 4.8;% C = 69. 39: 69.24

Example 106. N- (4-hydroxyphenyl) -5-methyl-N- (4-methylphenyl) -1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinoline- 2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 68.28: 67.63;% H = 5.73: 5.65;% N = 7.77: 7.53;% Cl− = 4.92: 4.81

Example 107. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -2,3-Dihydro-1H-inden-5-yl) -N-phenyl-1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 71.73: 71.34;% H = 6.16: 6.15;% N = 7.97: 7.87;% Cl− = 5.04: 4.73

Example 108. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -N-phenyl-1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical value / measured value)
% C = 67.93: 68.17;% H = 5.56: 5.43;% N = 7.92: 8.09;% Cl− = 5.01: 4.77

Example 109. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3- (morpholin-4-ylmethyl)- 3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured value)
% C = 67.93: 66.48;% H = 5.57: 5.52;% N = 9.21: 9.24;% Cl− = 4.66: 5.67
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₁ N ₅ O ₆
[M + H] ⁺ calculated value: 724.3135
[M + H] ⁺ Measured value: 724.3073

Example 110. N- (2,3-dihydro-1H-indol-5-yl) -N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3- (morpholin-4-ylmethyl) ) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -2,3-dihydro-1H-inden-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, Theoretical value / measured value)
% C = 67.69: 67.78;% H = 6.07: 6.04;% N = 8.97: 9.39;% Cl = 9.08: 7.96;% Cl- = 9. 08: 8.09

Example 111. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3R) -3-methyl-3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzo Dioxol-5-yl) -N- (1-methylpiperidin-4-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 67.23: 66.34;% H = 6.11: 6.01;% N = 8.71: 8.72;% Cl− = 5.51: 5.67

Example 112. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3R) -3-methyl-3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzo Dioxol-5-yl) -N- [3- (4-methylpiperazin-1-yl) phenyl] -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 68.37: 68.91;% H = 5.88: 5.34;% N = 9.72: 9.78;% Cl− = 4.92: 5.24

Example 113. N- (4-hydroxyphenyl) -1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3 -Benzodioxol-5-yl) -N-phenyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide hydrochloride In step A, the acid obtained in preparation 19 and obtained in preparation 2 ' The title compound is synthesized according to the method of Example 12 using (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline.
Trace element analysis: (%, theoretical value / measured value)
% C = 69.11: 68.82;% H = 5.8: 5.8;% N = 7.5: 7.45;% Cl− = 4.74: 4.46
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₂ N ₄ O ₆
[M + H] ⁺ calculated value: 711.3183
[M + H] ⁺ measured value: 711.3140

Example 114. N- (4-hydroxyphenyl) -5-methyl-N- (2-methyl-2,3-dihydro-1H-isoindol-5-yl) -1- (6-{[(3R) -3-methyl -3,4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical /measured value)
% C = 69.17: 68.95;% H = 5.51: 5.33;% N = 8.27: 8.05;% Cl− = 5.24: 5.23

Example 115. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-2,3-dihydro-1H-indol-5-yl) -1- (6-{[(3R) -3-methyl- 3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured value)
% C = 69.17: 69.32;% H = 5.51: 5.27;% N = 8.27: 8.48;% Cl− = 5.24: 5.18

Example 116. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3R) -3-methyl-3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzo Dioxol-5-yl) -N- {1- [2- (morpholin-4-yl) ethyl] -1H-indol-5-yl} -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: ( %, Theoretical value / measured value)
% C = 68.25: 67.87;% H = 5.73: 5.42;% N = 9.04: 8.8;% Cl− = 4.58: 4.81

Example 117. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1- (6-{[(3S) -3- (morpholin-4-ylmethyl)- 3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -2,3-dihydro-1H-inden-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical /measured value)
% C = 71.46: 70.88;% H = 6.13: 5.89;% N = 9.26: 9.12;% Cl− = 4.69: 4.37

Example 118. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1- (5-{[(3S) -3- (morpholin-4-ylmethyl)- 3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -2,3-dihydro-1-benzofuran-6-yl) -1H-pyrrole-3-carboxamide The acid obtained in Preparation A in Step A, According to the method of Example 12 using (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline obtained in Preparation 2 ′ and the appropriate NR ₃ R ₄ amine. A compound is synthesized.
Trace element analysis: (%, theoretical value / measured value)
% C = 73.21: 72.64;% H = 6: 6.03;% N = 9.7: 9.57

Example 119. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-indol-5-yl) -1- (5-{[(3S) -3- (morpholin-4-ylmethyl)- 3,4-Dihydroisoquinolin-2 (1H) -yl] carbonyl} -1-benzofuran-6-yl) -1H-pyrrole-3-carboxamide hydrochloride In step A, the acid obtained in preparation 21, preparation 2 ′ The title compound is synthesized according to the method of Example 12 using the resulting (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline and the appropriate NR ₃ R ₄ amine. .
Trace element analysis: (%, theoretical value / measured value)
% C = 69.88: 69.87;% H = 5.6: 5.29;% N = 9.26: 9.18;% Cl− = 4.69: 4.44

Example 120. N- (4-hydroxyphenyl) -5-methyl-1- (6-{[(3S) -3- [2- (morpholin-4-yl) ethyl] -3,4-dihydroisoquinoline-2 (1H) -Yl] carbonyl} -1,3-benzodioxol-5-yl) -N-phenyl-1H-pyrrole-3-carboxamide hydrochloride trace element analysis: (%, theoretical / measured)
% C = 68.28: 67.77;% H = 5.73: 5.59;% N = 7.77: 7.69;% Cl- = 4.92: 5

Example 121.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N, N-dibutyl-1H-indazole-3 Carboxamide The compound of Preparation 6d is treated according to the procedure described in Example 126.
_{LC / MS (C 33 H 39} N 5 O 2) 538 [M + H] +; RT2.33 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₃ H ₃₉ N ₅ O ₂
[M + H] ⁺ calculated value: 538.3177
[M + H] ⁺ measured value: 538.3169

Example 122.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N, N-diphenyl-1H-indazole-3 Carboxamide The compound of Preparation 6e was treated according to the procedure described in Example 126 and the product so obtained was purified by chromatography on silica gel with a gradient from dichloromethane to 94: 6 dichloromethane / methanol mixture. To do.
_{LC / MS (C 37 H 31} N 5 O 2) 578 [M + H] +; RT1.15 ( Method B)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₁ N ₅ O ₂
[M + H] ⁺ calculated value: 578.2551
[M + H] ⁺ Measured value: 578.2548

Example 123.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N, N-diphenyl-1H-indole-3 -Carboxamide The procedure is the same as Example 131 steps A and C, replacing the compound obtained in Preparation 3d with the compound obtained in Preparation 3f.
LC / MS (C ₃₈ H ₃₂ N ₄ O ₂ ) 577 [M + H] ⁺ ; RT 2.24 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₂ N ₄ O ₂
[M + H] ⁺ calculated value: 577.2598
[M + H] ⁺ measured value: 577.2600

Example 124.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -6- (benzyloxy) -N, N- Diphenyl-1H-indazole-3-carboxamide The compound of Preparation 6c was treated according to the procedure described in Example 126 and then purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture. To do.
_{LC / MS (C 44 H 37} N 5 O 3) 684 [M + H] +; RT2.45 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₃₇ N ₅ O ₃
[M + H] ⁺ calculated value: 6844.2969
[M + H] ⁺ measured value: 684.2982

Example 125.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -6-hydroxy-N, N-diphenyl-1H Indazole-3-carboxamide The compound obtained in Example 124 (30 mg, 0.04 mmol) is dissolved in dichloromethane (5 mL), cooled to −78 ° C. under nitrogen and then boron trichloride (1 M, 0.02 mL). 0.2 mmol). Allow the reaction mixture to warm to ambient temperature again and stir for 3 hours. The reaction mixture is inactivated with methanol, neutralized with triethylamine and concentrated. The residue is extracted with ethyl acetate, washed with water, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography with dichloromethane, 95: 5 dichloromethane / methanol mixture and then with 94: 6 dichloromethane / methanol mixture.
_{LC / MS (C 37 H 31} N 5 O 3) 594 [M + H] +; RT2.15 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₁ N ₅ O ₃
[M + H] ⁺ calculated value: 594.2500
[M + H] ⁺ Measured value: 594.2526

Example 126.1 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -6-methoxy-N, N-diphenyl-1H Indazole-3-carboxamide Step A: N-{[(3S) -2- {2- [3- (Diphenylcarbamoyl) -6-methoxy-1H-indazol-1-yl] benzoyl} -1,2,3 , 4-Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl Preparation of 6 g of the compound (39 mg, 0.08 mmol) in dichloromethane (8 mL) and N, N-dimethylformamide (1 drop) under nitrogen. At 0 ° C., then 2M oxalyl chloride (14 μl, 0.17 mmol) is added and the reaction mixture is stirred for 1 h and concentrated under reduced pressure. N-Boc-aminomethyl THIQ (44.2 mg, 0.17 mmol) and triethylamine (60 μl, 0.4 mmol) dissolved in dichloromethane (5 mL) were cooled to 0 ° C. under nitrogen and then acid chloride in dichloromethane. Are added dropwise and the reaction mixture is stirred overnight at ambient temperature. The reaction mixture is partitioned between dichloromethane and water according to its solubility, the organic phase is separated, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on silica gel with a gradient of isohexane to 1: 1 isohexane / ethyl acetate mixture to give a gum.
_{LC / MS (C 43 H 41} N 5 O 5) 608 [M-Boc] +; RT2.78 ( Method A)

Step B: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -6-methoxy-N, N-diphenyl-1H- Indazole-3-carboxamide A solution of the compound obtained in step A (58 mg, 0.08 mmol) in 4M HCl is stirred in dioxane (3 mL) at ambient temperature for 1 hour. The reaction mixture is neutralized with 2M NaOH and the product is extracted with ethyl acetate, dried over magnesium sulfate, filtered and concentrated. The product is purified on an SCX column, washed with methanol and eluted with a 1: 1 methanol / 7N ammonia mixture in methanol. Final purification is performed by preparative HPLC.
LC / MS (C ₃₈ H ₃₃ N ₅ O ₃ ) 608 [M + H] ⁺ ; RT 2.27 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₃ N ₅ O ₃
[M + H] ⁺ calculated value: 608.2656
[M + H] ⁺ Measured value: 608.2650

Example 127.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -6-hydroxy-N, N-diphenyl-1H -Indole-3-carboxamide Step A: N-{[(3S) -2- {2- [6- (benzyloxy) -3- (diphenylcarbamoyl) -1H-indol-1-yl] benzoyl} -1, The compound obtained in Preparation 3b (238 mg, 0.44 mmol) in tert-butyl 2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate dichloromethane (8 mL) and 1 drop of N, N-dimethylformamide Cool to 0 ° C. and then add oxalyl chloride (0.07 mL, 0.44 mmol). The reaction mixture is stirred for 1 hour and then concentrated under reduced pressure. This material is prepared in the form of a suspension / solution in dichloromethane (5 mL) in the form of a suspension of N-[(3S) -1,2,3,4-tetrahydroisoquinoline-3-3 obtained in Preparation 1 ′ in 5 mL of dichloromethane. Add to a solution of tert-butyl ylmethyl] carbamate (232 mg, 0.88 mmol) and triethylamine (0.31 mL, 2.2 mmol), cool the whole to 0 ° C. and stir the reaction mixture under nitrogen for about 16 hours. . The reaction mixture is extracted with ethyl acetate, washed with water, dried over magnesium sulfate, filtered and evaporated and purified by chromatography on silica gel with a gradient of isohexane to 1: 1 isohexane / ethyl acetate mixture. Give oil.
_{LC / MS (C 50 H 46} N 4 O 5) 783 [M + H] +; RT2.86 ( Method A)

Step B: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -6-hydroxy-N, N-diphenyl-1H- Indole-3-carboxamide The product obtained in Step A (155 mg, 0.20 mmol) is dissolved in dichloromethane (8 mL), cooled to −78 ° C. under nitrogen, then excess boron trichloride solution is added, Allow the reaction mixture to warm to ambient temperature again over 2 hours. Methanol is added to inactivate the reaction mixture, triethylamine is added to neutralize, evaporate and partition between ethyl acetate and water according to its solubility. The organic phase is dried over magnesium sulfate, the solvent is removed under reduced pressure, and the crude product is first chromatographed on a silica gel column eluting with a dichloromethane to 95: 5 dichloromethane / methanol mixture, followed by preparative HPLC. Purification gives the product in solid form.
LC / MS (C ₃₈ H ₃₂ N ₄ O ₃ ) 593 [M + H] ⁺ ; RT 1.06 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₂ N ₄ O ₃
[M + H] ⁺ calculated value: 593.2547
[M + H] ⁺ Measured value: 593.2550

Example 128.2-[(1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -3- (diphenylcarbamoyl)- 1H-indazol-6-yl) oxy] acetic acid methyl step A: 2-[(1- {2-[(3S) -3-({[(tert-butoxy) carbonyl] amino} methyl) -1,2, 3,4-Tetrahydroisoquinoline-2-carbonyl] phenyl} -3- (diphenylcarbamoyl) -1H-indazol-6-yl) oxy] ethyl acetate The compound of Example 133, Step B (175 mg, 0.25 mmol) was added to acetone. (10 mL), then potassium carbonate (46 mg, 0.33 mmol) and ethyl 2-bromoacetate (36 μl, 0.33 mmol) are added and the reaction mixture is refluxed under nitrogen. Heating night. The reaction mixture is concentrated, extracted with ethyl acetate, washed with water, the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography with a gradient of isohexane to 1: 1 isohexane / ethyl acetate mixture to give a gum.
_{LC / MS (C 46 H 45} N 5 O 7) 680.3 [M-Boc] +; RT2.77 ( Method A)

Step B: 2-[(1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -3- (diphenylcarbamoyl) -1H -Indazol-6-yl) oxy] methyl acetate The compound obtained in step A (102 mg, 0.13 mmol) is dissolved in dichloromethane (4 mL); 1 mL of trifluoroacetic acid is added and the reaction mixture is stirred at ambient temperature for 1 hour. To do. The reaction mixture is neutralized with triethylamine and concentrated, the residue is extracted with ethyl acetate and washed with saturated sodium bicarbonate solution. The organic phase is dried over magnesium sulfate, filtered and applied to an SCX column, which is washed with methanol and the compound is eluted with a 3: 1 methanol / 7N ammonia solution in methanol. Purification of the product by further chromatography on silica gel with dichloromethane to 98: 2 dichloromethane / methanol mixture, then 96: 4 dichloromethane / methanol, then 9: 1 dichloromethane / methanol yields a deprotected transesterification. A type compound (Example 128) and a fully deprotected compound (Example 129) are produced.
_{LC / MS (C 40 H 35} N 5 O 5) 666 [M + H] +; RT2.26 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₃₅ N ₅ O ₅
[M + H] ⁺ calculated value: 666.2711
[M + H] ⁺ measured value: 666.2745

Example 129.2-[(1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -3- (diphenylcarbamoyl)- 1H-indazol-6-yl) oxy] acetic acid Starting from step 128 of example 128, the compound of example 129 is isolated as a secondary product.
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₃₃ N ₅ O ₅
[M + H] ⁺ calculated value: 652.2554
[M + H] ⁺ measured value: 652.2584

Example 130.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- [4- (benzyloxy) phenyl] -N-phenyl-1H-indole-3-carboxamide To a solution of the compound obtained in Step 131 of Preparation 131 (50 mg, 0.06 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.5 mL); The reaction mixture is stirred at ambient temperature for about 16 hours. The reaction mixture is diluted with water, made alkaline with 2M aqueous NaOH and the product is extracted with dichloromethane. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give the product in solid form. give.
_{LC / MS (C 45 H 38} N 4 O 3) 683 [M + H] +; RT2.44 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₃₈ N ₄ O ₃
[M + H] ⁺ calculated value: 683.3017
[M + H] ⁺ measured value: 683.3997

Example 131.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N- Phenyl-1H-indole-3-carboxamide Step A: N-{[(3S) -2- [2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indole-1- Yl) benzoyl] -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl in tetrahydrofuran (5 mL) to a solution of the acid obtained in Preparation 3d (318 mg, 0.59 mmol) Triethylamine (0.16 mL, 1.18 mmol), HOBT (100 mg, 0.65 mmol), EDAC (125 mg, 0.65 mmol) and N-[(3S) -1, , 3,4-tetrahydroisoquinoline-3-ylmethyl] carbamic acid tert- butyl (186 mg, 0.71 mmol) was added and stirred for about 16 hours the reaction mixture at ambient temperature. The reaction mixture is diluted with ethyl acetate and washed with water, the organic phase is dried over magnesium sulfate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a gradient of isohexane to 1: 1 ethyl acetate / isohexane mixture to give the product in the form of a solid.
_{LC / MS (C 50 H 46} N 4 O 5) 783 [M + H] +; RT2.92 ( Method A)

Step B: N-{[(3S) -2- (2- {3-[(4-hydroxyphenyl) (phenyl) carbamoyl] -1H-indol-1-yl} benzoyl) -1,2,3,4 -Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl In a solution of the material obtained in step A (210 mg, 0.268 mmol) in ethanol (10 mL) degassed and washed with nitrogen, 10% palladium on carbon The catalyst is added and the reaction mixture is stirred under hydrogen for about 72 hours at ambient temperature, during which time an additional amount of 10% palladium on carbon catalyst is added. The reaction mixture is filtered through celite, washed with methanol and evaporated to give an oil. The product is used in subsequent steps without further purification.
_{LC / MS (C 43 H 40} N 4 O 5) 693 [M + H] +; RT2.68 ( Method A)

Step C: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl -1H-indole-3-carboxamide To a solution of the compound obtained in step B (200 mg, 0.29 mmol) in dichloromethane (5 mL) is added trifluoroacetic acid (0.5 mL) and the reaction mixture is stirred at ambient temperature 2 Stir for hours. The reaction mixture is diluted with water, made alkaline with 2M NaOH and the product is extracted with dichloromethane. The organic extract is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product in powder form. Give in.
LC / MS (C ₃₈ H ₃₂ N ₄ O ₃ ) 593 [M + H] ⁺ ; RT 2.12 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₂ N ₄ O ₃
[M + H] ⁺ calculated value: 593.2547
[M + H] ⁺ Measured value: 593.2545

Example 132.1- {6-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxole-5 Il} -N, N-diphenyl-1H-indazole-3-carboxamide Step A: N-{[(3S) -2- {6- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] -2H Tert-Butyl-1,3-benzodioxole-5-carbonyl} -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate obtained in Step A of Preparation 6a in tetrahydrofuran (5 mL). To a solution of acid (450 mg, 0.94 mmol), triethylamine (0.26 mL, 1.88 mmol), HOBT (158 mg, 1.03 mmol) and EDAC (197 mg, 1.03 mmol), and Compound of Preparation 1 '(247 mg, 0.94 mmol) is added. The reaction mixture was stirred at ambient temperature for the weekend, after which additional amounts of triethylamine (0.13 mL, 0.94 mmol), HOBT (79 mg, 0.52 mmol) and EDAC (99 mg, 0.5 mmol) were added and the reaction Stir the mixture overnight. The reaction mixture is diluted with ethyl acetate and washed with water and saturated sodium bicarbonate solution. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of isohexane to 1: 1 ethyl acetate / isohexane mixture to give the product in the form of an oil. Give in.
_{LC / MS (C 43 H 39} N 5 O 6) 622 [M-Boc] + observed; RT2.77 (Method A)

Step B: 1- {6-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinolin-2-carbonyl] -2H-1,3-benzodioxol-5-yl } -N, N-diphenyl-1H-indazole-3-carboxamide To a solution of the compound obtained in Step A (288 mg, 0.4 mmol) in dichloromethane (3 mL) is added trifluoroacetic acid (0.5 mL). The reaction mixture is stirred at ambient temperature for 1 hour. The reaction mixture is diluted with water and made alkaline with 2M NaOH. The organic phase is extracted with dichloromethane, dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture.
_{LC / MS (C 38 H 31} N 5 O 4) 622 [M-H] + observed; RT2.27 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₁ N ₅ O ₄
[M + H] ⁺ calculated value: 622.2449
[M + H] ⁺ Measured value: 622.2457

Example 133.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -3- (diphenylcarbamoyl) -1H-indazole- 6-carboxylic acid step A: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -6-hydroxy-1H-indazol-1-yl] benzoyl} -1,2,3,4 -Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl The compound obtained in Preparation 6h is treated according to the procedure described in Step A of Example 132.

Step B: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -6- (trifluoromethanesulfonyloxy-1H-indazol-1-yl] benzoyl} -1,2,3,4 Tert-butyl tetrahydroisoquinolin-3-yl] methyl} carbamate Compound of Step A (170 mg, 0.25 mmol) was dissolved in dichloromethane (10 mL), cooled to 0 ° C. under nitrogen and then triethylamine (0.28 mL). 2 mmol) and trifluoromethanesulfonic anhydride (62 μl, 0.37 mmol) are added (this is done before the whole is stirred for 1 hour at ambient temperature) The reaction mixture is diluted with dichloromethane and washed with water. Dry the magnesium sulfate, filter and concentrate the crude material with a gradient of isohexane to 3: 2 isohexane / ethyl acetate mixture. Purification by chromatography on a gel, give gum.
_{LC / MS (C 43 H 38} N 5 O 7 F 3 S) 726.2 [M-Boc] + observed; RT2.87 (Method A)

Step C: 1- {2-[(3S) -3-({[(tert-butoxy) carbonyl] amino} methyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -3- (Diphenylcarbamoyl) -1H-indazole-6-carboxylic acid To a solution of the compound obtained in Step B (92 mg, 0.11 mmol) in N, N-dimethylformamide / water mixture (9 mL: 3 mL) was added DPPP (9 mg, 0.022 mmol) is added and the mixture so obtained is degassed with nitrogen. Palladium (II) acetate (2.5 mg, 0.011 mmol) is added followed by degassing. The reaction mixture is then washed with carbon monoxide and then triethylamine (30 μl, 0.22 mmol) is added (this is done before heating the whole to 80 ° C. over 3 hours under CO atmosphere). The reaction mixture is concentrated and the residue is extracted with ethyl acetate and washed with dilute HCl. The organic phase is dried over magnesium sulfate, filtered and concentrated, applied to a PE-AX column, washed with methanol and the product eluted with a 9: 1 dichloromethane / formic acid mixture to give a solid.
_{LC / MS (C 43 H 39} N 5 O 6) 622 [M-Boc] + observed; RT2.67 (Method A)

Step D: 2- [3- (Diphenylcarbamoyl) -6-hydroxy-1H-indazol-1-yl] benzoic acid The compound of Step C is treated according to the procedure described in Step B of Example 132.
LC / MS (C ₃₈ H ₃₁ N ₅ O ₄ ) 622 [M + H] ⁺ ; RT 2.17 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₁ N ₅ O ₄
[M + H] ⁺ calculated value: 622.2449
[M + H] ⁺ measured value: 622.2439

Example 134.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (benzyloxy) -5-methoxyphenyl}- N, N-Diphenyl-1H-indazole-3-carboxamide To a solution of the acid from Preparation 6i (130 mg, 0.23 mmol) in tetrahydrofuran (3 mL) was added triethylamine (0.06 mL, 0.46 mmol), HOBT (39 mg). 0.253 mmol) and EDAC (49 mg, 0.253 mmol), followed by the compound of Preparation 1 ′ (60 mg, 0.23 mmol). The reaction mixture is stirred at ambient temperature for 7 hours and then diluted with ethyl acetate (this is done before washing with water and saturated sodium bicarbonate solution). The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of isohexane to 1: 1 ethyl acetate / isohexane to give the product in solid form .
Subsequent deprotection is performed according to Step B of Example 132.
_{LC / MS (C 45 H 39} N 5 O 4) 714 [M + H] +; RT2.47 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₃₉ N ₅ O ₄
[M + H] ⁺ calculated value: 714.3075
[M + H] ⁺ measured value: 714.3077

Example 135.1 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4-hydroxy-5-methoxyphenyl} -N, N -Diphenyl-1H-indazole-3-carboxamide To a solution of the compound of Example 134 (146 mg, 0.18 mmol) in ethanol (5 mL) is added 10% palladium on carbon catalyst; the mixture is degassed and washed with nitrogen To do. The reaction mixture is stirred overnight at ambient temperature under hydrogen. The reaction mixture is filtered through a celite cartridge, washed with methanol and concentrated. The product is used in subsequent steps without further purification as described in Step B of Example 132.
LC / MS (C ₃₈ H ₃₃ N ₅ O ₄ ) 624 [M + H] ⁺ ; RT 2.23 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₃ N ₅ O ₄
[M + H] ⁺ calculated value: 624.2605
[M + H] ⁺ Measured value: 624.2607

Example 136.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -5-hydroxy-N, N-diphenyl-1H Indazole-3-carboxamide The procedure is as described in Example 134, Step A, using the compound of Preparation 6j. The product so obtained is deprotected according to the method described in Example 135.
_{LC / MS (C 37 H 31} N 5 O 3) 594 [M + H] +; RT2.15 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₁ N ₅ O ₃
[M + H] ⁺ calculated value: 594.2500
[M + H] ⁺ Measured value: 5944.2482

Example 137.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4-nitrophenyl} -N, N-diphenyl-1H Indazole-3-carboxamide The procedure is the same as that described in Example 132, replacing the compound of Preparation 6a in Step A with the compound of Preparation 6b.
_{LC / MS (C 37 H 30} N 6 O 4) 623 [M + H] +; RT2.25 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₀ N ₆ O ₄
[M + H] ⁺ calculated value: 623.2401
[M + H] ⁺ measured value: 623.2380

Example 138.1- {4-amino-2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N, N-diphenyl-1H Indazole-3-carboxamide Step A: N-{[(3S) -2- {5-amino-2- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] benzoyl} -1,2,3 , 4-Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl In a solution of the compound obtained in Step A of Example 137 (360 mg, 0.5 mmol) in methanol (10 mL), zinc (327 mg, 5 mmol) was added. And ammonium chloride (267.5 mg, 5 mmol) are added and the reaction mixture is heated under reflux for 10 minutes under nitrogen. The reaction mixture is cooled to ambient temperature, filtered through celite, washed with hot methanol and concentrated. The residue is extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and concentrated. The material is used without further purification.
_{LC / MS (C 42 H 40} N 6 O 4) 593.3 [M-Boc] +; RT2.66 ( Method A)

Step B: 1- {4-amino-2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N, N-diphenyl-1H- Indazole-3-carboxamide The compound obtained in Step A is deprotected according to the procedure of Example B, Step B, then purified on an SCX column and the compound is eluted with a 4: 1 methanol / 7N ammonia mixture in methanol.
_{LC / MS (C 37 H 32} N 6 O 2) 593 [M + H] +; RT2.15 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₂ N ₆ O ₂
[M + H] ⁺ calculated value: 593.2660
[M + H] ⁺ Measured value: 593.2676

Example 139.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-hydroxyphenyl} -6-hydroxy-N, N -Diphenyl-1H-indazole-3-carboxamide The procedure is as in Preparation 6a, replacing the compound of Preparation 5a with the compound of Preparation 5c and using methyl 2-bromo-4-methoxybenzoate. The procedure described in Step B of Preparation 6b is applied, followed by the method described in Step A of Example 132.
The compound is dissolved in dichloromethane (3 mL), cooled to 0 ° C., then boron tribromide (1 M in dichloromethane, 0.4 mL, 0.4 mmol) is added and the reaction mixture is allowed to stand overnight at ambient temperature under nitrogen. Stir. The reaction mixture is cooled to 0 ° C. and inactivated with methanol. The crude material is purified by preparative HPLC.
_{LC / MS (C 37 H 31} N 5 O 4) 610 [M + H] +; RT2.08 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₁ N ₅ O ₄
[M + H] ⁺ calculated value: 610.2449
[M + H] ⁺ measured value: 610.2458

Example 140.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (methylamino) phenyl} -N, N- Diphenyl-1H-indazole-3-carboxamide Step A: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] -5- (methylamino) benzoyl} -1,2,3,4-Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl Compound (59 mg, 0.09 mmol) prepared in Step A of Example 138 in dichloromethane (5 mL) was added to 37 % Formaldehyde solution (12.4 μl, 0.09 mmol), then triacetoxyborohydride (54 mg, 0.255 mmol) and after 5 minutes 2 drops of acetic acid are added followed by nitrogen Under stirred overnight The reaction mixture at ambient temperature. The reaction mixture is partitioned between dichloromethane and brine according to its solubility, dried over magnesium sulfate, filtered and evaporated. The crude mixture of mono- and di-alkylated products is purified by chromatography on silica gel with an isohexane to 1: 1 isohexane / ethyl acetate mixture, then a 3: 2 isohexane / ethyl acetate mixture.
Compound _{1: LC / MS (C 43} H 42 N 6 O 4) 607.3 [M-Boc] +; RT2.7 ( Method A)
Compound _{2: LC / MS (C 44} H 44 N 6 O 4) 621.3 [M-Boc] +; RT2.78 ( Method A)

Step B: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (methylamino) phenyl} -N, N-diphenyl -1H-indazole-3-carboxamide The compound obtained in Step A is deprotected according to the procedure of Step B of Example 132, then purified on an SCX column and the compound is eluted with 7N ammonia in methanol.
LC / MS (C ₃₈ H ₃₄ N ₆ O ₂ ) 607 [M + H] ⁺ ; RT 2.23 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₄ N ₆ O ₂
[M + H] ⁺ calculated value: 607.2816
[M + H] ⁺ Measured value: 607.2788

Example 141.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (dimethylamino) phenyl} -N, N- Diphenyl-1H-indazole-3-carboxamide Compound 2 obtained in Step A of Example 140 was deprotected according to the procedure of Step B of Example 132 and then purified on an SCX column, eluting the compound with 7N ammonia in methanol. Let
_{LC / MS (C 39 H 36} N 6 O 2) 621 [M + H] +; RT2.31 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₃₉ H ₃₆ N ₆ O ₂
[M + H] ⁺ calculated value: 621.22973
[M + H] ⁺ measured value: 621.2955

Example 142.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (benzylamino) phenyl} -N, N- The compound was prepared using diphenyl-1H-indazole-3-carboxamide benzaldehyde according to the procedure described in Example 140, Step A, then deprotected according to the procedure of Example 132, Step B, purified on an SCX column, The compound is eluted with 4: 1 methanol / 7N ammonia solution in methanol.
_{LC / MS (C 44 H 38} N 6 O 2) 683 [M + H] +; RT2.37 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₃₈ N ₆ O ₂
[M + H] ⁺ calculated value: 683.3129
[M + H] ⁺ measured value: 683.3127

Example 143.1- {2-[(3S) -3-[(dimethylamino) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A: N- [4- (benzyloxy) phenyl] -1- {2-[(3S) -3-[(dimethylamino) methyl] -1,2, , 3,4-Tetrahydroisoquinoline-2-carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide The procedure of Example 131, Step A, with the compound of Preparation 1 ′ replaced with the compound of Preparation 12 ′. The method is the same.
_{LC / MS (C 47 H 42} N 4 O 3) 711 [M + H] +; RT2.44 ( Method A)

Step B: 1- {2-[(3S) -3-[(dimethylamino) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl)- N-phenyl-1H-indole-3-carboxamide To a solution of the compound obtained in Step A (200 mg, 0.28 mmol) in ethanol (10 mL) degassed with nitrogen is added 10% palladium on carbon catalyst. The reaction mixture is stirred under hydrogen at ambient temperature for about 16 hours. Filter the reaction mixture through celite, wash with ethanol, evaporate the solvent and purify the crude material by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give the product. Give in solid form.
_{LC / MS (C 40 H 36} N 4 O 3) 621 [M + H] +; RT2.09 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₃₆ N ₄ O ₃
[M + H] ⁺ calculated value: 621.2860
[M + H] ⁺ measured value: 621.2850

Example 144.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (2-phenoxyacetamido) phenyl} -N, N-diphenyl-1H-indazole-3-carboxamide Step A: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] -5- (2-phenoxy) Acetamido) benzoyl} -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl Compound (104 mg, 0.15 mmol) obtained in Step A of Example 138 in dichloromethane (5 mL) To this solution was added DIPEA (40 μl, 0.225 mmol), followed by 2-phenoxyacetyl chloride (25 μl, 0.18 mmol) and the reaction mixture under nitrogen. The mixture is stirred overnight at ambient temperature. The reaction mixture is diluted with dichloromethane, washed with water, dried over magnesium sulfate, filtered and concentrated (this is purified by chromatography on silica gel with a gradient of isohexane to 2: 1 ethyl acetate / isohexane mixture). The product is given in solid form.
_{LC / MS (C 50 H 46} N 6 O 6) 727.3 [M-Boc] +; RT2.79 ( Method A)

Step B: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (2-phenoxyacetamido) phenyl} -N, N -Diphenyl-1H-indazole-3-carboxamide The compound obtained in Step A was deprotected according to the procedure of Step B of Example 132 and then purified on an SCX column, and the compound was 4: 1 methanol / 7N ammonia mixture in methanol. Elute with.
_{LC / MS (C 45 H 38} N 6 O 4) 727 [M + H] +; RT2.33
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₃₈ N ₆ O ₄
[M + H] ⁺ calculated value: 727.3027
[M + H] ⁺ Measured value: 727.004

Example 145.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4-hydroxy-5-methoxyphenyl} -N- ( 4-Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure is the same as that of Example 131, replacing the compound of Preparation 3d with the compound of Preparation 3a.
_{LC / MS (C 39 H 34} N 4 O 5) 639 [M + H] +; RT2.03 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₃₄ N ₄ O ₅
[M + H] ⁺ calculated value: 639.2602
[M + H] ⁺ measured value: 639.2619

Example 146.1 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxyphenyl} -N- (4-hydroxyphenyl) ) -N-phenyl-1H-indole-3-carboxamide The procedure is the same as in Example 131, replacing the compound obtained in Preparation 3d with the compound obtained in Preparation 3e.
_{LC / MS (C 39 H 34} N 4 O 4) 623 [M + H] +; RT2.12 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₃₄ N ₄ O ₄
[M + H] ⁺ calculated value: 623.2653
[M + H] ⁺ Measured value: 623.2632

Example 147.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxyphenyl} -N, N-diphenyl-1H Indole-3-carboxamide The procedure is the same as that of Example 131, steps A and C, replacing the compound obtained in Preparation 3d with the compound obtained in Preparation 3g and purifying the final product by preparative HPLC. .
_{LC / MS (C 39 H 34} N 4 O 3) 607 [M + H] +; RT1.14 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₃₄ N ₄ O ₃
[M + H] ⁺ calculated value: 607.2704
[M + H] ⁺ Measured value: 607.2687

Example 148.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N- Phenyl-1H-indazole-3-carboxamide Step A: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- [ 4- (Benzyloxy) phenyl] -N-phenyl-1H-indazole-3-carboxamide The compound obtained in Preparation 6f was treated according to the procedure of Example 132, Step A, followed by Example 132. Deprotect according to procedure B.
Step B: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl -1H-indazole-3-carboxamide To a solution of compound (43 mg, 0.06 mmol) in methanol (4 mL) is added 10% palladium on carbon catalyst and the reaction mixture is washed with nitrogen. The reaction mixture is evacuated, filled with hydrogen and stirred under a hydrogen atmosphere for 2.5 hours. An additional amount of 10% palladium on carbon catalyst is added and stirring of the reaction mixture is continued for an additional 3 hours. Filter the reaction mixture through a celite cartridge, wash with methanol and then concentrate under reduced pressure to give a solid that is purified by flash chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture. (This is done before further purification with SCX). Before applying the compound in dichloromethane, the column is prewashed with methanol, then with dichloromethane, methanol and then with elution with a 1: 4 ammonia / methanol mixture in methanol.
_{LC / MS (C 37 H 31} N 5 O 3) 594 [M + H] +; RT2.11 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₇ H ₃₁ N ₅ O ₃
[M + H] ⁺ calculated value: 594.2500
[M + H] ⁺ measured value: 5944.2475

Example 149.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- [2- (phenylsulfanyl) acetamido] phenyl} -N, N-diphenyl-1H-indazole-3-carboxamide The procedure is the same as that described in Example 144 using 2- (phenylsulfanyl) acetyl chloride in Step A, and then the resulting compound Is deprotected according to the procedure described in Step B of Example 132.
_{LC / MS (C 45 H 38} N 6 O 3 S) 743 [M + H] +; RT2.39 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₃₈ N ₆ O ₃ S
[M + H] ⁺ calculated value: 7433.2799
[M + H] ⁺ measured value: 743.2772.

Example 150.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxyphenyl} -N, N-diphenyl-1H Indazole-3-carboxamide The procedure is as in Preparation 6a, replacing 6-bromo-2H-1,3-benzodioxole-5-carboxylic acid with 2-iodo-4-methoxybenzoic acid. . Then, the method described in Step A of Example 132 is applied.
The compound so obtained (0.18 g, 0.25 mmol) is then dissolved in anhydrous dichloromethane (5 mL), cooled to 0 ° C. under nitrogen and added dropwise with boron trichloride (0.09 mL, 1 mmol). Process and let it warm to ambient temperature overnight. The reaction mixture is then cooled to 0 ° C. and treated with boron tribromide (0.09 mL, 1 mmol) (after 4 hours, an additional 0.18 mL). The reaction mixture is inactivated with methanol, concentrated under reduced pressure, dissolved in ethyl acetate and washed with water. The organic phase is dried over magnesium sulfate, filtered and concentrated to give an oil which is purified by flash chromatography with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture.
LC / MS (C ₃₈ H ₃₃ N ₅ O ₃ ) 608.2 [M + H] ⁺ ; RT 2.25 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₃ N ₅ O ₃
[M + H] ⁺ calculated value: 608.2656
[M + H] ⁺ measured value: 608.2639

Example 151.1- {2-[(3S) -3-[(dimethylamino) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N, N-diphenyl-1H- Indole-3-carboxamide

Example 152.1- {4-amino-2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxyphenyl} -N, N -Diphenyl-1H-indazole-3-carboxamide Step A: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] -5-hydroxy-4-methoxy Benzoyl} -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl procedure is 6-bromo-2H-1,3-benzodioxole-5-carboxylic acid 5- As in preparation 6a, substituting (benzyloxy) -2-bromo-4-methoxybenzoic acid. Then, the method described in Step A of Example 132 is applied.
The compound so obtained (367 mg, 0.45 mmol) is dissolved in ethyl acetate (10 mL) and degassed, then 10% palladium on carbon catalyst is added. The reaction mixture is degassed and then stirred overnight at ambient temperature under a hydrogen atmosphere. The reaction mixture is filtered through celite, washed with ethyl acetate and concentrated to give a solid that is used in the subsequent step without further purification.
_{LC / MS (C 44 H 42} N 4 O 6) 723.3 [M + H] +; RT2.68 ( Method A)

Step B: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] -4-methoxy-5- (trifluoromethanesulfonyloxy) benzoyl} -1, To a solution of the compound obtained in Step A (236 mg, 0.33 mmol) in tert-butyl 2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate dichloromethane (10 mL) was added triethylamine (0.14 mL, 1 mmol). ) Is added. The reaction mixture is cooled to 0 ° C. under nitrogen and then trifluoromethanesulfonic anhydride (82.3 μl, 0.49 mmol) is added (this is done before stirring the whole at ambient temperature for 5 hours under nitrogen. ). The reaction mixture is diluted with dichloromethane, washed with water, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on silica gel with a gradient of isohexane to 6: 4 isohexane / ethyl acetate mixture to give the product in the form of a gum.
_{LC / MS (C 44 H 40} N 5 O 8 F 3 S) m / z Not observed; RT2.85 (Method A)

Step C: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indazol-1-yl] -5-[(diphenylmethylidene) amino] -4-methoxybenzoyl}- 1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl diphenylmethanimine (22.4 μl, 0.13 mmol), palladium (II) acetate (4.04 mg, 0.018 mmol), BINAP (11.2 mg, 0.018 mmol) and cesium carbonate (58.6 mg, 0.18 mmol) were suspended in toluene (1 mL) and then the compound obtained in step B (76 mg, 0.09 mmol) in toluene (4 mL). ) Solution. The reaction mixture is degassed with nitrogen for 5 minutes and then microwaved at 150 ° C. for 1.5 hours. Additional diphenylmethanimine (22.4 μl, 0.13 mmol) is added and the reaction mixture is subjected to microwave for 6 hours. The reaction mixture is concentrated, extracted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography with isohexane to 2: 1 isohexane / ethyl acetate mixture, 2: 1 isohexane / ethyl acetate, then 1: 1 isohexane / ethyl acetate to give the product in solid form.
_{LC / MS (C 56 H 50} N 6 O 5) 787.3 [M-Boc] +; RT2.91 ( Method A)
Step D: 1- {4-amino-2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxyphenyl} -N, N- Diphenyl-1H-indazole-3-carboxamide To the compound obtained in Step C (4 mg, 0.005 mmol) in dichloromethane (3 mL) is added trifluoroacetic acid (0.5 mL) and the reaction mixture is stirred at ambient temperature. . After 30 minutes, additional trifluoroacetic acid (0.5 mL) is added, followed by a few drops of 2N HCl after 30 minutes. After 15 minutes, the reaction mixture is made alkaline with 2N NaOH, the organic phase is separated off, dried over magnesium sulphate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a dichloromethane to 9: 1 dichloromethane / methanol mixture.
_{LC / MS (C 38 H 34} N 6 O 3) 623 [M + H] +; RT2.17 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₄ N ₆ O ₃
[M + H] ⁺ calculated value: 623.2765
[M + H] ⁺ Measured value: 6233.2768

Example 153.1- {6-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxole-5 Yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure is the same as that in Example 131, replacing the compound obtained in Preparation 3d with the compound obtained in Preparation 3h. It is.
_{LC / MS (C 39 H 32} N 4 O 5) 637 [M + H] +; RT2.11 ( Method A)

Example 154.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxy-4- (3-phenoxyazetidine- 1-yl) phenyl} -N, N-diphenyl-1H-indole-3-carboxamide Step A: N-{[(3S) -2- [5- (benzyloxy) -2- [3- (diphenylcarbamoyl) -1H-indol-1-yl] -4-methoxybenzoyl] -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl procedure prepared the compound obtained in Preparation 3d 3t Same as that in the method of step A of Example 131, substituting for the compound obtained in

Step B: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indol-1-yl] -4-methoxy-5- (trifluoromethanesulfonyloxy) benzoyl} -1, Compound tert-butyl 2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate in dichloromethane (15 mL) (245 mg, 0.34 mmol) and triethylamine (0.14 mL, 1.02 mmol) To the solution is added trifluoroacetic anhydride (85.5 μl, 0.51 mmol), cooled to 0 ° C. and the reaction mixture is stirred at ambient temperature under nitrogen. After 1 hour, the reaction mixture is partitioned between dichloromethane and water according to its solubility, dried over magnesium sulfate, filtered and concentrated (this is a gradient of isohexane to 6: 4 isohexane / ethyl acetate mixture, silica gel Performed prior to purification by chromatography above) gives the product in the form of an oil.
_{LC / MS (C 45 H 41} N 4 O 8 F 3 S) m / z Not observed; RT2.87 (Method A)

Step C: N-{[(3S) -2- {2- [3- (diphenylcarbamoyl) -1H-indol-1-yl] -4-methoxy-5- (3-phenoxyazetidin-1-yl) Benzoyl} -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl Compound obtained in Step B (58 mg, 0.07 mmol) in tetrahydrofuran (2 mL) degassed with nitrogen Of sodium tert-butoxide (19.8 mg, 0.2 mmol), 3-phenoxyazetidine hydrochloride (18.9 mg, 0.1 mmol) and bis (tri-tert-butylphosphine) palladium (0) (3 .47 mg, 0.01 mmol) and the reaction mixture is heated at 120 ° C. for 30 minutes by microwave irradiation. The reaction mixture is partitioned between ethyl acetate and water according to its solubility, dried over magnesium sulfate, filtered and concentrated (this is a gradient of isohexane to 1: 1 isohexane / ethyl acetate mixture on silica gel. Done before purification by chromatography).
Step D: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxy-4- (3-phenoxyazetidine-1 -Yl) phenyl} -N, N-diphenyl-1H-indole-3-carboxamide The procedure is the same as that in step C of Example 131.
_{LC / MS (C 48 H 43} N 5 O 4) 754 [M + H] +; RT2.5 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₈ H ₄₃ N ₅ O ₄
[M + H] ⁺ calculated value: 754.3388
[M + H] ⁺ Measured value: 754.3376

Example 155. N- (4-hydroxyphenyl) -1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] Phenyl} -N-phenyl-1H-indole-3-carboxamide Step A: N- [4- (benzyloxy) phenyl] -1- {2-[(3S) -3-[(4-methylpiperazine-1- Yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound of Preparation 1 ′ with the compound of Preparation 3 ′ This is the same as that in the method of Step A of Example 131.

Step B: N- (4-hydroxyphenyl) -1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide To a solution of the compound prepared in step A (122 mg, 0.16 mmol) in dichloromethane (3 mL) was added boron trichloride (1 M in dichloromethane, 0. 03 mL) and cool to 0 ° C. under nitrogen. The reaction mixture is allowed to warm to ambient temperature again and stirred for 2 days, during which time the addition of an aliquot of boron trichloride of 0.15 mL is performed twice.
The reaction mixture is inactivated with methanol, concentrated, and the residue is purified by column chromatography with a dichloromethane-methanol (5%) / dichloromethane mixture.
_{LC / MS (C 43 H 41} N 5 O 3) 676 [M + H] +; RT2.15 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₁ N ₅ O ₃
[M + H] ⁺ calculated value: 766.3282
[M + H] ⁺ measured value: 676.3259

Example 156.1 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-chlorophenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A: N-{[(3S) -2- [2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indole -1-yl) -4-chlorobenzoyl] -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl The compound (0.48 g, 0.84 mmol) obtained in Preparation 3i was obtained. Dissolve in 10 mL of anhydrous dichloromethane. Oxalyl chloride (0.63 mL, 1.26 mmol) is added followed by a few drops of N, N-dimethylformamide and the reaction mixture is stirred at ambient temperature for about 16 hours. The reaction mixture was concentrated to dryness, then again dissolved in 10 mL of anhydrous dichloromethane and cooled to 0 ° C., triethylamine (0.21 mL, 1.53 mmol), then the compound obtained in Preparation 1 ′ (0.24 g, .0. 92 mmol) is added and the reaction mixture is stirred for 1.5 hours. The reaction mixture is partitioned between dichloromethane and water according to its solubility, the organic phase is washed with brine, dried over magnesium sulfate and concentrated. The crude material is purified by chromatography on a silica column eluting with isohexane to ethyl acetate to give the product in the form of an oil.
_{LC / MS (C 50 H 45} N 4 O 5 Cl) 817 [M + H] +; RT2.96 ( Method A)

Step B: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-chlorophenyl} -N- (4-hydroxyphenyl)- N-phenyl-1H-indole-3-carboxamide To a solution of the compound obtained in Step A (0.20 g, 0.24 mmol) in anhydrous dichloromethane (5 mL) was added boron trichloride (0.21 mL, 2 mL) under nitrogen. .4 mmol) is added dropwise and cooled to 0 ° C. The reaction mixture is then allowed to warm up to temperature and stirred for about 16 hours. The solution is cooled to 0 ° C. and additional boron trichloride solution (0.21 mL, 2.4 mmol) is added. After 6 hours, the reaction mixture is cooled and then boron tribromide (0.23 mL, 2.4 mmol) is added. The reaction mixture is allowed to warm to ambient temperature again and stirred for about 16 hours. Add another 0.23 mL of boron tribromide solution twice and cool for an additional 7 hours. The reaction mixture is inerted with methanol and concentrated, then partitioned between ethyl acetate and water according to its solubility. The organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica using a gradient of dichloromethane to methanol (20%) / dichloromethane mixture, followed by further purification by preparative HPLC.
_{LC / MS (C 38 H 31} N 4 O 3 Cl) 627 [M + H] +; RT107 ( Method B)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₁ N ₄ O ₃ Cl
[M + H] ⁺ calculated value: 627.2157
[M + H] ⁺ measured value: 627.2178

Example 157.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- [2- (phenylsulfanyl) acetamido] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A: 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indole-1 -Yl) -5-nitrobenzoic acid To a solution of the compound obtained in Preparation 2a (175 mg, 0.42 mmol) in N, N-dimethylformamide (10 mL) was added potassium carbonate (87 mg, 0.63 mmol) and 2-fluoro. Methyl -5-nitrobenzoate (93 mg, 0.5 mmol) is added and the reaction mixture is stirred at 110 ° C. under nitrogen. Additional potassium carbonate (29 mg, 0.21 mmol) and methyl 2-fluoro-5-nitrobenzoate (46.5 mg, 0.25 mmol) are added and the temperature is raised to 130 ° C. The reaction mixture is stirred overnight. It is then concentrated and extracted with ethyl acetate, washed with 1M HCl, the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude residue is purified by chromatography on a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to yield an oil.
_{LC / MS (C 35 H 25} N 3 O 6) 584.2 [M + H] +; RT2.69 ( Method A)

Step B: N-{[(3S) -2- [5-amino-2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) benzoyl]- Tert-Butyl 1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate The compound obtained in Step A is treated according to the procedure of Step A of Example 131. The compound so obtained (300 mg, 0.36 mmol) is dissolved in methanol (10 mL). To this is added zinc (235 mg, 3.6 mmol) and ammonium chloride (193 mg, 3.6 mmol). The reaction mixture is refluxed for 5 minutes under nitrogen and allowed to cool to ambient temperature. This is filtered through celite, washed with hot ethanol and then concentrated. The residue is dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution, dried over magnesium sulfate, filtered and concentrated to yield a solid that is used in further steps without purification.
_{LC / MS (C 50 H 47} N 5 O 5) 798.4 [M + H] +; RT2.83

Step C: N-{[(3S) -2- [2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -5- [2- ( Phenylsulfanyl) acetamido] benzoyl] -1,2,3,4-tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl Dichloromethane (10 mL) and DIPEA (0.1 mL, 0.6 mmol) in Step B To a solution of the resulting compound (304 mg, 0.38 mmol) is added 2- (phenylsulfanyl) acetyl chloride (68 μL, 0.46 mmol) and the reaction mixture is stirred at ambient temperature overnight. The reaction mixture is partitioned between dichloromethane and brine according to its solubility, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on isohexane to 6: 4 ethyl acetate / isohexane mixture and then 2: 1 ethyl acetate / isohexane mixture to yield the title product in the form of a solid.
_{LC / MS (C 58 H 53} N 5 O 6 S) m / z Not observed; RT2.93 (Method A)

Step D: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- [2- (phenylsulfanyl) acetamido] phenyl}- N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The compound obtained in Step C is treated according to the procedure of Example 131, Step C. The compound so obtained (100 mg, 0.12 mmol) is dissolved in dichloromethane (10 mL) and cooled to -78 ° C. Thereto, boron trichloride (1M, 0.6 mL, 0.6 mmol) is added. The reaction mixture is allowed to warm to ambient temperature again and stirred for 4 hours. This is inactivated with methanol, neutralized with triethylamine and washed with brine. The organic phase is dried over magnesium sulfate, filtered and concentrated. The resulting residue is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (8%) / dichloromethane mixture. The product obtained is dissolved in ethyl acetate, washed with dilute HCl, dried over magnesium sulfate, filtered and concentrated.
_{LC / MS (C 46 H 39} N 5 O 4 S) 758.2 [M + H] +; RT1.83

Example 158.1- {6-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2- (2-methylpropyl) -2H-1, 3-benzodioxol-5-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound obtained in Preparation 3d with the compound obtained in Preparation 3j. This is the same as that in the method of Example 131. The product is isolated in the form of a mixture of diastereoisomers.
_{LC / MS (C 43 H 40} N 4 O 5) 693 [M + H] +; RT2.39 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₀ N ₄ O ₅
[M + H] ⁺ calculated value: 693.3071
[M + H] ⁺ measured value: 693.3096

Example 159.1- {5-chloro-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl } -N- (4-Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A: N- [4- (Benzyloxy) phenyl] -1- {5-chloro-2-[(3S) -3-[(4-Methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinolin-2-carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide The procedure was prepared The compound obtained in 3d is replaced with the compound obtained in Preparation 3i, and the compound obtained in Preparation 1 ′ is replaced with the compound obtained in Preparation 3 ′.

Step B: 1- {5-chloro-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The compound obtained in Step A (0.39 g, 0.48 mmol) was dissolved in anhydrous dichloromethane (10 mL) and cooled to 0 ° C. To do. A solution of boron tribromide (0.45 mL, 4.8 mmol) is added dropwise and the reaction mixture is allowed to warm to ambient temperature again (this is done before stirring for about 16 hours). An additional 0.23 mL of boron tribromide solution is added at 0 ° C. and the reaction mixture is allowed to warm to ambient temperature again. After 4 hours, the reaction mixture is inactivated with methanol, concentrated, and then partitioned between ethyl acetate, a minimum amount of methanol and brine according to its solubility. The aqueous phase is extracted with dichloromethane and the combined organic extracts are dried over magnesium sulfate and concentrated under reduced pressure. The crude material is first purified by flash chromatography on a silica gel column using a gradient of dichloromethane to methanol (10%) / dichloromethane mixture and then further purified by preparative HPLC (pH 4).
LC / MS (C ₄₃ H ₄₀ N ₅ O ₃ Cl) 710 [M + H] ⁺ ; RT 1.14 (Method B)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₀ N ₅ O ₃ Cl
[M + H] ⁺ calculated value: 710.2892
[M + H] ⁺ measured value: 710.2923

Example 16 0.1- {4,5-dimethoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl ] Phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound of Preparation 3d with the compound of Preparation 3k and replaces the compound of Preparation 1 ′ with the compound of Preparation 3 ′. It is the same as that in the method of step A of Example 131 replaced with Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 45 H 45} N 5 O 5) 736 [M + H] +; RT2.17 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₄₅ N ₅ O ₅
[M + H] ⁺ calculated value: 736.3493
[M + H] ⁺ measured value: 736.3465

Example 161.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4,5-dimethoxyphenyl} -N- (4- Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure is the same as that in the method of Example 131, replacing the compound of Preparation 3d with the compound of Preparation 3k.
_{LC / MS (C 40 H 36} N 4 O 5) 653 [M + H] +; RT2.11 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₀ H ₃₆ N ₄ O ₅
[M + H] ⁺ calculated value: 6533.2758
[M + H] ⁺ measured value: 6533.2754

Example 162.1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxy-4- [2- (phenylsulfanyl) Acetamido] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A: 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H -Indol-1-yl) -4-methoxy-5-nitrobenzoic acid The procedure is similar to that of Preparation 3a, using 4-chloro-2-fluoro-5-nitrobenzoic acid. The compound so obtained (162 mg, 0.26 mmol) in methanol (3 mL) is added to a solution of sodium methoxide (0.1 mL) in methanol (2 mL) and the reaction mixture is stirred under nitrogen. Reflux overnight. The reaction mixture is diluted with ethyl acetate and neutralized with 2M HCl, then the organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated to give a gum which is further purified. Use without.
_{LC / MS (C 36 H 27} N 3 O 7) 612 [M-H] -; RT2.7 ( Method A)

Step B: N-{[(3S) -2- (5-amino-2- {3-[(4-hydroxyphenyl) (phenyl) carbamoyl] -1H-indol-1-yl} -4-methoxybenzoyl) -1,2-3,4-Tetrahydroisoquinolin-3-yl] methyl} carbamate tert-butyl The compound obtained in Step A was treated with the compound of Preparation 1 ′ according to the procedure of Step C of Example 166. To do. The compound so obtained (92 mg, 0.11 mmol) is dissolved in ethyl acetate (10 mL) and purged under nitrogen. Next, a catalytic amount of 10% palladium on carbon catalyst is added. The reaction mixture is degassed and then stirred for 2 days under a hydrogen atmosphere. Filter the reaction mixture through celite, wash with hot ethyl acetate, concentrate and purify by chromatography on silica gel with a gradient of dichloromethane to methanol (3%) / dichloromethane mixture to give a solid.
_{LC / MS (C 44 H 43} N 5 O 6) 738.3 [M + H] +; RT2.59 ( Method A)

Step C: 4- (N-phenyl-1- {2-[(3S) -3-({[(tert-butoxy) carbonyl] amino} methyl) -1,2,3,4-tetrahydroisoquinoline-2- Carbonyl] -5-methoxy-4- [2- (phenylsulfanyl) acetamido] phenyl} -1H-indole-3-amido) phenyl 2- (phenylsulfanyl) acetate Compound obtained in Step B in dichloromethane (4 mL) ( To a solution of 44 mg, 0.06 mmol) was added DIPEA (0.04 mL, 0.24 mmol) and 2- (phenylsulfanyl) acetyl chloride (33.4 mg, 0.18 mmol) and the reaction mixture was washed over the weekend under nitrogen. Stir at ambient temperature during. The reaction mixture is diluted with dichloromethane, washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica gel with a gradient of isohexane to 6: 4 ethyl acetate / isohexane mixture.
LC / MS (C ₆₀ H ₅₅ N ₅ O ₈ S ₂ ) m / z not observed; RT 2.72 (Method A)

Step D: 1- {2-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxy-4- [2- (phenylsulfanyl) acetamide Phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide To a solution of the compound obtained in Step C (45 mg, 0.04 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid. (1 mL) is added and the reaction mixture is stirred at ambient temperature for 1 hour. The reaction mixture is made alkaline with 2M NaOH and stirred for 15 minutes. The reaction mixture is extracted with dichloromethane, dried over magnesium sulfate, filtered and concentrated. The intermediate product is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture. The product is then resuspended in tetrahydrofuran (4 mL) and 2M NaOH (2 mL) and stirred at ambient temperature for 2 hours. The reaction mixture is extracted with dichloromethane, dried over magnesium sulfate, filtered and concentrated, then purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture.
_{LC / MS (C 47 H 41} N 5 O 5 S) 788 [M + H] +; RT2.29 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₇ H ₄₁ N ₅ O ₅ S
[M + H] ⁺ calculated value: 788.2901
[M + H] ⁺ Measured value: 788.2939

Example 163. N- (4-hydroxyphenyl) -1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- [2- (Phenylsulfanyl) acetamido] phenyl} -N-phenyl-1H-indole-3-carboxamide Step A: 5-amino-2- {3-[(4-hydroxyphenyl) (phenyl) carbamoyl] -1H-Indol-1-yl} benzoic acid The compound obtained in Step A of Example 157 (180 mg, 0.31 mmol) in ethyl acetate (10 mL) is degassed with nitrogen. To this is added a catalytic amount of 10% palladium on carbon. The reaction mixture is degassed and then stirred overnight under a hydrogen atmosphere. Additional catalyst is added and the reaction mixture is stirred at 28 ° C. for a further 2 days under a hydrogen atmosphere. The catalyst is added again and the reaction mixture is stirred for another day under a hydrogen atmosphere. The incomplete reaction is filtered through celite, washed with hot ethyl acetate and concentrated. The crude material was purified by chromatography on silica gel with a gradient of dichloromethane to methanol (15%) / dichloromethane mixture and then DMAW 240 to give a small amount of the aniline protected (O-Bn group) compound (compound Along with 1) the desired compound (compound 2) is obtained.
Compound _{1 LC / MS (C 35 H} 27 N 3 O 4) 554.2 [M + H] +; RT2.6 ( Method A)
Compound _{2 LC / MS (C 28 H} 21 N 3 O 4) 464.2 [M + H] +; RT2.22 ( Method A)

Step B: 2- {3- [phenyl (4-{[2- (phenylsulfanyl) acetyl] oxy} phenyl) carbamoyl] -1H-indol-1-yl} -5- [2- (phenylsulfanyl) acetamide] Benzoic acid Compound 2 obtained in Step A is treated according to the procedure described in Step C of Example 162. The compound so obtained is purified on a PE-AX column, washed with dichloromethane and eluted with a formic acid (10%) / dichloromethane mixture to produce a gum.
_{LC / MS (C 44 H 33} N 3 O 6 S 2) 764.2 [M + H] +; RT2.75 ( Method A)

Step C: 4- (N-phenyl-1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl ] -4- [2- (Phenylsulfanyl) acetamido] phenyl} -1H-indole-3-amido) phenyl 2- (phenylsulfanyl) acetate The compound obtained in Step B was prepared in Example 166 using Preparation 3 ′. Is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture. The compound is used in subsequent steps without further purification.
_{LC / MS (C 59 H 54} N 6 O 5 S 2) 991.4 [M + H] +; RT2.16 ( Method A)
Step D: N- (4-hydroxyphenyl) -1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] -4- [2- (phenylsulfanyl) acetamido] phenyl} -N-phenyl-1H-indole-3-carboxamide Compound obtained in Step C (19 mg, 0.02 mmol) in tetrahydrofuran (1.5 mL) To the solution is added 2M NaOH (1.5 mL) and the reaction mixture is stirred at ambient temperature for 1 hour and then at 32 ° C. for an additional hour. The reaction mixture is partitioned between ethyl acetate and water according to its solubility, the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture.
_{LC / MS (C 51 H 48} N 6 O 4 S) 841.4 [M + H] +; RT1.87 ( Method A)

Example 164. N- (4-hydroxyphenyl) -1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride Step A: N- [4- (benzyloxy) phenyl] -1- {6 -[(3S) -3-[(4-Methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxole-5 -Il} -N-phenyl-1H-indole-3-carboxamide The procedure was as described in Step 131 of Example 131, replacing the compound of Preparation 3d with the compound of Preparation 3h and the compound of Preparation 1 'with the compound of Preparation 3'. Who Is the same as that in.

Step B: N- (4-hydroxyphenyl) -1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] -2H-1,3-benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride The compound obtained in Step A (1.44 g, 1.79 mmol) was obtained. Dissolve in anhydrous dichloromethane (15 mL), cool to 0 ° C. under nitrogen, then add boron trichloride (1 M, 3.6 mL, 3.58 mmol) and allow the reaction mixture to warm to ambient temperature again (this is Before stirring for about 16 hours). The reaction mixture is cooled to 0 ° C., inactivated with methanol and then concentrated. The residue is dissolved in dichloromethane, washed with saturated aqueous sodium bicarbonate solution, dried over magnesium sulfate and evaporated. The crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give a foam. Dissolve the material in hot isopropyl alcohol (5 mL) and stir the resulting solution vigorously while adding excess HCl (2M in ether, 4 mL) dropwise. The resulting pulp-like material is stirred for 5 minutes, then filtered and washed with ether to give the product in solid form.
_{LC / MS (C 44 H 41} N 5 O 5) 720.3 [M + H] +; RT2.19 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₁ N ₅ O ₅
[M + H] ⁺ calculated value: 720.3180
[M + H] ⁺ measured value: 720.3151

Example 165.1 1- {4-Hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide dihydrochloride Step A: 1- [4- (Benzyloxy) -5-methoxy-2-[( 3S) -3-[(4-Methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinolin-2-carbonyl] phenyl] -N- [4- (benzyloxy) phenyl] -N -Phenyl-1H-indole-3-carboxamide To a solution of the acid obtained in Preparation 3a (944 mg, 1.4 mmol) in N, N-dimethylformamide (10 mL) was added HBTU (531 mg, 1 4 mmol) and DIPEA (0.49 mL, 2.8 mmol), followed by (3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydro obtained in Preparation 3 ′. Isoquinoline (343 mg, 1.4 mmol) is added. The reaction mixture is stirred at ambient temperature for 3 hours, then diluted with water and the resulting precipitate is filtered and washed with water, dissolved in dichloromethane and washed with saturated sodium bicarbonate solution. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give the product as a gum. Give in form.
_{LC / MS (C 58 H 55} N 5 O 5) m / z Not observed; RT2.63 (Method A)

Step B: 1- {4-Hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2- Carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide To a solution of the product obtained in Step A (1.14 g, 1.26 mmol) in methanol (20 mL). , Ammonium formate (793 mg, 12.6 mmol) followed by 10% palladium on carbon (130 mg) and the reaction mixture is heated under reflux for 2.5 h under nitrogen. The reaction mixture is allowed to cool to ambient temperature, filtered through celite, washed with methanol and concentrated under reduced pressure. The material is dissolved in dichloromethane and washed with water, then dried over magnesium sulfate, filtered and evaporated. The crude product is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product in the form of a foam.
_{LC / MS (C 44 H 43} N 5 O 5) 722 [M + H] +; RT2.17 ( Method A)
Step C: 1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2- Carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide dihydrochloride A solution of the compound obtained in Step B (535 mg, 0.74 mmol) in isopropyl alcohol (5 mL). To is added 2M HCl in ether (3.70 mL, 7.4 mmol). The resulting suspension is diluted with ether (5 mL) and then cooled to 0 ° C. over 30 minutes (this is done before filtration). The solid is washed with cold ether and dried under reduced pressure.
_{LC / MS (C 44 H 43} N 5 O 5) 722 [M + H] +; RT2.16 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₃ N ₅ O ₅
[M + H] ⁺ calculated value: 722.3337
[M + H] ⁺ Measured value: 722.3344

Example 166. N- (4-hydroxyphenyl) -1- {2-[(3S) -3- (4-methylpiperazine-1-carbonyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl}- N-phenyl-1H-indole-3-carboxamide Step A: tert-butyl (3S) -3- (4-methylpiperazine-1-carbonyl) -1,2,3,4-tetrahydroisoquinoline-2-carboxylate N , N-dimethylformamide (600 mL) in a solution of (3S) -2-[(tert-butoxy) carbonyl] -1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (15 g, 54.1 mmol). Under nitrogen, DIPEA (11.3 mL, 65 mmol), N-methylpiperazine (12 mL, 108 mmol) and then HBTU (24.6 g, 65 mmol) were added in small portions, The response mixture is stirred at ambient temperature for 16 hours. The mixture is concentrated under reduced pressure, diluted with saturated NaHCO ₃ solution and extracted with ethyl acetate. The organic phase is washed with saturated NaHCO ₃ solution and brine, then dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material is applied to a silica column in the dry state and eluted with isohexane, ethyl acetate, then 19: 1 ethyl acetate: 7M ammonia mixture in methanol to give the product in solid form.
_{LC / MS (C 20 H 29} N 3 O 3) 360 [M + H] +; RT1.83 ( Method A)

Step B: (3S) -3- (4-Methylpiperazine-1-carbonyl) -1,2,3,4-tetrahydroisoquinoline A solution of the compound obtained in Step A (19.68 g, 54.75 mmol) in dichloromethane. To the mixture is slowly added trifluoroacetic acid (42.2 mL, 547.5 mmol) at ambient temperature, then the reaction mixture is heated to 40 ° C. and stirred for 6 hours, then cooled again to ambient temperature and stirred for 16 hours. To do. The reaction mixture is then concentrated under reduced pressure, diluted with water, cooled to 0 ° C. and made alkaline with concentrated NH ₄ OH to pH = 12. The aqueous phase is extracted with ethyl acetate and the organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material is applied to a silica column in the dry state and eluted with isohexane, ethyl acetate, then 19: 1 ethyl acetate: 7M ammonia mixture in methanol, and finally 9: 1 ethyl acetate: 7M ammonia mixture in methanol. The product is redissolved in dichloromethane and washed with 5% NH ₄ OH solution, brine, then dried over magnesium sulfate, filtered and concentrated under reduced pressure to produce a glass.
_{LC / MS (C 15 H 21} N 3 O) 260 [M + H] +; RT0.18 ( Method A)

Step C: N- [4- (benzyloxy) phenyl] -1- {2-[(3S) -3- (4-methylpiperazine-1-carbonyl) -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide Solution of compound obtained according to Preparation 3a (135 mg, 251 μmol) using 2-iodobenzoic acid in N, N-dimethylformamide (4 mL) Is added DIPEA (52 μL, 301 μmol), the compound obtained in Step B (71.5 mg, 275.7 μmol), then HBTU (114 mg, 300.8 μmol) and the reaction mixture is stirred at ambient temperature for 16 hours. The reaction mixture is diluted with saturated NaHCO ₃ solution and extracted with ethyl acetate. The organic phase is then washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material is applied to a silica column in the dry state and eluted with isohexane, ethyl acetate, then 19: 1 ethyl acetate: methanol mixture, then 19: 1 ethyl acetate: 7M ammonia mixture in methanol to produce a foam. .
_{LC / MS (C 50 H 45} N 5 O 4) 780 [M + H] +; RT2.5 ( Method A)

Step D: N- (4-hydroxyphenyl) -1- {2-[(3S) -3- (4-methylpiperazine-1-carbonyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] Phenyl} -N-phenyl-1H-indole-3-carboxamide The compound obtained in Step C (146 mg, 187 μmol) is dissolved in methanol. To this is added ammonium formate (118 mg, 1.87 mmol) and 10% palladium on carbon (106 mg, 18.7 μmol) and the reaction mixture is refluxed for 3 hours under nitrogen. It is then diluted with brine and extracted with ethyl acetate. The organic phase is washed with water, dried over magnesium sulfate, filtered through celite and concentrated under reduced pressure. The crude material is applied to a silica column in the dry state and eluted with isohexane, ethyl acetate, then 19: 1 ethyl acetate: 7M ammonia mixture in methanol, and finally 9: 1 ethyl acetate: 7M ammonia mixture in methanol.
_{LC / MS (C 43 H 39} N 5 O 4) 690 [M + H] +; RT2.17 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₃₉ N ₅ O ₄
[M + H] ⁺ calculated value: 690.3075
[M + H] ⁺ measured value: 690.063

Example 167.1- {5-Chloro-4-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound of Preparation 3d with the compound of Preparation 3l and prepares the compound of Preparation 1 ' This is the same as that in the method of Step A of Example 131 in which the above compound was replaced. Deprotection is performed according to the procedure of Example 155.
_{LC / MS (C 44 H 42} N 5 O 4 Cl) 740.4 [M + H] +; RT1.85 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₂ N ₅ O ₄ Cl
[M + H] ⁺ calculated value: 740.2998
[M + H] ⁺ measured value: 740.2977

Example 168. N- (4-hydroxyphenyl) -1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline- 2-Carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride The procedure is the same as in the method of Example 164, replacing the compound obtained in Preparation 3d with the compound obtained in Preparation 3e. .
_{LC / MS (C 44 H 43} N 5 O 4) 706 [M + H] +; RT1.75 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₃ N ₅ O ₄
[M + H] ⁺ calculated value: 706.3388
[M + H] ⁺ measured value: 706.3415

Example 169. N- (4-hydroxyphenyl) -1- {5-methoxy-2-[(3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N-Phenyl-1H-indole-3-carboxamide hydrochloride The procedure is as in Example 164, replacing the compound obtained in Preparation 3h with the compound obtained in Preparation 3e and replacing the compound in Preparation 3 'with the compound in Preparation 11'. It is the same as that in the method.
_{LC / MS (C 44 H 42} N 4 O 4) 691 [M + H] +; RT2.25 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₂ N ₄ O ₄
[M + H] ⁺ calculated value: 691.3279
[M + H] ⁺ measured value: 691.3256

Example 170. N- (4-hydroxyphenyl) -1- {7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl} -N-phenyl-1H-indole-3-carboxamide 7-bromo-2,3-dihydro-1,4-benzodioxin-6-carvone The compound is prepared using acid according to the procedure of Preparation 3a and the whole is placed in a microwave apparatus at 150 ° C. for 40 minutes. The procedure described in Step C of Example 166 is then applied using the compound of Preparation 3 ′. The material was purified by chromatography on silica gel with dichloromethane to 5% methanol / dichloromethane mixture and finally deprotected according to the procedure of Example 166, step D, and silica gel with dichloromethane to 8% methanol / dichloromethane mixture. Purify by chromatography above.
_{LC / MS (C 45 H 43} N 5 O 5) 734 [M + H] +; RT2.2 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₄₃ N ₅ O ₅
[M + H] ⁺ calculated value: 734.3337
[M + H] ⁺ measured value: 734.3323

Example 171.1- {5-chloro-2-[(3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4 -Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure of Example 131 wherein the compound of Preparation 3d was replaced with the compound of Preparation 3i and the compound of Preparation 1 'was replaced with the compound of Preparation 11'. It is the same as that in the method A. Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 43 H 39} N 4 O 3 Cl) 695 [M + H] +; RT2.31 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₃₉ N ₄ O ₃ Cl
[M + H] ⁺ calculated value: 695.2783
[M + H] ⁺ measured value: 695.22771

Example 172.1- {2-[(3S) -3- (hydroxymethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N- The phenyl-1H-indole-3-carboxamide procedure is similar to that in Example 131, step A method, in which the compound of Preparation 1 ′ was replaced with (3S) -1,2,3,4-tetrahydroisoquinolin-3-ylmethanol. The same. Deprotection is performed according to the procedure of Example B, Step B.
LC / MS (C ₃₈ H ₃₁ N ₃ O ₄ ) 594 [M + H] ⁺ ; RT 2.47 (Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₈ H ₃₁ N ₃ O ₄
[M + H] ⁺ calculated value: 5944.2387
[M + H] ⁺ Measured value: 594.2368

Example 173. N- (4-hydroxyphenyl) -N-phenyl-1- {2-[(3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -1H-indole-3-carboxamide The procedure is the same as in Example 131, step A method, replacing the compound of Preparation 1 'with the compound of Preparation 11'. Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 43 H 40} N 4 O 3) 661 [M + H] +; RT2.21 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₀ N ₄ O ₃
[M + H] ⁺ calculated value: 661.3173
[M + H] ⁺ measured value: 661.3156

Example 174. N- (4-hydroxyphenyl) -N-phenyl-1- {6-[(3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H -1,3-Benzodioxol-5-yl} -1H-indole-3-carboxamide The procedure is the same as in the method of Example 164, replacing the compound of Preparation 3 ′ with the compound of Preparation 11 ′.
_{LC / MS (C 44 H 40} N 4 O 5) 705 [M + H] +; RT2.24 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₀ N ₄ O ₅
[M + H] ⁺ calculated value: 705.3071
[M + H] ⁺ Measured value: 705.3040

Example 175.1- {2-[(3S) -3-[(dimethylamino) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -5-methoxyphenyl} -N- (4 -Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure was performed by replacing the compound obtained in Preparation 3h with the compound obtained in Preparation 3e and replacing the compound of Preparation 3 'with the compound of Preparation 12'. Same as in the method of Example 164.
_{LC / MS (C 44 H 38} N 4 O 4) 651 [M + H] +; RT2.18 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₁ H ₃₈ N ₄ O ₄
[M + H] ⁺ calculated value: 651.2966
[M + H] ⁺ Measured value: 651.2941

Example 176.1 1- {4-Hydroxy-5-methoxy-2-[(3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl}- N- (4-Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide hydrochloride The procedure was obtained in Preparation 3 ′ (3S) -3-[(4-Methylpiperazin-1-yl) methyl] The method of Example 165 in which 1,2,3,4-tetrahydroisoquinoline was replaced with (3S) -3- (piperidin-1-ylmethyl) -1,2,3,4-tetrahydroisoquinoline obtained in Preparation 11 ′. It is the same as that in
_{LC / MS (C 44 H 42} N 4 O 5) 707 [M + H] +; RT2.17 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₂ N ₄ O ₅
[M + H] ⁺ calculated value: 707.3228
[M + H] ⁺ measured value: 707.3206

Example 177.1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1, 3-benzodioxol-5-yl} -N, N-diphenyl-1H-indole-3-carboxamide dihydrochloride Example 164, replacing the compound obtained in Preparation 3h with the compound obtained in Preparation 3p It is the same as that in the method.
_{LC / MS (C 44 H 41} N 5 O 4) 704 [M + H] +; RT2.33 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₁ N ₅ O ₄
[M + H] ⁺ calculated value: 704.3231
[M + H] ⁺ Measured value: 704.3245

Example 178.1- {5-chloro-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl } -N, N-diphenyl-1H-indole-3-carboxamide dihydrochloride The procedure is the same as in the method of Example 164, replacing the compound obtained in Preparation 3h with the compound obtained in Preparation 3q.
_{LC / MS (C 43 H 40} N 5 O 2) 694 [M + H] +; RT2.89 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₀ N ₅ O ₂ Cl
[M + H] ⁺ calculated value: 694.2943
[M + H] ⁺ Measured value: 694.2918

Example 179.1- {5-chloro-2-[(3S) -3-[(dimethylamino) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4 -Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide hydrochloride The procedure replaces the compound obtained in Preparation 3h with the compound obtained in Preparation 3i and the compound in Preparation 3 'with the compound of Preparation 12'. This is the same as that in the method of Example 164.
_{LC / MS (C 40 H 35} N 4 O 3 Cl) 655 [M + H] +; RT2.3 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₃₅ N ₄ O ₃ Cl
[M + H] ⁺ calculated value: 6555.2470
[M + H] ⁺ measured value: 655.2446

Example 180.1- {6-[(3S) -3-[(dimethylamino) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxole -5-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide hydrochloride The procedure of Example 164 wherein the compound of Preparation 3 ′ was replaced with the compound of Preparation 12 ′ It is the same as that in
_{LC / MS (C 41 H 36} N 4 O 5) 665 [M + H] +; RT2.16 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₁ H ₃₆ N ₄ O ₅
[M + H] ⁺ calculated value: 665.2758
[M + H] ⁺ measured value: 6655.2756

Example 181.1- {4-Hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N, N-diphenyl-1H-indole-3-carboxamide dihydrochloride The procedure is the same as that in the method of Example 165 with the compound of Preparation 3a used in Step A replaced by the compound of Preparation 3c. Yes, the product is given in solid form.
_{LC / MS (C 44 H 43} N 5 O 4) 706 [M + H] +; RT1.78 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₃ N ₅ O ₄
[M + H] ⁺ calculated value: 706.3388
[M + H] ⁺ measured value: 706.3398

Example 182.1- {2,2-difluoro-6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl ] -2H-1,3-benzodioxol-5-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A: 6-Bromo-2H-1,3 -Methyl benzodioxole-5-carboxylate To a suspension of 6-bromo-1,3-benzodioxole-5-carboxylic acid (10.29 g, 0.04 mol) in methanol under stirring, Concentrated sulfuric acid is added dropwise over about 1 minute. The mixture is refluxed and stirred overnight. When the reaction mixture is allowed to cool to ambient temperature, precipitation occurs. Add ice to the mixture and stir until the ice melts. The mixture is then filtered and washed with a water-methanol mixture (2: 1). The solid is dried by suction to produce a powder.
LC / MS (C ₉ H ₇ O ₄ Br) m / z not observed; RT 1.22 (Method B)

Step B: Methyl 2-bromo-4,5-dihydroxybenzoate To a solution of the compound obtained in Step A (2 g, 7.72 mmol) in anhydrous dichloromethane (20 mL) under stirring was added boron trichloride (1M in dichloromethane). 15.5 mL, 0.02 mol) is added in portions over 5 minutes, cooled to 0 ° C. under nitrogen, and the reaction mixture is then allowed to warm to ambient temperature again overnight. The reaction mixture is slowly poured into methanol (20 mL) with stirring, cooled with ice and then stirred over the weekend. The solvent is removed under reduced pressure and the residue is dissolved in a dichloromethane / methanol mixture, dried over magnesium sulfate, filtered and concentrated to yield a solid upon drying under reduced pressure. The product is used directly in the subsequent steps without further purification.
LC / MS (C ₈ H ₇ O ₄ Br) 245 [M−H] ⁻ ; RT 0.94 (Method B)

Step C: Methyl 2-bromo-4,5-bis (methoxymethoxy) benzoate To a solution of the compound obtained in Step B (200 mg, 0.81 mmol) in chloroform (5 mL) and dimethoxymethane (5 mL) was added P _2. Add O ₅ (1.15 g, 8.1 mmol) and cool to 0 ° C. The reaction mixture is stirred for 5 minutes under nitrogen and then allowed to warm to ambient temperature again. At the end of 5 hours, the reaction mixture is again cooled to 0 ° C. and an additional 200 mg of P ₂ O ₅ is added. The reaction mixture is stirred overnight at ambient temperature. This is then poured into ice, extracted with ethyl acetate, dried over magnesium sulfate, filtered and concentrated. The crude material is purified by chromatography on silica gel with a gradient of isohexane to 2: 1 isohexane / ethyl acetate mixture to give an oil.
_{LC / MS (C 12 H 15} O 6 Br) 337.1 [M + H] +; RT2.38 ( Method A)

Step D: Methyl 2- (3-{[4- (benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -4,5-dihydroxybenzoate The compound obtained in Step C was prepared. Process according to procedure 3a and heat in a microwave apparatus at 160 ° C. for 2 hours. The resulting compound is taken up in 4M HCl in dioxane (4 mL) and stirred at ambient temperature for 1 hour under nitrogen. The reaction mixture is partitioned between ethyl acetate and 2N NaOH solution according to its solubility, then the organic phase is dried over magnesium sulfate, filtered and concentrated to give a solid which is further purified without further purification. Used in.
_{LC / MS (C 36 H 28} N 2 O 6) 585.4 [M + H] +; RT2.69 ( Method A)

Step E: 6- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -2,2-difluoro-2H-1,3-benzodioxole- To a solution of the compound obtained in Step D (90 mg, 0.15 mmol) in methyl 5-carboxylate N, N-dimethylformamide (3 mL) was added dibromodifluoromethane (70 μL, 0.77 mmol) followed by cesium carbonate (147 mg, 0.45 mmol) is added and the reaction mixture is heated in a microwave apparatus at 150 ° C. for 10 minutes. The reaction mixture is partitioned between ethyl acetate and water according to its solubility, dried over magnesium sulfate, filtered and concentrated (this is a gradient of isohexane to 3: 1 isohexane / ethyl acetate mixture on silica gel. When done prior to purification by chromatography) yields an oil.
_{LC / MS (C 37 H 26} N 2 O 6 F 2) 633.3 [M + H] +; RT2.94 ( Method A)

Step F: 6- (3-{[4- (Benzyloxy) phenyl] (phenyl) carbamoyl} -1H-indol-1-yl) -2,2-difluoro-2H-1,3-benzodioxole- 5-Carboxylic acid To a solution of the compound obtained in step E (39 mg, 0.06 mmol) in tetrahydrofuran (1 mL) and ethanol (1 mL), 2N NaOH (1 mL, 2 mmol) is added and the reaction mixture is stirred at ambient temperature. Stir for hours. This is partitioned between ethyl acetate and water according to its solubility, dried over magnesium sulfate, filtered and concentrated to yield a gum that is used in subsequent steps without further purification.
_{LC / MS (C 36 H 24} N 2 O 6 F 2) 619.3 [M + H] +; RT2.84 ( Method A)

Step G: 1- {2,2-difluoro-6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxol-5-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The compound obtained in Step F was prepared as the compound of Preparation 3 ′ Is purified by silica gel with a dichloromethane-methanol (5%) / dichloromethane mixture and finally deprotected according to the procedure of Example 166, Step D. It occurs slowly over 7 days and requires several additional additions of 10% palladium on carbon, ammonium formate and ethanol. The final product is purified by chromatography on silica gel with a dichloromethane-methanol (6%) / dichloromethane mixture.
_{LC / MS (C 44 H 39} N 5 O 5 F 2) 756 [M + H] +; RT2.33 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical _{formula: C 44 H 39 N 5 O} 5 F 2
[M + H] ⁺ calculated value: 756.29292.
[M + H] ⁺ measured value: 756.2985

Example 183.1- {4,5-dihydroxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl ] Phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound of Preparation 1 ′ with the compound of Preparation 3 ′ and replaces the compound of Preparation 3d with the compound of Preparation 3r It is the same as that in the method of step A of Example 131 replaced with Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 43 H 41} N 5 O 5) 708 [M + H] +; RT2.07 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₃ H ₄₁ N ₅ O ₅
[M + H] ⁺ calculated value: 708.3180
[M + H] ⁺ Measured value: 708.3194

Example 184. N- (4-hydroxyphenyl) -1- {6-[(3S) -3- (morpholin-4-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3 -Benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide hydrochloride The procedure is the same as that in Example 164, replacing the compound of Preparation 3 'with the compound of Preparation 2'. is there.
_{LC / MS (C 43 H 38} N 4 O 6) 707 [M + H] +; RT2.24 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical _{formula: C 43 H 38 N 4 O} 6
[M + H] ⁺ calculated value: 707.2864
[M + H] ⁺ measured value: 707.2870

Example 185.1 1- {2-ethyl-7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl]- 2,3-dihydro-1,4-benzodioxin-6-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure prepares the compound of Preparation 1 ′ 3 ′ Same as that in Example 131, step A, with the compound of Preparation 3d replaced with the compound of Preparation 3m. Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 47 H 47} N 5 O 5) 762 [M + H] +; RT1.84 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₇ H ₄₇ N ₅ O ₅
[M + H] ⁺ calculated value: 762.3650
[M + H] ⁺ measured value: 762.3614

Example 186.1 1- {5-chloro-2-[(3S) -3- (morpholin-4-ylmethyl) -1,2,3,4-tetrahydroisoquinolin-2-carbonyl] phenyl} -N- (4 -Hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide hydrochloride The procedure replaces the compound obtained in Preparation 3h with the compound obtained in Preparation 3q and the compound of Preparation 3 'with the compound of Preparation 2'. This is the same as that in the method of Example 164.
_{LC / MS (C 42 H 37} N 4 O 4 .HCl) 697 [M + H] +; RT2.38 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₂ H ₃₇ N ₄ O ₄ Cl
[M + H] ⁺ calculated value: 697.2576
[M + H] ⁺ measured value: 697.2569

Example 187. N-cyclohexyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride Step A: 5- (Benzyloxy) -4-methoxy-2- [3- (methoxycarbonyl) -1H-indole-1- Yl] benzoic acid In N, N-dimethylformamide (60 mL), 5- (benzyloxy) -2-bromo-4-methoxybenzoic acid (7.5 g, 22.24 mmol), methyl indole-3-carboxylate (3 .9 g, 22.24 mmol) and potassium carbonate (6.15 g, 44.48 mmol) are degassed by bubbling nitrogen through them. Copper iodide (490 mg, 2.22 mmol) is added and the reaction mixture is stirred at 90 ° C. for about 16 hours under nitrogen. The reaction mixture is cooled to ambient temperature, diluted with water and acidified with 2M aqueous HCl. The resulting precipitate is filtered off and washed with water, then suspended in dichloromethane and washed with brine. The organic phase is dried over magnesium sulphate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane-methanol (5%) / dichloromethane mixture to give the product in powder form. give.
_{LC / MS (C 25 H 21} NO 6) 432 [M + H] +; RT2.62 ( Method A)

Step B: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline Methyl-2-carbonyl] phenyl] -1H-indole-3-carboxylate To a solution of the acid obtained in Step A (2.3 g, 5.4 mmol) in N, N-dimethylformamide (20 mL) was added DIPEA (4 7 mL, 27 mmol) and HBTU (2 g, 5.4 mmol), then the compound from Preparation 3 ′ (1.92 g, 5.4 mmol) are added and the reaction mixture is stirred at ambient temperature for about 72 hours. The reaction mixture is diluted with dichloromethane, washed with water, saturated sodium bicarbonate solution, then dried over magnesium sulfate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give the product in the form of a foam.
_{LC / MS (C 40 H 42} N 4 O 5) 659 [M + H] +; RT2.31 ( Method A)

Step C: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline 2-Carbonyl] phenyl] -1H-indole-3-carboxylate To a solution of the ester obtained in Step B (2.18 g, 3.31 mmol) in methanol (20 mL) was added 2M aqueous NaOH (10 mL) and tetrahydrofuran. (10 mL) is added and the suspension is stirred at 50 ° C. for 7 hours. The reaction mixture is cooled to ambient temperature and concentrated to dissolve the residue in ethyl acetate, dried over magnesium sulfate, filtered and evaporated to give a solid.
LC / MS (C ₃₉ H ₃₉ N ₄ O ₅ .Na) 645 [M + H] ⁺ ; RT 1.77 (Method A) [mass of acid type parent molecule]

Step D: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline 2-Carbonyl] phenyl] -1H-indole-3-carbonyl chloride To a solution of the compound prepared in Step C (1.18 g, 1.77 mmol) in anhydrous dichloromethane (15 mL), a solution of 2M oxalyl chloride in dichloromethane ( 1.77 mL, 3.54 mmol) and then a few drops of N, N-dimethylformamide are added and the reaction mixture is stirred under nitrogen at an ambient temperature of about 16 hours. Removal of the solvent gives a solid.
LC / MS (C ₃₉ H ₃₉ N ₄ O ₄ Cl) 659 [M + H] ⁺ ; RT 1.85 [methyl ester observed for methanol inactivation observed]

Step E: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline 2-Carbonyl] phenyl] -N-cyclohexyl-N-phenyl-1H-indole-3-carboxamide To a solution of the acid chloride obtained in Step D (500 mg, 0.75 mmol) in anhydrous dichloromethane (6 mL) was added N- Cyclohexylaniline (145 mg, 0.83 mmol) and pyridine (305 μl, 3.77 mmol) are added and cooled to 0 ° C. under nitrogen and the reaction mixture is allowed to warm to ambient temperature again. The reaction mixture is stirred for about 16 hours, after which a further 70 mg (0.4 mmol) of N-cyclohexylaniline is added and stirring of the reaction mixture is continued at ambient temperature. The reaction mixture is cooled, diluted with dichloromethane and washed with water, 2M NaOH and brine. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give a gum.
_{LC / MS (C 51 H 55} N 5 O 4) 802 [M + H] +; RT2.58 ( Method A)

Step F: N-cyclohexyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydro Isoquinoline-2-carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide To a solution of the compound obtained in step E (180 mg, 0.22 mmol) in methanol (10 mL) was added ammonium formate (150 mg, 2. 2 mmol) and 10% palladium on carbon catalyst. Under nitrogen, the reaction mixture is heated under reflux for 1 hour. The reaction mixture is cooled to ambient temperature, filtered through celite, washed with methanol and concentrated. The crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product in solid form.
_{LC / MS (C 44 H 49} N 5 O 4) 712 [M + H] +; RT1.35 ( Method B)

Step G: N-cyclohexyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydro Isoquinoline-2-carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride To a solution of the compound obtained in step F (100 mg, 0.14 mmol) in isopropyl alcohol (2 mL) was added 2 M in ether. HCl (0.35 mL, 0.7 mmol) is added. The solution is diluted with ether (10 mL) and the resulting suspension is stirred for 30 minutes and then allowed to concentrate. The residue is triturated with ether, filtered and washed with a further amount of ether, and the solid is dried under reduced pressure.
_{LC / MS (C 44 H 49} N 5 O 4) 712 [M + H] +; RT2.37 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₄ H ₄₉ N ₅ O ₄
[M + H] ⁺ calculated value: 712.3857
[M + H] ⁺ Measured value: 712.3828

Example 188.1-[(2S) -2-[(benzyloxy) methyl] -7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3 4-tetrahydroisoquinoline-2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl] -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide Step A Methyl 2-bromo-4,5-dihydroxybenzoate To a solution of methyl 2-bromo-4,5-dimethoxybenzoate (5.62 g, 20.43 mmol) in dichloromethane (60 mL) was added boron tribromide (1M 11.62 mL, 122.6 mmol) is added and cooled to −78 ° C. under nitrogen. Allow the reaction mixture to warm to ambient temperature again and stir overnight. The reaction mixture is poured into 500 mL of cold methanol with stirring, then concentrated and partitioned between ethyl acetate and water according to its solubility. The organic phase is dried over magnesium sulfate, filtered and concentrated to give a solid.
_{LC / MS (C 8 H 7} O 4 Br) 247 [M + H] +; RT1.82 ( Method A)

Step B: (3S) -7-Bromo-3- (hydroxymethyl) -2,3-dihydro-1,4-benzodioxin-6-carboxylate methyl N, N-dimethylformamide (16 mL) in Step A To a solution of the obtained compound (1 g, 4.05 mmol), 4-methylbenzyl (1.11 g, 4.86 mmol) (2R) -oxiran-2-ylmethanesulfonate, then potassium carbonate (1.12 g, 8.5 mmol). 1 mmol) is added and the reaction mixture is heated in a microwave apparatus at 120 ° C. for 20 minutes. The reaction mixture is concentrated and partitioned between ethyl acetate and water according to its solubility, the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica gel with a mixture of isohexane to 1: 1 ethyl acetate / isohexane to give an oil.
LC / MS (C ₁₁ H ₁₁ O ₅ Br) m / z not observed; RT 1.62 (Method A)

Step C: (3S) -3-[(Benzyloxy) methyl] -7-bromo-2,3-dihydro-1,4-benzodioxin-6-carboxylate methyl in N, N-dimethylformamide (15 mL) To a solution of the compound obtained in Step B (1.04 g, 3.44 mmol) under nitrogen, 60% sodium hydride (165 mg, 4.13 mmol) and after 15 minutes benzyl bromide (0.49 mL, 4.4 mmol). 13 mmol) is added and the reaction mixture is stirred at 50 ° C. for 4 hours. It is then concentrated and partitioned between ethyl acetate and water according to its solubility. The organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica gel with a mixture of isohexane to 7: 1 ethyl acetate / isohexane to give an oil.
_{LC / MS (C 18 H 17} O 5 Br) 393.1 [M + H] +; RT2.72 ( Method A)

Step D: (3S) -3-[(Benzyloxy) methyl] -7-bromo-2,3-dihydro-1,4-benzodioxin-6-carboxylic acid Compound obtained in Step C (0.5 g, 1 .28 mmol) in a methanol / tetrahydrofuran mixture (1.5 mL: 1.5 mL) is added 2M NaOH (3 mL, 6 mmol) and the reaction mixture is stirred at 50 ° C. for 2 h. The reaction mixture is concentrated, diluted with water, acidified with 2M HCl, extracted with ethyl acetate, dried over magnesium sulfate, filtered and concentrated to give a solid.
LC / MS (C ₁₇ H ₁₅ O ₅ Br) 379 [M + H] ⁺ ; RT 2.48 (Method A)

Step E: 1-[(2S) -2-[(benzyloxy) methyl] -7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl] -1H-indole-3-carboxylate The compound obtained in Step D was prepared according to Step 3 of Preparation 3d. Treat according to the procedure and heat in a microwave apparatus at 130 ° C. for 40 minutes (this is done with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture before purification by chromatography on silica gel). The resulting compound is then treated with the compound of Preparation 3 ′ according to the procedure of Example C, Step C and chromatographed on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture. To give an oil.
_{LC / MS (C 42 H 44} N 4 O 6) 701.4 [M + H] +; RT2.42 ( Method A)

Step F: 1-[(2S) -2-[(benzyloxy) methyl] -7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl] -1H-indole-3-carboxylic acid in THF (1.5 mL) and methanol (1.5 mL) The compound obtained in step E (301 mg, 0.43 mmol) is stirred with 2M NaOH (3 mL, 6 mmol) and then heated at 50 ° C. overnight. The reaction mixture is concentrated, taken up in water, acidified with 2M HCl to pH = 4 and the product is extracted with ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated to give a solid.
_{LC / MS (C 41 H 42} N 4 O 6) 697.3 [M + H] +; RT2.3 ( Method A)

Step G: 1-[(2S) -2-[(benzyloxy) methyl] -7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl] -N- {4-[(tert-butyldimethylsilyl) oxy] phenyl} -N-phenyl-1H Indole-3-carboxamide The compound obtained in step F (207 mg, 0.3 mmol) in dichloromethane (5 mL) is cooled to 0 ° C. under nitrogen. Oxalyl chloride (2M, 0.45 mL, 0.9 mmol) and 1 drop of N, N-dimethylformamide are added. After 3 hours, the reaction mixture is concentrated and then coevaporated twice more with dichloromethane. The residue is resuspended in dichloromethane (5 mL) and stirred under nitrogen. To this was added a solution of 4-[(tert-butyldimethylsilyl) oxy] -N-phenylaniline (135 mg, 0.45 mmol) and pyridine (0.036 mL, 0.45 mmol) in a minimum volume of dichloromethane. The reaction mixture is stirred overnight. The incomplete reaction was inactivated with 2M NaOH, the organic phase separated with a phase separator, then concentrated and applied to a PE-AX column, then eluted with dichloromethane followed by formic acid (5%) / dichloromethane mixture. Let The resulting material is subjected to azeotropic distillation with toluene and then used in subsequent steps without further purification.
LC / MS (C ₅₉ H ₆₅ N ₅ O ₆ Si) 968.5 [M + H] ⁺ ; RT 2.81 (Method A)

Step H: 1-[(2S) -2-[(benzyloxy) methyl] -7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl] -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide THF (3 mL ) To the compound obtained in step G (103 mg, 0.11 mmol) in ethylene glycol (21.4 μL, 0.32 mmol) and TBAF (1M in tetrahydrofuran, 0.32 mL, 0.32 mmol) are added and the reaction mixture Is heated in a microwave apparatus at 120 ° C. for 20 minutes. The reaction mixture is concentrated and partitioned between ethyl acetate and saturated sodium bicarbonate solution according to its solubility, then the organic phase is dried over magnesium sulfate, filtered and concentrated. The crude product is purified by preparative HPLC chromatography.
_{LC / MS (C 53 H 51} N 5 O 6) 854.4 [M + H] +; RT1.35 ( Method B)

Example 189.1- {3-Chloro-4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4- Tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound of Preparation 1 ′ with the compound of Preparation 3 ′. Identical to that of Example 131, Step A method, substituting compound of Preparation 3n. Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 44 H 42} N 5 O 5 Cl) 756.3 [M + H] +; RT2.14 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₂ N ₅ O ₅ Cl
[M + H] ⁺ calculated value: 756.2947
[M + H] ⁺ measured value: 756.2948

Example 190. N- (4-fluorophenyl) -1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride The procedure is as in Example 164, replacing the compound obtained in Preparation 3h with the compound obtained in Preparation 3u. It is the same.
_{LC / MS (C 44 H 42} N 5 O 4 F) 724 [M + H] +; RT2.26 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₂ N ₅ O ₄ F
[M + H] ⁺ calculated value: 724.3294
[M + H] ⁺ Measured value: 724.3301

Example 191. N, N-dibutyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline -2-Carbonyl] phenyl} -1H-indole-3-carboxamide dihydrochloride The procedure is the same as that in the method of Example 187 in which N-cyclohexylaniline used in Step E was replaced with dibutylamine.
_{LC / MS (C 40 H 51} N 5 O 4) 666 [M + H] +; RT2.31 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₀ H ₅₁ N ₅ O ₄
[M + H] ⁺ calculated value: 666.4014
[M + H] ⁺ measured value: 666.3987

Example 192. N, N-dibutyl-1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- Nitrophenyl} -1H-indole-3-carboxamide The compound of Preparation 3s (280 mg, 0.64 mmol) in N, N-dimethylformamide was added to the compound of Preparation 3 ′ (173 mg, 0.7 mmol), DIPEA (0. 22 mL, 1.28 mmol) and HBTU (291 mg, 0.77 mmol) are added and the reaction mixture is stirred at ambient temperature for 16 h. The reaction mixture is concentrated under reduced pressure, diluted with saturated aqueous NaHCO ₃ and extracted with ethyl acetate. The organic extract is washed successively with saturated aqueous NaHCO ₃ solution and brine, dried over magnesium sulfate and concentrated under reduced pressure. The crude material is applied to a 20 g silica column in the dry state and eluted with isohexane, then ethyl acetate, then a 19: 1 mixture of ethyl acetate / methanol, then a 9: 1 mixture to give the product.
_{LC / MS (C 39 H 48} N 6 O 4) 665 [M + H] +; RT2.41 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₄₈ N ₆ O ₄
[M + H] ⁺ calculated value: 665.3810
[M + H] ⁺ Measured value: 665.3817

Example 193.1 1- {4-Hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (4-methylphenyl) -N-phenyl-1H-indole-3-carboxamide The procedure replaces the compound of Preparation 1 'with the compound of Preparation 3' and prepares the compound of Preparation 3d 3v This is the same as that in the method of Step A of Example 131 in which Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 45 H 45} N 5 O 4) 720 [M + H] +; RT2.28 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₅ H ₄₅ N ₅ O ₄
[M + H] ⁺ calculated value: 720.3544
[M + H] ⁺ measured value: 720.3520

Example 194. N-butyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N-phenyl-1H-indole-3-carboxamide dihydrochloride The procedure is the same as in the method of Example 187, replacing N-cyclohexylaniline used in Step E with N-butylaniline.
_{LC / MS (C 42 H 47} N 5 O 4 .2HCl) 686.4 [M + H] +; RT2.28 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₂ H ₄₇ N ₅ O ₄
[M + H] ⁺ calculated value: 686.3701
[M + H] ⁺ Measured value: 686.3672.

Example 195.5 5-Fluoro-N- (4-hydroxyphenyl) -1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] -2H-1,3-benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide The procedure prepares the compound of Preparation 1 'and the compound of Preparation 3' And is the same as in the method of Step 131 of Example 131, replacing the compound of Preparation 3d with the compound of Preparation 3o. Deprotection is performed according to the procedure of Example B, Step B.
_{LC / MS (C 44 H 40} N 5 O 5 F) 738 [M + H] +; RT2.22 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₀ N ₅ O ₅ F
[M + H] ⁺ calculated value: 738.38.66
[M + H] ⁺ Measured value: 738.3066

Example 196.1 1- {4-amino-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl } -N, N-dibutyl-1H-indole-3-carboxamide To a solution of the compound obtained in Example 192 (294 mg, 0.44 mmol) in tetrahydrofuran (15 mL) was added 10% palladium on carbon and nitrogen was added. Degas and then stir for 20 hours at ambient temperature by shaking under a hydrogen atmosphere, after which the reaction mixture is treated with a further amount of 10% palladium on carbon and again in a hydrogen atmosphere over 45 hours. Heat to ° C. The reaction mixture is cooled to ambient temperature and filtered through celite, which is then washed with tetrahydrofuran, and the combined organic phases are concentrated under reduced pressure. The crude material is applied dry to a silica column 20 g, dichloromethane, then dichloromethane / methanol 19: 1, 15: 1, and then 9: 1 mixture, then ethyl acetate: 7: 1 ammonia in methanol 19: 1, and then Eluting with a 15: 1 mixture gives the product.
_{LC / MS (C 39 H 50} N 6 O 2) 635 [M + H] +; RT2.31 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₃₉ H ₅₀ N ₆ O ₂
[M + H] ⁺ calculated value: 635.4068
[M + H] ⁺ Measured value: 635.4056

Example 197.6-Fluoro-N- (4-hydroxyphenyl) -1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinolin-2-carbonyl] -2H-1,3-benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide The procedure is 6-fluoro-1H-indole-3-carboxylic Follow Step A of Preparation 2a using methyl acid, then Step B of heating the reaction mixture at 50 ° C., then Step C. The resulting compound is then treated with 6-bromo-2H-1,3-benzodioxol-5-carboxylic acid according to the procedure of Preparation 3a, which is heated in a microwave apparatus at 130 ° C. for 2 hours. (This is done prior to purification by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture). The compound of Preparation 3 ′ is then treated according to the procedure of Example C, step C and purified by chromatography on silica gel with a dichloromethane-methanol (5%) / dichloromethane mixture, and finally Deprotect according to the procedure of Example 166, Step D and purify by chromatography on silica gel with a dichloromethane-methanol (8%) / dichloromethane mixture.
_{LC / MS (C 44 H 40} N 5 O 5 F) 738 [M + H] +; RT2.1 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₀ N ₅ O ₅ F
[M + H] ⁺ calculated value: 738.38.66
[M + H] ⁺ measured value: 73.83077

Example 198.1- {4-Hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (1H-indol-5-yl) -N-phenyl-1H-indole-3-carboxamide Step A: 5- {N-phenyl-1- [4- (benzyloxy) -5 -Methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinolin-2-carbonyl] phenyl] -1H-indole-3- Amide} -1H-indole-1-carboxylate tert-butyl procedure is to prepare 4-[(tert-butyldimethylsilyl) oxy] -N-cyclohexylaniline used in Step B. Niruamino)-1H-indole-1 is the same as that in the method of Example 204 is replaced with a carboxylic acid tert- butyl.
_{LC / MS (C 58 H 58} N 6 O 6) 935 [M + H] +; RT2.64 ( Method A)

Step B: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline -2-carbonyl] phenyl] -N- (1H-indol-5-yl) -N-phenyl-1H-indole-3-carboxamide The compound obtained in Step A (2.18 g, 2. To a solution of 33 mmol) trifluoroacetic acid (2 mL) is added. The reaction mixture is stirred at ambient temperature for 5 hours and then diluted with dichloromethane and water (this is done before making it alkaline with 2M aqueous NaOH). The organic phase is separated and washed with brine, dried over magnesium sulfate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give a foam.
_{LC / MS (C 53 H 50} N 6 O 4) 835 [M + H] +; RT2.41 ( Method A)

Step C: 1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2- Carbonyl] phenyl} -N- (1H-indol-5-yl) -N-phenyl-1H-indole-3-carboxamide of the compound obtained in Step B (1.03 g, 1.23 mmol) in methanol (15 mL). To the solution was added ammonium formate (775 mg, 12.3 mmol) and 10% palladium on carbon (catalyst) and the reaction mixture was heated to 80 ° C. over 6 hours under nitrogen, then a further amount of ammonium formate ( 775 mg, 12.3 mmol) and 10% palladium on carbon (catalyst) are added and heating of the reaction mixture is continued for 16 hours. The reaction mixture is allowed to cool to ambient temperature, then filtered through celite, washed with methanol and the solvent is removed by evaporation. The crude material is dissolved in dichloromethane and washed with water, then the organic phase is dried over magnesium sulfate, filtered and evaporated. The crude product is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / ammonia / dichloromethane mixture.
_{LC / MS (C 46 H 44} N 6 O 4) 745.4 [M + H] +; RT2.19
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₆ H ₄₄ N ₆ O ₄
[M + H] ⁺ calculated value: 745.3497
[M + H] ⁺ measured value: 745.3465

Example 199. N, N-dibutyl-1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- [2- (Phenylsulfanyl) acetamido] phenyl} -1H-indole-3-carboxamide To a solution of the compound obtained in Example 196 (82 mg, 0.13 mmol) in dichloromethane (4 mL) was added DIPEA (45 μl, 0.26 mmol). ) And cooled to 0 ° C. under nitrogen, then 2- (phenylsulfanyl) acetyl chloride (21 μl, 0.14 mmol) is added slowly. When the addition is complete, the reaction mixture is stirred at 0 ° C. for 15 minutes, then again heated to ambient temperature and stirred for 3 hours. The reaction mixture is treated with additional amounts of DIPEA (45 μl) and acid chloride (21 μl) and the whole is stirred for a further 16 hours. The reaction mixture is diluted with 5% aqueous ammonium hydroxide and extracted with ethyl acetate. The organic extract is then washed successively with 5% aqueous ammonium hydroxide and brine (this is done before drying over magnesium sulfate and concentrating under reduced pressure). Purification is performed by preparative HPLC (pH 9).
_{LC / MS (C 47 H 56} N 6 O 3 S) 785 [M + H] +; RT2.5 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₇ H ₅₆ N ₆ O ₃ S
[M + H] ⁺ calculated value: 785.4207
[M + H] ⁺ measured value: 785.4183

Example 200. N, N-dibutyl-1- {2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -4- (2-Phenoxyacetamido) phenyl} -1H-indole-3-carboxamide The procedure is the same as in the method of Example 199 where 2- (phenylsulfanyl) acetyl chloride was replaced with 2-phenoxyacetyl chloride.
_{LC / MS (C 47 H 56} N 6 O 4) 769 [M + H] +; RT2.49 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₇ H ₅₆ N ₆ O ₄
[M + H] ⁺ calculated value: 769.4436
[M + H] ⁺ measured value: 769.4446

Example 201. N- (4-fluorophenyl) -1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4 -Tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide dihydrochloride The procedure is 4-[(tert-butyldimethylsilyl) oxy]-used in step B Same as in the method of Example 204, replacing N-cyclohexylaniline with 4-[(tert-butyldimethylsilyl) oxy] -N- (4-fluorophenyl) aniline.
_{LC / MS (C 44 H 42} N 5 O 5 F) 740 [M + H] +; RT2.15 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₂ N ₅ O ₅ F
[M + H] ⁺ calculated value: 740.3243
[M + H] ⁺ measured value: 740.3213

Example 202.1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1H-indole-3-carboxamide Step A: 5- (N- {4-[(tert-butyl Dimethylsilyl) oxy] phenyl} -1- [4- (benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3 , 4-Tetrahydroisoquinoline-2-carbonyl] phenyl] -1H-indole-3-amide) -1H-indole-1-carboxylate Implementation of Preparation 5 ″ with 5-({4-[(tert-butyldimethylsilyl) oxy] phenyl} amino) -1H-indole-1-carboxylate tert-butyl Same as in the method of Example 204.
_{LC / MS (C 64 H 72} N 6 O 7 Si) 533 [M + 2H] 2+; RT2.85 ( Method A)

Step B: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline 2-Carbonyl] phenyl] -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1H-indole-3-carboxamide The material obtained in Step A in methanol (20 mL) (1 To a solution of .49 g, 1.4 mmol) is added potassium hydroxide (1M, 2.1 mL, 2.1 mmol) and the reaction mixture is stirred at ambient temperature for about 16 hours. The reaction mixture is concentrated and the residue is dissolved in dichloromethane and washed with dilute HCl. The organic phase is dried over magnesium sulfate, filtered and evaporated. The residue is redissolved in dichloromethane (20 mL) and trifluoroacetic acid (3 mL) is added thereto. The reaction mixture is stirred at ambient temperature for about 72 hours. The residue is dissolved in dichloromethane and neutralized with 2M aqueous NaOH. The organic phase is separated, washed with water, dried over magnesium sulphate, filtered and evaporated. The crude product is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product in the form of a solid.
_{LC / MS (C 53 H 50} N 6 O 5) 851 [M + H] +; RT2.31 ( Method A)

Step C: 1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2- Carbonyl] phenyl} -N- (4-hydroxyphenyl) -N- (1H-indol-5-yl) -1H-indole-3-carboxamide The procedure is the same as that in the method of Example 204, Step D; Purification is performed by preparative HPLC.
_{LC / MS (C 46 H 44} N 6 O 5) 761.2 [M + H] +; RT1.12 ( Method B)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₆ H ₄₄ N ₆ O ₅
[M + H] ⁺ calculated value: 761.3446
[M + H] ⁺ measured value: 761.3429

Example 203. N-butyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide dihydrochloride procedure prepared 4-[(tert-butyldimethylsilyl) oxy] -N-cyclohexylaniline of Preparation 4a. Same as in the method of Example 204, replacing 4b with 4- (benzyloxy) -N-butylaniline.
_{LC / MS (C 42 H 47} N 5 O 5) 702.4 [M + H] +; RT2.19 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Empirical formula: C ₄₂ H ₄₇ N ₅ O ₅
[M + H] ⁺ calculated value: 702.3650
[M + H] ⁺ measured value: 702.3623

Example 204. N-cyclohexyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2 -Carbonyl] phenyl} -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide dihydrochloride Step A: 1- [4- (benzyloxy) -5-methoxy-2-[(3S) -3 -[(4-Methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl] -1H-indole-3-carboxylate in dioxane (30 mL) To a solution of the ester obtained in Step B of 187 (4 g, 6.07 mmol), LiOH (1 M, 7.28 mL, 7.28 mmol) was added and the reaction mixture was added at reflux for about 16 hours. heat. An additional amount of LiOH (1M, 9.1 mL) is added to the reaction mixture which is then heated at reflux for about 16 hours. The reaction mixture is allowed to cool to ambient temperature, the solvent is removed under reduced pressure, and the residue is subjected to azeotropic distillation with toluene to give a solid that is used in subsequent steps without further purification.
LC / MS (C ₃₉ H ₃₉ N ₄ O ₅ .Li) 645 [M + H] ⁺ ; RT2.23 (Method A) [mass of acid type parent molecule]

Step B: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline -2-carbonyl] phenyl] -N- {4-[(tert-butyldimethylsilyl) oxy] phenyl} -N-cyclohexyl-1H-indole-3-carboxamide lithium obtained in Step A in anhydrous dichloromethane (16 mL) To a solution of salt (1 g, 1.54 mmol) is added thionyl chloride (0.22 mL, 3.08 mmol) and cooled to 0 ° C. under nitrogen. Allow the reaction mixture to warm to ambient temperature again and stir for 2 hours (this is done before additional thionyl chloride (0.11 mL, 1.54 mmol) is added and then stirred for about 16 hours). The solvent is removed and the residue is resuspended in dichloromethane and evaporated once more. Co-evaporation with dichloromethane is repeated twice more (this is done before azeotropic distillation with toluene) to give a solid which is dissolved in anhydrous dichloromethane (10 mL). A solution of the aniline obtained in Preparation 4a (640 mg, 2.07 mmol) and pyridine (0.2 mL, 2.31 mmol) in dichloromethane (6 mL) is added and the solution is stirred at ambient temperature for 4 hours under nitrogen. The reaction mixture is diluted with dichloromethane and washed successively with water, saturated sodium bicarbonate solution and brine. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (5%) / dichloromethane mixture to give the product as a foam. Give in form.
_{LC / MS (C 57 H 69} N 5 O 5 Si) 932 [M + H] +; RT2.79 ( Method A)

Step C: 1- [4- (Benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline 2-Carbonyl] phenyl] -N-cyclohexyl-N- (4-hydroxyphenyl) -1H-indole-3-carboxamide To a solution of the material obtained in Step B (758 mg, 0.81 mmol) in methanol (10 mL). Aqueous potassium hydroxide (1M, 1.22 mL, 1.22 mmol) is added and the reaction mixture is stirred at ambient temperature for 3 hours. The reaction mixture is concentrated, the aqueous phase is acidified (slightly) with 2M aqueous HCl, the product is extracted with ethyl acetate, dried over magnesium sulfate, filtered and evaporated. The crude product is used in subsequent steps without further purification.
_{LC / MS (C 51 H 55} N 5 O 5) 818 [M + H] +; RT2.39 ( Method A)

Step D: N-cyclohexyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydro Isoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide To a solution of the compound obtained in Step C (665 mg, 0.81 mmol) in methanol (15 mL) was added ammonium formate. (510 mg, 8.1 mmol) and 10% palladium on carbon (catalyst) are added and the reaction mixture is heated under reflux for 2 days under nitrogen, during which time ammonium formate (510 mg, 8.1 mmol) and carbon supported Add another 2 parts of 10% palladium (catalyst). Allow the reaction mixture to cool to ambient temperature. It is then filtered through celite, washed with methanol and the solvent is removed by evaporation. The crude material is purified by preparative HPLC (pH 4), then the purified material is dissolved in dichloromethane and washed with water and saturated sodium bicarbonate solution (this is done before drying with magnesium sulfate).

Step E: N-cyclohexyl-1- {4-hydroxy-5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydro Isoquinoline-2-carbonyl] phenyl} -N- (4-hydroxyphenyl) -1H-indole-3-carboxamide dihydrochloride To a solution of the compound obtained in Step D (330 mg, 0.45 mmol) in isopropanol (5 mL). HCl in ether (2M, 1.13 mL, 2.25 mmol) is added and the solution so obtained is diluted with ether (5 mL) and stirred at ambient temperature for 20 minutes. The solid is then filtered off, washed with ether and dried under reduced pressure.
_{LC / MS (C 44 H 49} N 5 O 5) 728 [M + H] +; RT2.21 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₄ H ₄₉ N ₅ O ₅
[M + H] ⁺ calculated value: 728.3806
[M + H] ⁺ Measured value: 728.3786

Example 205. N- (4-hydroxyphenyl) -1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline- 2-Carbonyl] phenyl} -N- (1-methyl-1H-indol-5-yl) -1H-indole-3-carboxamide Step A: 4-methoxy-2- [3- (methoxycarbonyl) -1H-indole -1-yl] benzoic acid methyl indole-3-carboxylate (2 g, 11.42 mmol), potassium carbonate (2.32 g, 16.8 mmol) and 2-iodo-4-methoxybenzoic acid (3.17 g, 11. 42 mmol) are combined under nitrogen, suspended in N, N-dimethylformamide (30 mL), degassed with nitrogen, and then copper iodide (217 mg, 1.14 mmol) is added. The reaction mixture is heated to 80 ° C. under nitrogen for about 16 hours. Allow the reaction mixture to cool to ambient temperature. It is then diluted with water and acidified with 2M aqueous HCl. The organic phase is extracted with dichloromethane, washed with water, dried over magnesium sulphate, filtered and evaporated. The crude material is purified by chromatography on silica gel with a gradient of isohexane to 1: 1 isohexane / ethyl acetate mixture to give the product in the form of an oil.
LC / MS (C ₁₈ H ₁₅ NO ₅ ) 326 [M + H] ⁺ ; RT 2.36 (Method A)

Step B: 1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} Methyl -1H-indole-3-carboxylate To a solution of the acid obtained in Step A (3.08 g, 9.47 mmol) in N, N-dimethylformamide (30 mL), DIPEA (8.25 mL, 47.35 mmol) was added. And HBTU (2.6 g, 7 mmol), then the compound of Preparation 3 ′ (3 g, 8.52 mmol) is added and the reaction mixture is stirred at ambient temperature for about 16 hours. The reaction mixture is diluted with dichloromethane and washed successively with water and saturated sodium bicarbonate solution. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product in the form of an oil. Give in.
_{LC / MS (C 33 H 36} N 4 O 4) 553 [M + H] +; RT2.14 ( Method A)

Step C: 1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} 1H-indole-3-carboxylate lithium The procedure is 1- [4- (benzyloxy) -5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl]- Same as in the method of Example 204, Step A, replacing methyl 1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl] -1H-indole-3-carboxylate with the compound of Step B.
LC / MS (C ₃₂ H ₃₃ N ₄ O ₄ .Li) 539 [M + H] ⁺ ; RT 2.04 (Method A) [mass of acid type parent molecule]

Step D: 1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -1H-indole-3-carbonyl chloride To a solution of the lithium salt obtained in Step C (540 mg, 0.99 mmol) in anhydrous dichloromethane (10 mL) was added thionyl chloride (0.14 mL, 1.98 mmol) and nitrogen was added. Cool down to 0 ° C. Allow the reaction mixture to warm to ambient temperature again and stir for 5 hours (this is done before a further amount of thionyl chloride (0.035 mL, 0.5 mmol) is added and then stirred for about 16 hours). . The solvent is removed and the residue is resuspended in dichloromethane and evaporated once more. Co-evaporation with dichloromethane is repeated two more times (which is done before azeotropic distillation with toluene) to give a solid that is used in subsequent steps without further purification.
LC / MS (C ₃₂ H ₃₃ N ₄ O ₃ Cl) 553 [M + H] ⁺ ; RT 2.13 (Method A) [methyl ester obtained by inactivation of methanol is observed]

Step E: N- {4-[(tert-butyldimethylsilyl) oxy] phenyl} -1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (1-methyl-1H-indol-5-yl) -1H-indole-3-carboxamide in dichloromethane (10 mL), step D To a solution of the acid chloride obtained in step (550 mg, 0.99 mmol) in dichloromethane (8 mL) under nitrogen, the aniline obtained in preparation 4c (348 mg, 0.99 mmol) and pyridine (0.13 mL, 1.5 mmol) And the reaction mixture is stirred at ambient temperature for about 72 hours. The reaction mixture is diluted with dichloromethane and washed successively with water, saturated sodium bicarbonate solution and brine. The organic phase is dried over magnesium sulfate, filtered and evaporated, and the crude material is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture to give the product in solid form. give.
LC / MS (C ₅₃ H ₆₀ N ₆ O ₄ Si) 873 [M + H] ⁺ ; RT 2.67 (Method A)

Step F: N- (4-hydroxyphenyl) -1- {5-methoxy-2-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4- Tetrahydroisoquinoline-2-carbonyl] phenyl} -N- (1-methyl-1H-indol-5-yl) -1H-indole-3-carboxamide The material obtained in step E (451 mg, 0. 1 in methanol (10 mL)). To a solution of 52 mmol) potassium hydroxide (1 M, 0.78 mL, 0.78 mmol) is added and the reaction mixture is stirred overnight at ambient temperature. The solvent is removed and the residue is dissolved in dichloromethane, washed with water (+ 2M HCl drops), dried over magnesium sulfate, filtered and evaporated. The crude product is purified by chromatography on silica gel with a gradient of dichloromethane to methanol (10%) / dichloromethane mixture, then triturated with ether, filtered and dried under reduced pressure to give a powder.
_{LC / MS (C 47 H 46} N 6 O 4) 759 [M + H] +; RT2.2 ( Method A)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₇ H ₄₆ N ₆ O ₄
[M + H] ⁺ calculated value: 759.3653
[M + H] ⁺ measured value: 759.3628

Example 206. N- (4-hydroxyphenyl) -5-methyl-N- (1-methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) -1- (6-{[(3S) -3- (Morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-pyrrole-3-carboxamide hydrochloride trace element Analysis:% measured value (theoretical value)
% C = 66.28 (66.27);% H = 0.08 (5.43);% N = 10.70 (11.04);% Cl− = 5.41 (4.66)
High resolution mass spectroscopy (ESI ⁺ ):
Experimental formula: C ₄₂ H ₄₀ N ₆ O ₆
[M + H] ⁺ calculated value: 725.3082
[M + H] ⁺ measured value: 725.3090

Example 207. N- (4-hydroxyphenyl) -N- (1-methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) -1- (6-{[(3S) -3- (morpholine-4 -Ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -4,5,6,7-tetrahydro-1H-indole-3 Carboxamide hydrochloride In Step A, the acid obtained in Preparation 19, (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline obtained in Preparation 2 ′ and Preparation 24 ″ Of N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1-methyl-1H-pyrrolo [2,3-b] pyridin-5-amine obtained in Example 12 The title compound is synthesized according to the method.
Trace element analysis:% measured value (theoretical value)
% C = 67.26 (67.45);% H = 5.73 (5.66);% N = 10.22 (10.49);% Cl− = 4.70 (4.42)
High resolution mass spectroscopy (ESI ⁺ / FIA):
Empirical formula: C ₄₅ H ₄₄ N ₆ O ₆
[M + H] ⁺ calculated value: 765.3395
[M + H] ⁺ Measured value: 765.3398

Example 208.4-[(1-Methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) {[1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -4,5,6,7-tetrahydro-1H-indol-3-yl] Carbonyl} amino] phenyl phosphate disodium Step A: Dibenzyl 4-[(1-methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) {[1- (6-{[(3S)- 3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -4,5,6,7-tetrahydro -1H-indol-3-yl] Rubonyl} amino] phenyl phosphate To a suspension of 80 mg (2 mmol) of sodium hydride in 8 mL of anhydrous THF at 0 ° C., 719 mg (0.9 mmol) of the compound of example 207 are added in small portions. After stirring at 0 ° C. for 30 minutes and at ambient temperature for 30 minutes, at 0 ° C. tetrabenzyl pyrophosphate (580 mg; 1 mmol) is added and the reaction mixture is stirred overnight at ambient temperature. After evaporation of the solvent, the crude reaction mixture is diluted with dichloromethane (40 mL) and washed with saturated NaHCO ₃ solution and then with saturated NaCl solution. The organic phase is then dried over MgSO ₄ , filtered, concentrated to dryness and purified by chromatography on silica gel (CH ₂ Cl ₂ / MeOH gradient). The title product is then obtained in the form of a solid.

Step B: 4-[(1-Methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) {[1- (6-{[(3S) -3- (morpholin-4-ylmethyl)- 3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -4,5,6,7-tetrahydro-1H-indol-3-yl] carbonyl } Amino] phenylphosphate disodium To a solution of the product obtained in Step A (395 mg; 0.39 mmol) in methanol (6 mL) was added 40 mg of 10% Pd / C, and then the reaction mixture was hydrogenated for 2 hours. Put down (1 bar). After filtering off the catalyst and concentrating to dryness, the crude reaction mixture was dissolved in methanol (5 mL) and treated with 0.8 mL of 1N sodium hydroxide solution. The solvent is then evaporated and the crude reaction mixture is purified by chromatography on an OASIS ™ phase (acetonitrile / H ₂ O gradient) to give a solid.

Example 209.1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -4,5-dimethyl-N- (1-methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) -1H-pyrrole-3-carboxamide hydrochloride Step A: 1 -(5-Chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -4,5-dimethyl-1H -Methyl pyrrole-3-carboxylate In step A, the acid obtained in Preparation 22 and (3S) -3- (4-morpholinylmethyl) -1,2,3,4-tetrahydroisoquinoline obtained in Preparation 2 ' Of Example 8 According to the protocol of the degree A, to give a compound.
¹ H-NMR: (400 MHz, dmso-d6) δ ppm: 9.85 (sl, OH), 7.77 (d, 1H), 7.72 (d, 1H), 7.63 (s, 1H), 7.45-6.81 (m, 4H), 6.88 (m, 1H), 5.27 (m, 1H), 4.51 / 4.28 (m, 2H), 4 / 3.69 ( m, 4H), 3.61-3.01 (m, 6H), 3.55 (m, 3H), 2.57 (s, 2H), 1.79 (m, 6H)
IR (ATR) cm ⁻¹ : 1698 ν aromatic —C═O ester, 1639 ν—C═O amide

Step B: 1- (5-Chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -4,5 -Lithium dimethyl-1H-pyrrole-3-carboxylate The compound is obtained according to the protocol of Step B of Example 8, starting from the compound obtained in the previous step.
¹ H-NMR: (500 MHz, dmso-d6) δ ppm: 7.72-7.56 (m, 3H), 7.66 (m, 1H), 7.4-6.92 (m, 4H), 4 .85 / 3.72 (m, 1H), 4.82 / 4.31 / 4.24 / 4.14 (m, 2H), 3.5 (m, 4H), 2.99 / 2.85 / 2.67 / 2.52 (m, 2H), 2.62-1.94 (m, 6H), 2.14 / 2.07 / 2.02 / 1.78 / 1.74 (m, 6H)
IR (ATR) cm ⁻¹ : 2575 ν—OH, 1696-1670 ν—C═O, 1626 ν—C═O, 1595 νAr, 1230-1180-1114 ν—C—O—C, 867-833-743 ν-CH-Ar

Step C: N- (4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3, 4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -4,5-dimethyl-N- (1-methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) -1H-pyrrole -3-Carboxamide The compound is obtained according to the protocol of Step 8 of Example 8 replacing the compound of Preparation 1 "with the compound of Preparation 24".
LC / MS [M + H] ⁺ = 717.45 + 719.45
(Theoretical values for these are 717.30 + 719.30)

Step D: 1- (5-Chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- ( 4-hydroxyphenyl) -4,5-dimethyl-N- (1-methyl-1H-pyrrolo [2,3-b] pyridin-5-yl) -1H-pyrrole-3-carboxamide hydrochloride obtained in the previous step The compound (1.16 g, 1.38 mmol) is directly dissolved in 15 mL of THF. 1M TBAF solution in THF (1.51 mL, 1.51 mmol) is added dropwise with a syringe. The reaction mixture is then stirred at ambient temperature for 12 hours. The progress of the reaction is monitored by LC-MS. The solution is diluted with dichloromethane and washed with saturated NaHCO ₃ solution and then with water. The organic phase is dried over magnesium sulphate, filtered and then evaporated to dryness. The compound is purified on a silica gel column using dichloromethane and ethanol as solvents to give the free base.

When 450 mg of the product so obtained are dissolved in 5 mL of ethanol and 4 mL of 1M hydrochloric acid solution in ether are slowly added, the corresponding hydrochloride precipitates. This is filtered off, washed with ether and lyophilized in an acetonitrile: water mixture. 470 mg of the hydrochloride are obtained in the form of a white powder.
¹ H-NMR: (500 MHz, dmso-d6) δ ppm: 11.46 (sl, NH), 9.5 (sl, OH), 8.14 (m, 1H), 7.9 (m, 1H), 7.63 / 7.51 (m, 1H), 7.63 (m, 1H), 7.51 (m, 1H), 7.33-6.99 (m, 6H), 6.8-6. 6 (m, 2H), 6.7 / 6.62 (m, 2H), 6.41 (m, 1H), 5.23 (m, 1H), 4.82 / 4.11 (m, 2H) 4.03 / 3.88 (m, 4H), 3.8 (m, 3H), 3.73 / 3.4 / 3.13 / 3.01 (m, 4H), 3.28 / 3. 15 (m, 2H), 2.78 / 2.65 (m, 2H), 1.93-1.56 (m, 6H)
IR (ATR) cm ⁻¹ : 2000 to 3500 ν—NH + / OH, 1628 ν—C═O, 1260-1230-1186 ν—C—O—C, 830-736 ν—CH—Ar
High resolution mass spectroscopy (ESI ⁺ / FIA):
Empirical formula: C ₄₂ H ₄₁ ClN ₆ O ₄
[M + H] ⁺ calculated value: 729.2951
[M + H] ⁺ measured value: 759.2949
(Isotope ratio is consistent with one chlorine atom)

Example 210.1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-Hydroxyphenyl) -4,5-dimethyl-N- (1-methyl-2,3-dihydro-1H-pyrrolo [2,3-b] pyridin-5-yl) -1H-pyrrole-3-carboxamide Hydrochloride The free base of the compound of Example 209 (490 mg, 0.671 mmol) is dissolved in 6.5 mL of acetic acid. Sodium cyanoborohydride (370 mg, 5.90 mmol) is added in 3 portions. The reaction mixture is stirred at ambient temperature for 70 hours. The progress of the reaction is monitored by LC-MS. The reaction mixture is evaporated and then coevaporated with toluene. The compound so obtained is purified on a silica gel column using dichloromethane and ethanol as solvents. The compound is then dissolved in 5 mL of ethanol and 4 mL of 1M hydrochloric acid solution in ether is slowly added to precipitate the hydrochloride salt. This is filtered off, washed with ether and lyophilized in an acetonitrile: water mixture. The hydrochloride is obtained in the form of a white powder.
¹ H-NMR: (500 MHz, dmso-d6) δ ppm: 11.6 (sl, 1H), 8.16 (m, 1H), 7.67 (m, 1H), 7.55-7.01 (m 11H), 6.91 (m, 1H), 6.65 (m, 1H), 5.21 (m, 1H), 4.82 / 4.14 (m, 2H), 4.14-3. 81 (m, 4H), 3.85-2.94 (m, 4H), 3.27 / 3.15 (m, 2H), 3.11 (m, 3H), 3.09 (m, 2H) 2.62 (m, 2H), 2.03 / 1.78 / 1.63 (m, 6H)
IR (ATR) cm ⁻¹ : 2000 to 3500 νNH + / OH, 1628 ν—C═O, 1361 ν—C—O—C, 1264 ν—CH—Ar
High resolution mass spectroscopy (ESI ⁺ / FIA):
Empirical formula: C ₄₂ H ₄₃ ClN ₆ O ₄
[M + H] ⁺ calculated value: 731.3107
[M + H] ⁺ measured value: 731.3111

Example 211.1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (5-Cyano-1,2-dimethyl-1H-pyrrol-3-yl) -N- (4-hydroxyphenyl) -4,5-dimethyl-1H-pyrrole-3-carboxamide hydrochloride Step A: N- ( 4-{[tert-butyl (dimethyl) silyl] oxy} phenyl) -1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinoline-2 (1H) -yl] carbonyl} phenyl) -N- (5-cyano-1,2-dimethyl-1H-pyrrol-3-yl) -4,5-dimethyl-1H-pyrrole-3-carboxamide in step C. Preparation 24 " According to the protocol process A~C of Example 209 substituting the compound to the compound of Preparation 26 ', to give a compound.
¹ H-NMR: (500 MHz, dmso-d6) δ ppm: 7.67 (m, 1H), 7.62 / 7.6 (m, 1H), 7.44 (m, 1H), 7.39 (m , 1H), 7.25-6.95 (m, 4H), 6.9 (m, 2H), 6.78 / 6.63 (m, 1H), 6.74 / 6.68 / 6.61. (M, 2H), 5.03 / 4.79 / 3.56 (m, 1H), 4.88 / 4.32 / 4.22 / 4.03 (m, 2H), 3.64-3. 41 (m, 4H), 3.59 (s, 3H), 2.97 / 2.82 / 2.7 / 2.63 (m, 2H), 2.56-1.92 (m, 6H), 2.1-1.68 (m, 9H), 0.88 (m, 9H), 0.1 (s, 6H)
IR (ATR) cm < ^-1 >: 2211 [nu] -CN, 1637, [nu] -C = O, 1253 [nu] -C-O-C-, 910 [nu] -Si-O-C-, 837 [nu] -Si-C-, 782 -744 ν-CH-Ar

Step B: 1- (5-Chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- ( 5-cyano-1,2-dimethyl-1H-pyrrol-3-yl) -N- (4-hydroxyphenyl) -4,5-dimethyl-1H-pyrrole-3-carboxamide hydrochloride Compound of Step A (440 mg, 0.530 mmol) is dissolved in 10 mL of tetrahydrofuran and tetrabutylammonium fluoride (580 μL, 1M in THF, 0.580 mmol) is added dropwise. The reaction mixture is stirred at ambient temperature for 1 hour. A saturated aqueous bicarbonate solution is then added to the mixture, which is extracted three times with dichloromethane. The organic phase is dried over magnesium sulphate, filtered and then evaporated to dryness. The compound so obtained is purified on a silica gel column using dichloromethane and ethanol + 0.1% ammonia as solvent. The desired compound is obtained in the form of a white powder. Dissolve the latter in 5 mL of ethanol and slowly add 4 mL of 1M hydrochloric acid solution in ether to precipitate the hydrochloride. This is filtered off, washed with ether and lyophilized in an acetonitrile: water mixture.
¹ H-NMR: (500 MHz, dmso-d6) δ ppm: 11.3 (sl, 1H), 9.4 (s, 1H), 8.1 (sl, 1H), 7.65 (d, 1H), 7.4 (s, 1H), 7.3-6.7 (several m, 7H), 6.7 (m, 2H), 6.5-5.5 (sl, 1H), 5.2 (M, 1H), 4.75 / 4.1 (m + m, 1 + 1H), 4 / 3.9 (m + m, 2 + 2H), 3.75 / 3.15 (m + m, 1 + 1H), 3.6 (s, 3H ), 3.4 / 3 (m + m, 1 + 1H), 3.3 / 3.15 (m + m, 1 + 1H), 2.75-2.5 (m, 2H), 2.1-1.55 (several s, 9H)
IR (ATR) cm ⁻¹ : 3373 ν-OH, 2700-2200 ν-NH +, 2211 ν-CN, 1625 ν-C═O
High resolution mass spectroscopy (ESI ⁺ / FIA):
Empirical formula: C ₄₁ H ₄₁ ClN ₆ O ₄
[M + H] ⁺ calculated value: 717.2951
[M + H] ⁺ measured value: 717.2941

Pharmacological Study Example A: Method of inhibiting Bcl-2 by fluorescence polarization method A:
The fluorescence polarization test was performed on a microplate (384 well). In a buffer solution (NaPO ₄ 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4) in the presence or absence of increasing concentrations of test compound, a final concentration of 2.50 × 10 ⁻⁸ M labeled Bcl-2 protein ( histag-Bcl-2, Bcl-2 corresponds to Uniplot KB® primary accession number: P10415), final concentration of 1.50 × 10 ⁻⁸ M fluorescent peptide (fluorescein-REIGAQLRRMADDLNAQY) Mix with. Fluorescence polarization is measured after 2 hours of incubation.

Method B:
The fluorescence polarization test was performed on a microplate (384 well). Labeled Bcl-2 protein at a final concentration of 2.50 × 10 ⁻⁸ M in buffer solution (Hepes 10 mM, NaCl 150 mM, Tween 20 0.05%, pH 7.4) in the presence or absence of increasing concentrations of test compound. (Histag-Bcl-2, Bcl-2 corresponds to Uniplot KB (registered trademark) primary accession number: P10415) and fluorescent peptide (fluorescein-REIGAQLRRMADDLNAQY at a final concentration of 1.00 × 10 ⁻⁸ M). ). Fluorescence polarization is measured after 2 hours of incubation.

The results are expressed in IC ₅₀ (concentration of a compound that inhibits fluorescence polarization by 50%) and are shown in Table 1 below. The IC ₅₀ for Bcl-2 inhibition obtained using Method B is underlined.

  The results show that the compounds of the present invention inhibit the interaction between Bcl-2 protein and the fluorescent peptide.

Example B: In Vitro Cytotoxicity Cytotoxicity studies were performed on the RS4; 11 leukemia cancer cell line.
Cells are dispensed into microplates and exposed to test compounds for 48 hours. Subsequently, the viability of the cells was quantified by a colorimetric microculture tetrazolium assay (Cancer Res., 1987, 47, 939-942).
The results are expressed as IC ₅₀ (concentration of a compound that inhibits cell viability by 50%) and are shown in Table 1 below.

ＮＤ：測定せず
部分阻害剤については、所与の濃度の試験化合物についての百分率蛍光偏光阻害を示す。したがって、４５．１％＠１０μＭは、１０μＭに等しい試験化合物の濃度について、４５．１％の蛍光偏光阻害が観測されることを意味する。 The results show that the compounds of the present invention are cytotoxic.

ND: not measured, for partial inhibitors, indicates percent fluorescence polarization inhibition for a given concentration of test compound. Thus, 45.1%@10 μM means that 45.1% fluorescence polarization inhibition is observed for a concentration of test compound equal to 10 μM.

Example C: Induction of Caspase Activity In Vivo The ability of the compounds of the invention to activate caspase 3 is evaluated in an RS4; 11 leukemia cell xenograft model.
1 × 10 ⁷ RS4; 11 cells are implanted subcutaneously into immunosuppressed mice (SCID strain). 25-30 days after transplantation, animals are treated orally with various compounds. After 60 hours of treatment, the mass is collected and lysed, and caspase 3 activity in the lysate is measured. This enzyme measurement is performed by analyzing the appearance of a fluorescent cleavage product (DEVDase activity, manufactured by Promega). It is expressed in the form of an activation factor corresponding to the ratio between the two caspase activities, ie the activity in the treated mice divided by the activity in the control mice.

  The results show that the compounds of the present invention can induce apoptosis in RS4; 11 cancer cells in vivo.

Example D: Quantification of Cleaved Caspase 3 In Vivo The ability of the compounds of the invention to activate caspase 3 is evaluated in the RS4; 11 leukemia cell xenograft model.
1 × 10 ⁷ RS4; 11 cells are implanted subcutaneously into immunosuppressed mice (SCID strain). 25-30 days after transplantation, animals are treated orally with various compounds. Following treatment, the mass is collected (after time T) and lysed, and the cleaved (activated) caspase 3 activity in the tumor lysate is quantified. This quantification is performed using the “Meso Scale Discovery (MSD) ELISA platform” test, which specifically analyzes cleaved caspase 3 activity. It is expressed in the form of an activation factor corresponding to the ratio of the amount of cleaved caspase 3 in treated mice divided by the amount of cleaved caspase 3 in control mice.

The results show that the compounds of the present invention can induce apoptosis in RS4; 11 cancer cells in vivo.

Example E: In vivo anti-cancer activity The anti-cancer activity of the compounds of the invention is evaluated in a RS4; 11 leukemia cell xenograft model.
1 × 10 ⁷ RS4; 11 cells are implanted subcutaneously into immunosuppressed mice (SCID strain). 25-30 days after implantation, once the mass has reached about 150 mm ³ , two different regimens (once daily, 5 days a week for 2 weeks, or twice a week for 2 weeks) Mice are treated orally with various compounds. The mass is measured twice a week from the start of treatment.

  The results thus obtained indicate that the compounds of the invention can induce significant cancer regression during the treatment period.

Example F: Pharmaceutical composition: Tablets 1000 tablets containing a compound selected from Examples 1-211 at a dose of 5 mg 5 g
Wheat starch 20g
Corn starch 20g
Lactose 30g
Magnesium stearate 2g
Silica 1g
Hydroxypropylcellulose 2g

Claims (25)

Formula (I):

[Where:
W represents a group _{C-A 3;}
A _{1, A 2} and _{A 3} is each independently of one another, hydrogen Moshiku is either a halogen atom, or a linear Moshiku represents a branched _(C 1 -C ₆₎ alkyl group, walk is
A ₁ and A _2, together with the carbon atoms having them form a cycloalkyl or benzo ring, these two groups can optionally is substituted by halogen atoms;
T is methyl, aminomethyl, dimethylaminomethyl, morpholinylmethyl, (4-methyl-1-piperazinyl) methyl, (4-cyclopentyl-piperazin-1-yl) methyl, (4-cyclobutylpiperazine-1- Yl) represents a group selected from methyl, pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl and 2- (morpholin-4-yl) ethyl ;
R ₃ represents a linear Moshiku represents branched (C 1 _{-C 6)} alkyl group, a cycloalkyl group, hetero cycloalkyl group, an aryl group or a heteroaryl group, one of the radicals or more carbon atoms or carbon atoms thereof of possible substituents, are rather good be deuterated;
R ₄ represents a 4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl or 3-fluoro-4-hydroxyphenyl group, one or more carbon atoms of said group, or carbons of their possible substituents atoms, rather than good be deuterated;
R ₅ represents a hydrogen or halogen atom;
R _a 及 beauty _{R d} is to table each hydrogen atom, and pair _(R b, _{R c),} together with the carbon atoms which carry them, the following groups: 1,3-dioxolane; 1,4-dioxane; cyclo pentane; tetrahydrofuran; or 2,3 or forms one of the dihydrofuran, or
R _a , R _c and R _d each represent a hydrogen atom and R _b represents a hydroxy or methoxy group, or a halogen atom, or
One or two of the groups R _a , R _b , R _c and R _d represent a halogen atom, the other represents a hydrogen atom, or
R _a and R _d each represent a hydrogen atom, R _b represents hydrogen, halogen, hydroxy or methoxy group, and R _c represents the following groups: hydroxy, methoxy, 3-phenoxyazetidine, 2- ( Selected from the group of one of phenylsulfanyl) acetamide and 2- (phenoxy) acetamide ;
Where
“Aryl” means a phenyl, naphthyl, biphenyl or indenyl group;
"Heteroaryl", containing at least one has an aromatic unit content, and oxygen, 1-4 heteroatoms selected Ri by nitrogen containing sulfur and quaternary nitrogen, 5-10 It means a monocyclic or bicyclic group that is composed of ring members,
"Cycloalkyl" means a 3-10 containing ring members, mono- or bicyclic non-aromatic carbocyclic group,
"Heterocycloalkyl" is composed of 3 to 10 ring members, and oxygen, sulfur, SO, containing 1 to 3 heteroatoms selected from SO ₂ and nitrogen, monocyclic or bicyclic It means a non-aromatic group;
The far-Ri being defined aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups, and said alkyl, alkenyl, for alkynyl and an alkoxy group, a linear Moshiku is branched (C ₁ -C _{6) alkyl, (C} 3 -C ₆₎ spiro, linear Moshiku is branched _(C 1 -C _{6) alkoxy, (C} 1 -C ₆₎ alkyl -S-, hydroxy, oxo or N- oxy-de, nitro, cyano, -COOR ', - OCOR', NR'R ", linear Moshiku is branched polyhalo _(C 1 -C ₆₎ alkyl, _{trifluoromethoxy, (C} 1 -C ₆₎ alkylsulfonyl, halogen, the aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, and by one or more halogen atoms Moshiku alkyl group optionally Conversion has been and heterocycloalkyl (R 'and R "are each independently of one another, also a hydrogen atom linear Moshiku is branched (C 1 _{-C 6)} to display the alkyl group) is selected from it may be substituted by one to three groups that]
In the compound represented, its addition salts walk from its enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base. W is a group C-H, A ₁ and A ₂ each represents a hydrogen atom or a methyl group, compounds of claim 1 Symbol placement, or its enantiomers or diastereoisomers or pharmaceutically acceptable acid Or its addition salt with a base . W represents a group C—H and A ₁ And A ₂ The compound according to claim 1, wherein each represents a methyl group, or an enantiomer or diastereoisomer thereof or an addition salt thereof with a pharmaceutically acceptable acid or base. W is a group C-H, A ₁ and A _2, together with the carbon atom to which they have to form a cyclohexenyl or benzo ring substituted with a halogen atom optionally claim 1 serial mounting of compounds, or their addition salts and their enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base. R ₃ is phenyl, 1H-indole, benzothiophene, benzofuran, 2,3-dihydro-1H-indole, 1H-indazole, 2,3-dihydro-1H-isoindole, 1H-pyrrolo [2,3-b] Represents a group selected from pyridine, phenoxyphenyl, 2,3-dihydro-1H-pyrrolo [2,3-b] pyridine, and 1H-pyrrole, these groups optionally halogen, linear or branched One or more substituents selected from: (C ₁ -C ₆ ) alkyl, trifluoromethoxy, 4-methylpiperazinyl, linear or branched (C ₁ -C ₆ ) alkoxy , and cyano A compound according to claim 1 or an enantiomer or diastereoisomer thereof or an addition salt thereof with a pharmaceutically acceptable acid or base . The following groups:
N- (4-hydroxyphenyl) -1- {6-[(3S) -3- (morpholin-4-ylmethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H-1,3 -Benzodioxol-5-yl} -N-phenyl-1H-indole-3-carboxamide N- (4-hydroxyphenyl) -N- (1-methyl-1H-pyrrolo [2,3-b] pyridine- 5-yl) -1- (6-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxy Sole-5-yl) -4,5,6,7-tetrahydro-1H-indole-3-carboxamide 1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3 , 4-Dihydroiso Norin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -4,5-dimethyl-N- (1-methyl-2,3-dihydro-1H-pyrrolo [2,3- b] Pyridin-5-yl) -1H-pyrrole-3-carboxamide 1- (5-chloro-2-{[(3S) -3- (morpholin-4-ylmethyl) -3,4-dihydroisoquinoline-2 ( 1H) -yl] carbonyl} phenyl) -N- (5-cyano-1,2-dimethyl-1H-pyrrol-3-yl) -N- (4-hydroxyphenyl) -4,5-dimethyl-1H-pyrrole -3-carboxamide N- (4-hydroxyphenyl) -N- (4-methylphenyl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3 , 4-Dihydroiso Norin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indole-3-carboxamide N- (4-hydroxyphenyl) -N- (1H-indole-5 -Yl) -1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1, 3-benzodioxol-5-yl) -1H-indole-3-carboxamide N- (4-hydroxyphenyl) -N- (1-methyl-1H-indol-5-yl) -1- (6- { [(3S) -3-[(4-Methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} -1,3-benzodioxol-5-yl ) -1H-India 3-Carboxamide 1- (5-chloro-2-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl ] Carbonyl} phenyl) -N- (4-chlorophenyl) -N- (4-hydroxyphenyl) -5-methyl-1H-pyrrole-3-carboxamide 1- (5-chloro-2-{[(3S) -3 -[(4-Methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinolin-2 (1H) -yl] carbonyl} phenyl) -N- (4-hydroxyphenyl) -N- (1H-indole- 5-yl) -1H-indole-3-carboxamide and N- (4-hydroxyphenyl) -1- {6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1 , , 3,4-tetrahydroisoquinolin-2-carbonyl]-2H-1,3-benzodioxol-5-yl} -N- phenyl -1H- indole-3-carboxamide 請 Motomeko 1, wherein that will be selected from of compound, its addition salts walk from its enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base. Less than:
1- {6-[(3S) -3- (aminomethyl) -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2- (2-methylpropyl) -2H-1,3-benzodio Xol-5-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide
1- {2,2-difluoro-6-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2H- 1,3-benzodioxol-5-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide
1- {2-ethyl-7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline-2-carbonyl] -2,3- Dihydro-1,4-benzodioxin-6-yl} -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide
1-[(2S) -2-[(benzyloxy) methyl] -7-[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -1,2,3,4-tetrahydroisoquinoline -2-carbonyl] -2,3-dihydro-1,4-benzodioxin-6-yl] -N- (4-hydroxyphenyl) -N-phenyl-1H-indole-3-carboxamide, and
4-[(4-Methylphenyl) {[1- (6-{[(3S) -3-[(4-methylpiperazin-1-yl) methyl] -3,4-dihydroisoquinoline-2 (1H)- Yl] carbonyl} -1,3-benzodioxol-5-yl) -1H-indol-3-yl] carbonyl} amino] phenyl acetate
A compound selected from the group consisting of: or an enantiomer or diastereoisomer thereof or an addition salt thereof with a pharmaceutically acceptable acid or base. The compound of claim 1, wherein or A method for preparing the addition salt thereof with a enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base,
Formula (II):

[Wherein Alk represents a (C ₁ -C ₆ ) alkyl group, and W, A ₁ , A ₂ , R _a , R _b , R _c and R _d are as defined in claim 1 ]
As a starting material,
Next, the compound represented by the formula (II) is converted into the formula (III):

[Wherein T and R ₅ are as defined in claim 1 ]
Is subjected to peptide coupling with a compound represented by the following formula (IV):

Wherein, Alk is far Ride previously _{defined, W, A 1, A 2} , R a, R b, R c, R d, R 5 and T are as defined in claim 1 Is]
To obtain a compound represented by
The ester functional group of the compound represented by the formula (IV) is hydrolyzed to give the corresponding carboxylic acid or carboxylate, the corresponding carboxylic acid or carboxylate, amine NHR 3 _R 4 _(wherein, R ₃ and R _4, claim 1 as a is as defined) and was coupled, before obtaining a compound represented by the formula (I), the converted to the acid derivative containing the corresponding acyl chloride or anhydride Well,
Compound represented by the formula (I) may be purified according to a conventional separation technique, if desired, it is converted into its addition salts with acids or bases acceptable drug histological so, and, optionally Separated into its isomers according to conventional separation techniques,
At any time deemed appropriate developing of the methods described above, certain groups of reagents or intermediates in the synthesis, protected as required by the synthesis, then but it may also be deprotected
And wherein a call, method. Wherein the compound represented by (I) (wherein group R ₃ or one of R ₄ is substituted by hydroxy functional group), or its enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base a way of claim 8, wherein for the preparation of the addition salts with, the amine NHR ₃ R _4, with carboxylic acid formed from the compound represented by the formula (IV), or the corresponding prior to mosquito Ppuringu with its derivatives, previously subjected to a reaction for protecting the hydroxyl functional group, a compound represented by the protected obtained the formula (I) is subjected to deprotection reaction continues, then optionally, medicine characterized in that it is converted into one of its addition salts with a biological acceptable acid or base, method. The compound of claim 1, wherein or A method for preparing the addition salt thereof with a enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base,
Formula (V):

[Wherein W, A ₁ , A ₂ , R _a , R _b , R _c , R _d , R ₃ and R ₄ are as defined in claim 1 ]
As a starting material,
Next, the compound represented by the formula (V) is converted into the formula (III):

[Wherein T and R ₅ are as defined in claim 1 ]
Subjected to peptide coupling with the compound represented in, to give a compound of formula (I),
Compound represented by the formula (I) may be purified according to a conventional separation technique, if desired, it is converted into its addition salts with acids or bases acceptable drug histological so, and, optionally Separated into its isomers according to conventional separation techniques,
At any time deemed appropriate developing of the methods described above, certain groups of reagents or intermediates in the synthesis, protected as required by the synthesis, then but it may also be deprotected
And wherein a call, method. A compound according to any one of claims 1 to 7 , or an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base, and one or more pharmaceutically acceptable excipients. a pharmaceutical composition comprising a drug. For use as a pro-apoptotic agent, pharmaceutical composition according to claim 11 wherein. Cancer, for treating autoimmune diseases or immune system disorders, pharmaceutical composition according to claim 11 wherein. Bladder, brain, breast or uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal or liver cancer, lymphoblastic leukemia, non-Hodgkin lymphoma, melanoma, malignant blood disease, myeloma, ovarian cancer, non-small cell lung cancer, for treating prostate cancer, or small cell lung cancer, according to claim 13 pharmaceutical composition. For the manufacture of a medicament for use as a pro-apoptotic agent, the use of pharmaceutical composition according to claim 11 wherein. Cancer, for the manufacture of a medicament for Remedy autoimmune diseases or immune system disorders, use of pharmaceutical composition according to claim 11 wherein. Bladder, brain, breast or uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal or liver cancer, lymphoblastic leukemia, non-Hodgkin lymphoma, melanoma, malignant blood disease, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer, or for the small-cell lung cancer you Remedy medicament for manufacturing, the use of claim 16 pharmaceutical composition. Bladder, brain, breast or uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal or liver cancer, lymphoblastic leukemia, non-Hodgkin lymphoma, melanoma, malignant blood disease, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer, or small cell lung cancer to treat, that the claims 1-7 any one compound or its enantiomers or diastereoisomers or a pharmaceutically acceptable acid or base according to Addition salt . Bladder, brain, breast or uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal or liver cancer, lymphoblastic leukemia, non-Hodgkin lymphoma, melanoma, malignant blood disease, myeloma, ovarian cancer, non-small cell lung cancer, in the manufacture of a medicament for you Remedy prostate cancer, or small cell lung cancer, can compound or acceptable enantiomers or diastereoisomers or a pharmaceutically any one of claims 1-7 Use of its addition salt with acid or base . A compound according to any one of claims 1 to 7 , or an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base, a genotoxic substance, a fission toxin, an antimetabolite, a proteasome A pharmaceutical composition comprising an inhibitor, a kinase inhibitor, and an anticancer agent selected from antibodies. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7, or an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base, comprising a genotoxic substance, nuclear fission A pharmaceutical composition characterized by being used in combination with an anticancer agent selected from poisons, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies. Comprising one or more pharmaceutically acceptable excipients, according to claim 20 or 21 pharmaceutical composition. For treating cancer, claim 20 or 21 pharmaceutical composition. The use of in the manufacture of a medicament for treating cancer, claim 20 or 21 pharmaceutical composition. And have you in the treatment of cancer, characterized by radiation therapy paired viewed together using, pharmaceutical composition according to claim 11 wherein.